Progress in Medicinal Chemistry 44
i
This page intentionally left blank
ii
Progress in Medicinal Chemistry 44 Editors: F.D. KING, B.SC., D.PHIL., C.CHEM., F.R.S.C. GlaxoSmithKline New Frontiers Science Park (North) Third Avenue Harlow, Essex CM19 5AW United Kingdom and G. LAWTON, B.SC.,
PH.D., C.CHEM.
Garden Fields Stevenage Road St. Ippolyts Herts SG4 7PE United Kingdom
AMSTERDAM BOSTON HEIDELBERG LONDON NEW YORK OXFORD PARIS SAN DIEGO SAN FRANCISCO SINGAPORE SYDNEY TOKYO
iii
Elsevier Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First edition 2006 Copyright r 2006 Elsevier B.V. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email:
[email protected]. Alternatively you can submit your request online by visiting the Elsevier web site at http://elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress British Library Cataloging in Publication Data A catalogue record for this book is available from the British Library ISBN-13: 978-0-444-51737-1 ISBN-10: 0-444-51737-5 ISSN: 0079-6468 For information on all Elsevier publications visit our website at books.elsevier.com
Printed and bound in The Netherlands 06 07 08 09 10 10 9 8 7 6 5 4 3 2 1
iv
v
Preface The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, i.e. those, which are critical to disease pathology and are ‘druggable’, is the best starting point for improved productivity. The seven chapters of this volume describe recent progress towards drugs acting at a range of ‘druggable’ targets. One chapter addresses kinases, one covers an ion channel, two feature proteases and three of the chapters cover G-protein coupled receptors, which have historically perhaps been the most fruitful area for medicinal chemists. It is increasingly apparent that productivity depends not only on the target selection, but also on the quality of the lead compounds. Good leads produce a double effect on productivity by reducing the downstream failure rate and also the timeline of a project. Chapter 1 provides an excellent review of the use of biostructures to find high-quality leads. The emphasis is on the kinase inhibitor field where there is an abundance of available biostructures. Technology for screening by X-ray crystallography and by NMR has advanced rapidly in recent years and in silico screening methods continue to improve. All three approaches are covered in this review. The hepatitis C virus (HCV) is responsible for a world-wide epidemic with approximately 170 million people infected. It was identified only in the 1980s and since that time great efforts have been made in the search for treatments. Genetic analysis of the virus revealed coding for a serine protease (NS3) and the first clinical studies on inhibitors of the protease have recently been carried out. Chapter 2 presents a review of the medicinal chemistry approaches to this target. The major successes in treating bacterial infections that were achieved by the antibiotics discovered in the middle part of the last century are now under severe threat from the emergence of resistant strains. Very few new classes of antibacterial have been created in the past 20 years. Peptide deformylase represents a new biochemical target and clinical candidates are beginning to emerge. Chapter 3 reviews progress to date.
vi
PREFACE
The Transient Receptor Potential Vanilloid 1 (TRPV1) (vanilloid receptor 1) is a cation channel, which mediates the neuronal response to hot components of chilli peppers. Desensitisation using agonists provides a useful mechanism of pain control. Antagonists also show this effect and are reviewed in Chapter 4. They may find use in a range of clinical situations. Ligands acting at histamine receptors have been a valuable source of medicines. The recent cloning of the H3 receptor has led to a resurgence of interest in the field. Several neurotransmitter systems are subject to modulation by neuronal H3 receptors and it is anticipated that the antagonists will be useful in the treatment of a range of diseases including narcolepsy and attention deficit hyperactivity disorder as well as improving cognition in situations such as Alzheimer’s disease. Chapter 5 updates the medicinal chemistry of H3 receptor ligands which was last reviewed in this series in Volume 38. The cannabinoid field was reviewed in Progress in Medicinal Chemistry Volume 35. Since that time great advances have been made in our understanding of cannabinoid receptor pharmacology. Many novel ligands have been discovered and several are expected to have exciting clinical utility. Medicinal chemistry approaches to the modulation of cannabinoid receptors are extensively reviewed in Chapter 6. Preterm labour is the major cause of perinatal morbidity and mortality. Oxytocin antagonists offer an attractive approach to prevention. Chapter 7 reviews three decades of medicinal chemistry in this field. The peptide approach has resulted in valuable injectable products. Selectivity over the related vasopressin receptors and improvement in pharmacokinetic profile have been the key challenges for more recent non-peptide programmes, and these seem likely to yield orally available medicines. October 2005
Dr. F. D. King Dr. G. Lawton
vii
Contents Preface
v
List of Contributors
ix
1
Finding Protein Kinase Hits using Structural Information Mike Cherry, John Reader and David Williams
1
2
Blunting the Swiss Army Knife of Hepatitis C Virus: Inhibitors of NS3/4A Protease Peter W. White, Montse Llinas-Brunet and Michael Bo¨s
65
3
Peptide Deformylase Inhibitors Kelly Aubart and Magdalena Zalacain
109
4
Clinically Useful Vanilloid Receptor TRPV1 Antagonists: Just around the Corner (or too Early to Tell)? Giovanni Appendino and Arpad Szallasi
145
5
Recent Medicinal Chemistry of the Histamine H3 Receptor Michael A. Letavic, Ann J. Barbier, Curt A. Dvorak and Nicholas I. Carruthers
181
6
Recent Progress in Cannabinoid Research Julia Adam, Phillip M. Cowley, Takao Kiyoi, Angus J. Morrison and Christopher J.W. Mort
207
7
Oxytocin Antagonists as Potential Therapeutic Agents for the Treatment of Preterm Labour Michael J. Allen, David G.H. Livermore and Jacqueline E. Mordaunt
331
Subject Index
375
Author Index (Vols. 1–44)
379
Subject Index (Vols. 1–44)
385
This page intentionally left blank
viii
ix
List of Contributors Julia Adam Organon Research, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK Michael J. Allen GlaxoSmithKline, New Frontiers Science Park (North), Third Avenue, Harlow, Essex, CM19 5AW, UK Giovanni Appendino Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche, Universita` del Piemonte Orientale, 28100 Novara, Italy Kelly Aubart Microbial, Musculoskeletal, and Proliferative Diseases CEDD, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA Ann J. Barbier Johnson and Johnson Pharmaceutical Research and Development L.L.C., San Diego, CA 92121, USA Michael Bo¨s Boehringer Ingelheim (Canada) Ltd, 2100 Cunard St., Laval, QC H7S 2G5, Canada Nicholas I. Carruthers Johnson and Johnson Pharmaceutical Research and Development L.L.C., San Diego, CA 92121, USA Mike Cherry Sareum Ltd, 2 Pampisford Park, Cambridge CB2 4EE, UK
x
LIST OF CONTRIBUTORS
Phillip M. Cowley Organon Research, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK Curt A. Dvorak Johnson and Johnson Pharmaceutical Research and Development L.L.C., San Diego, CA 92121, USA Takao Kiyoi Organon Research, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK Michael A. Letavic Johnson and Johnson Pharmaceutical Research and Development L.L.C., San Diego, CA 92121, USA David G.H. Livermore GlaxoSmithKline, New Frontiers Science Park (North), Third Avenue, Harlow, Essex, CM19 5AW, UK Montse Llinas-Brunet Boehringer Ingelheim (Canada) Ltd, 2100 Cunard St., Laval, QC H7S 2G5, Canada Jacqueline E. Mordaunt GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK Angus J. Morrison Organon Research, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK Christopher J.W. Mort Organon Research, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK John Reader Sareum Ltd, 2 Pampisford Park, Cambridge CB2 4EE, UK
LIST OF CONTRIBUTORS
Arpad Szallasi Department of Pathology and Laboratory Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA Peter W. White Boehringer Ingelheim (Canada) Ltd, 2100 Cunard St., Laval, QC H7S 2G5, Canada David Williams Sareum Ltd, 2 Pampisford Park, Cambridge CB2 4EE, UK Magdalena Zalacain Microbial, Musculoskeletal, and Proliferative Diseases CEDD, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA
xi
This page intentionally left blank
xii
Progress in Medicinal Chemistry – Vol. 44, Edited by F.D. King and G. Lawton r 2006 Elsevier B.V. All rights reserved.
1 Finding Protein Kinase Hits using Structural Information MIKE CHERRY, JOHN READER and DAVID WILLIAMS Sareum Ltd, 2 Pampisford Park, Cambridge CB2 4EE, UK
INTRODUCTION
2
SCREENING BY X-RAY CRYSTALLOGRAPHY
4
SCREENING BY NMR
15
FUNDAMENTALS OF NMR SPECTROSCOPY Using Chemical Shift Changes Nuclear-spin Relaxation Nuclear Overhauser Effects Exchange Phenomena
16 16 17 17 18
APPLICATIONS OF NMR IN SCREENING Target-based Screening Ligand-based Screening
18 18 19
EXAMPLES OF NMR METHODS FOR DISCOVERING KINASE INHIBITORS The Shapes Strategy NMR Screening by Waterlogsy Method NMR Screening of Protein Kinases by ATP–STD Method NMR Backbone Assignment of a Kinase Designing Novel Kinase Inhibitors from the NMR-based Screening of Fragments Design of Libraries for use in NMR Screening
20 20 23 24 25 27 30
IN SILICO METHODS
31
RECEPTOR-BASED SCREENING Compound Database and Receptor Preparation Protein–Ligand Docking Scoring Functions Development and Evaluation of Docking and Scoring Virtual Screening and Protein Kinases
32 33 34 36 37 41
DOI: 10.1016/S0079-6468(05)44401-X
1
2
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
FAULTS AND FIXES FOR VIRTUAL SCREENING Consensus Scoring Knowledge-based Screening Protein Flexibility and Induced Fit High Throughput Docking as a Virtual Screening Tool
44 44 45 48 50
ALTERNATIVES TO HIGH THROUGHPUT DOCKING
51
COMPARATIVE HOMOLOGY MODELLING
53
DE NOVO DESIGN
55
SUMMARY
58
REFERENCES
59
INTRODUCTION The discovery and selection of suitable compounds to start a medicinal chemistry programme is a fundamental stage in the process of drug discovery, where decisions are made that ultimately affect the probability of success for that project. Decisions are made, however, at a time in the project where data are limited, hence, where possible, multiple chemical series are taken forward on the basis that a degree of attrition is inevitable. Recent years, though, have seen a marked shift in the philosophy of finding hit compounds, returning to the idea that quality is better than quantity, as strategies that simply increase numbers, using technologies such as combinatorial chemistry and high throughput screening, have not lived up to expectation. Investment is now focused on alternative and complementary technologies that increase efficiency and productivity, and make better use of the extensive amount of information available both in-house and within the public domain. One such area of development is in the use of structural information regarding the interaction of hit compounds with a receptor. A medicinal chemist’s dream would be to immediately see every molecule synthesised matched up against the target macromolecule, giving the exact mode of binding and the degree of inhibition or stimulation. These data would then allow focused, informed design in the next phase of medicinal chemistry, not only allowing efficient use of resources, but also shortening the chemistry cycle time and therefore reducing the pre-clinical drug discovery time. Ideally, such a capability would apply to all types of target and take into account not only the flexibility of the macromolecule, but also the effect of other macromolecular-binding partners. Naturally, these data would be available at the merest touch of a button. This dream situation is
M. CHERRY, J. READER AND D. WILLIAMS
3
already starting to become reality with the systematic and timely use of analytical procedures of X-ray diffraction and nuclear magnetic resonance (NMR) spectroscopy. Once thought of as a luxury often only obtained towards the end of lead optimisation and used to post-rationalise structure–activity relationship (SAR), structural data can now play a pivotal role in both discovering and selecting hit compounds. The ability to generate a wealth of structural data at the very beginning of a drug discovery project would allow the early selection of different chemical lead series based on their interactions with the target macromolecule, as well as on their intellectual property status and ease of synthesis. There are technical limitations on the speed of obtaining data from both X-ray crystallography and NMR, and it is to be expected that not all targets are amenable for these techniques. The present review, therefore, discusses three alternative approaches to finding hits using structural information; X-ray crystallography, NMR and in silico methods, which have arisen as powerful complementary techniques. The review focuses on the much studied and therapeutically important protein kinase family [1, 2] of targets, and so an introduction to the kinase structure is presented prior to discussion of X-ray crystallographic techniques. The abundance of structural information for protein kinases provides an ideal background for structure-guided drug discovery. Knighton et al. [3] first elucidated the three-dimensional (3D) structure of the catalytic domain of a protein kinase, cyclic adenosine monophosphate (cAMP)-dependent protein kinase and there are now more than 300 entries of kinase structures in the Protein Data Bank (PDB). The catalytic domain typically has 250–300 amino acids and adopts a two-lobed structure that can be further subdivided into 12 ‘subdomains I–XII’. The smaller N-terminal lobe is primarily antiparallel b-sheets with the important exception of a-helix C and constitutes subdomains I–IV. Subdomain V, a single polypeptide chain known as the linker region, connects the N-terminal lobe to the larger, predominantly helical C-terminal lobe comprising subdomains VIa–XI. A full explanation of the structure and function of each region is available elsewhere at the PKR website (pkr.sdsc.edu/html/index.shtml). The abundance of structural information has led to a significant increase in the use of structure-based methods both to identify and to optimise inhibitors of protein kinases. The focus to date has centred upon small molecule ATP-competitive inhibitors and there are numerous examples of protein–ligand complexes available to guide design strategies. ATP binds in the cleft formed between the N- and C-terminal lobes of the protein kinase, forming several key interactions conserved across the protein kinase family. The adenine moiety lies in a hydrophobic region between the b-sheet structure of subdomains I and II and residues from subdomains V and VIb. A
4
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
large number of protein kinase inhibitors have been observed to mimic the donor–acceptor pair of hydrogen bonds made between the protein backbone and the adenine. A hydrogen bond is also observed between a residue from the linker region and the ribose group. The phosphate chain occupies a groove in the protein formed by a number of polar residues that participate in the catalytic function of the enzyme. For reference purposes, the ATPbinding site can be described by means of the ATP-binding mode as the adenine pocket, the ribose pocket and the phosphate groove. There are two additional non-conserved regions that are often noted in the development of inhibitors. The hydrophobic pocket lies directly behind the amino group of adenine (further into the cleft), the size of which is, to a large extent, determined by a single non-conserved residue called the gatekeeper residue. The selectivity profiles of chemical series have been ascribed to variations in the gatekeeper residue, where functionality exploits the hydrophobic pocket of kinases, such as the serine/threonine kinase p38. Another less apparent region, the specificity surface, lies at the opening of the cleft and has also been used to great effect in the design of selective protein kinase inhibitors. Figure 1.1 shows a schematic representation of the ATP pocket in a protein kinase.
SCREENING BY X-RAY CRYSTALLOGRAPHY In order to determine a macromolecular crystal structure, a number of processes have to be performed in a linear fashion with each stage dictating the outcome of the next. Initially, good quality protein crystals have to be made that are amenable to X-ray diffraction analysis. The routine use of cryopreservation techniques [4] over the last 10 years has meant that the required size of usable protein crystal has decreased, removing much of the burden of teasing out ordered growth conditions for making relatively large crystals. In addition, the physical damage to protein crystals from high-energy X-ray irradiation is greatly reduced by maintaining crystals frozen in conditions where ice crystal formation is prevented. This allows data sets to be collected from crystals as small as 10 mm in size, whereas previously crystals had to be larger to allow for major damage during the X-ray irradiation procedure. Advancements in the optical devices used to focus high-energy X-ray beams at the crystal have matched the advances in crystal cryopreservation meaning that good quality data sets can also be collected. Traditionally, particle accelerator facilities, known as synchrotrons, have been used as a source of very high-energy X-rays for protein crystallography. While this is still the case for allowing very rapid collection of good quality data sets, the
M. CHERRY, J. READER AND D. WILLIAMS
gatekeeper residue (MET120) hydrophobic pocket GLU121
VAL123
H
N H O
LYS72 H3N
O
TYR122
5
N
H N
N N
N
O
O O O O P O O P P O O O O
O
O
specificity surface Fig. 1.1 ATP bound to cAMP protein kinase and a schematic representation indicating the nonconserved regions (hydrophobic pocket and specificity surface) of the pocket utilised in the development of protein kinase inhibitors.
usable X-ray flux of home sources has also increased significantly as a combination of improvements that have been made to rotating anode generators, X-ray optical systems and detector systems. This improvement to in-house systems means that a good laboratory single crystal X-ray diffraction machine can now be used for relatively rapid data collection, so
6
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
that data which may have taken several days to collect on older systems can now be collected in as little as a couple of hours. The increase in productivity of in-house systems has meant that the process of putting the crystal in the beam can be a bottleneck during 24/7 operation. For this reason, automated systems have been developed to replace this manual operation, taking crystal containing cryoloops from liquid nitrogen storage and placing them in the X-ray beam prior to data collection [5]. Some synchrotron facilities now also have automated crystal-mounting systems that can be utilised in a remote fashion. In this process, a user cryopreserves many crystals on data collection loops, places them in a specialist carrier cassette, and then sends them over to the remote synchrotron in a cryostorage container by courier. The data are collected and the data sets returned by courier or via the Internet without the scientist needing to set foot outside their own laboratory. The number and quality of the software tools available, coupled with the availability of cheap computational processing, means that the data analysis part of the structure-determination process is greatly enhanced with ever decreasing timelines [6]. The events required for structural solution are the processing of collected data sets, structural solution, molecular refinement and building the structural model. The molecular replacement and model building are continued in cycles until the model is of acceptable quality to the structural biologist. On attempting to derive a novel structure, the parts of the process that can be bottlenecks are the structural solution and the model building, especially in the case of relatively large proteins of >50 kDa. Structural solution is becoming far more straightforward with the increasing numbers of proteins deposited in the public protein database (at the time of writing there were 33,000 macromolecular structures). The greater the number of available structures, the greater the probability that there is a homologous structure, which can be used as a computational search model to provide a structural solution to a novel protein by molecular replacement, a very straightforward and rapid computational process. Where no homologous structure is available, more direct experimental methods need to be performed in order to provide data for direct phase solution, which can add significant time to a project. Once a structure of the desired protein has been solved, it is a very rapid process to produce subsequent high-quality structures and, in fact, some groups have even linked various scripts together, or modified software tools to provide much more automated software aids to repeated crystal structure solution, such as when solving multiple ligand complexes of the same protein [7]. Despite the major advances in X-ray crystallography, the process of producing multiple protein–ligand complexes is not able to handle anywhere
M. CHERRY, J. READER AND D. WILLIAMS
7
near the same number of compounds as high throughput compound screening (HTS) methods. Ambitious X-ray structure campaigns can produce hundreds of protein–ligand complexes in several months [8], whereas HTS can handle at least a million compounds over the same time period using in vitro screening technologies. The use of X-ray crystallography as a direct screening tool for conventional compound libraries is therefore limited, especially as corporate collections tend to range from 100,000 to several million unique compounds [9]. A method that has been developed in an attempt to enable X-ray structure determination to be used as a primary screening tool has been the use of compound cocktails in protein crystal soaking experiments [10]. This method relies on a supply of well-diffracting protein crystals amenable to ligand soaking. This means that the packing of the molecules in the crystalline matrix of the protein crystal is arranged so that ligand can easily diffuse into the active site of many of the target molecules making up the crystal, without causing the structural movements of the protein, which could reduce the crystal diffraction quality. Each compound cocktail is selected so that members are diverse in shape to facilitate identification of the ‘hit’ (Figure 1.2). Once the crystals have been soaked in compound, rapid X-ray data are collected sufficient to allow the generation of an electron density map. The difference in density between empty unsoaked crystals and those where a
Soak
Compound library cocktail
Protein crystal X-ray
Further lead optimisation chemistry (aided by structure)
Compound identified & binding mode determined
Binding site electron density solved
Fig. 1.2 Schematic diagram to show the process involved in crystallographic screening of compound cocktails.
8
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
compound has bound provides ligand electron density that allows the identification of the bound compound from the cocktail. This process is only possible due to the diverse nature of the compounds in each cocktail, which unambiguously allows the density to be assigned to a specific shape of compound. This technique filters out the most potent-binding ligands from the mixture. To identify less potent ligands in the same mixture, this compound would have to be removed from the cocktail and re-screening performed. The number of compounds in each cocktail is limited by two factors. Firstly, sufficient shape diversity to allow unambiguous identification of compound by electron density at the structural resolution must be achieved. Secondly, the concentration of each compound in the cocktail has to be high enough to allow a relatively high occupancy in the protein crystal, and that saturating concentration decreases as the number of compounds in the cocktail increases. Despite these limitations, this technique has been used to screen cocktails containing as many as 100 compounds, which potentially allows the screening of low thousands of compounds per day on some in-house systems and potentially more at synchrotron facilities. This crystallographic screening method is a tool to complement existing approaches and certainly has the potential of bringing structural data to the early phase of drug discovery. Another crystallographic screening method is one known by a number of names including needle, shape or fragment screening [11, 12] where compounds, in many cases much smaller than conventional high throughput screening compounds, are used in structure solution campaigns to provide hits for structure-based design chemistry programmes. The philosophy behind using smaller molecules is that these relatively simple chemicals can be used to probe more binding sites than conventional larger high throughput screening compounds, due to their lack of extensive functionality. For example, an inappropriate side chain, which caused steric or electronic clashes within an active site, could render an exciting chemical scaffold inactive in a screen. A simple model of ligand–receptor interactions [13] has proposed that the probability of a compound binding to a receptor decreases as the molecular weight of the compound increases. For example, the authors show from statistical modelling that for a binding site with a complexity score of 12, the probability of randomly selecting a compound with a unique binding mode is 39.9% for a ligand of complexity 3, but only 1% for a ligand with a complexity of 11. Generally, compounds of lower molecular weight and complexity are less potent binders, with activities typically between 100 mM and 10 mM, as they are usually capable of making fewer interactions with the binding site. This means that selection by screening and subsequent chemistry programmes have to be modified to accommodate a
M. CHERRY, J. READER AND D. WILLIAMS
9
different approach than hits discovered by conventional high throughput screening, where compounds of less than 10 mM activity are sought. One major problem with screening compounds at high assay concentration is that they can aggregate in solution and associate and inhibit enzymes non-selectively [14]. These effects have been observed for a number of generic protein kinase inhibitors, which can form aggregates in solution, becoming promiscuous inhibitors and reduce the enzyme activity of nonATP-dependent enzymes [15]. Fortunately, this effect can be monitored and also largely prevented by running identical assays in the presence of detergent, which reduces the effect by reducing compound aggregate formation [16, 17]. The effect of light absorbing compounds can be a problem in fluorometric kinase assays, so high compound concentration kinase assays should either be radiometric or involve a compound wash out step prior to signal detection. A multi-stage screening approach was adopted for developing ATP site inhibitors of DNA gyrase [11]. In this approach, the authors first used an in silico screen using a model structure to select an initial compound screening set of 600 compounds. This set was increased to 3,000 by the addition of close analogues. Many of these compounds had an MW o300 and none were selected with an MW >400. The authors referred to these compounds as needles, because they were small enough to have been able to penetrate deep into active site pockets and clefts. An in vitro assay was then used which was selected to tolerate compound assay concentrations of 0.5 mM. The high concentration in vitro screen identified 150 hits with significant inhibition activity. The objective of the overall screening approach was to identify compounds whose mode of action was through binding in the ATP-binding pocket. For this reason the 24 kDa N-terminal fragment of DNA gyrase subunit B, which contains the ATP-binding site of the enzyme was used for further studies. These studies initially consisted of analytical centrifugation and surface plasma resonance, with the more interesting compounds also being analysed by 15N-labelled protein in NMR experiments. The use of NMR allowed the identification of residues within the active site that had a shifted N–H signal upon ligand binding and so more clearly defined how different series of compounds were binding in the ATP-binding site. For final confirmation of binding, and as the aid to structure-guided design, X-ray crystal structures were then generated with a loop-deleted version of the ATP-binding subunit fragment, which was amenable to crystallography. This approach allowed the authors to develop novel inhibitors 10-fold more potent than the clinical competitor drug using their structure-based chemistry iterations, increasing the potency of an original weak indazole needle hit by a factor of 266 (Figure 1.3).
10
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Needle Hit
After Lead Optimisation H N
H N N
N
SBDD O
S
Ph
O
O
Me t-Bu
MNEC = 8 µg/ml
MNEC = 0.03 µg/ml
Fig. 1.3 The increase in DNA gyrase inhibition activity (MNEC ¼ maximum non-effective concentration in supercoiling assay) of weak indazole needle hit to optimised compound achieved using structure-based drug design (SBDD).
An alternative approach to generating leads for X-ray-directed drug design known as tethering has also been developed [18]. In this technique, libraries of compounds containing disulphides are used and the enzyme target either has an active site cysteine, or is engineered to contain a cysteine at the appropriate position. The enzyme is then exposed to the library compounds in reducing conditions that favour reversible interactions between the disulphides and the cysteine. Compounds that make interactions and bind in the active site drive the equilibrium towards intermolecular disulphide bond formation and the compound is covalently bound to the enzyme. Erlanson et al. [18] screened cocktails of 8–15 compounds against thymidylate synthase and detected binding by mass spectrometry. By ensuring the compound cocktails contained compounds of different molecular weight, on mass spectrometry analysis, the mass of the unmodified enzyme could be subtracted from the library-exposed enzyme to give the deconvoluted mass and thus the identity of the bound compound. A compound library of 1,200 was screened and resulted in SARs being generated for N-tosyl-D-proline. The disulphide-free version of N-tosyl-D-proline was then shown to bind to thymidylate synthase with a Ki of 1.1 mM. X-ray crystallography demonstrated that the tosyl group of N-tosyl-D-proline occupied almost the same position as the benzamidine portion of the enzyme’s natural cofactor methylenetetrahydrofolate. This suggested binding affinity
M. CHERRY, J. READER AND D. WILLIAMS
11
could then be achieved by addition of glutamate, present on the natural cofactor, to the methyl group of N-tosyl-D-proline. The strategy was successful, increasing the Ki of the compound to 24 mM. Further modification of the carboxyl group, rationalised by use of the X-ray structure, took the potency up to 330 nM, resulting in an overall increase of more than 3,000-fold from the original weak-binding hit (Figure 1.4). Enzyme-adduct formation has also been successfully achieved with the Erb1 and 2 (receptor tyrosine kinases from EGFR subfamily) [19, 20], suggesting that the tethered library-screening approach would also be amenable to protein kinases. The probing of the active site of an enzyme by using multiple crystal structures containing different small molecules was originally described using different organic solvents as the probe molecules [21]. This technique showed how the information derived from the small molecules binding in Me
HO2C
HN
H
O
CO2H
S O N
CO2H
O
Ki = 1.1 mM N
O
H2N
N
HO2C
HO2C
N
HN
N H
H
H HN
CO2H
CO2H
HN
O
O
Methylenetetrahydrofolate (Natural co-factor) O
O S O N
CO2H
Ki = 24 µM
S O N
O N H
CO2H
Ki = 330 nM
Fig. 1.4 The increase in thymidylate synthase inhibition activity obtained from an initial hit identified as a disulphide-bound enzyme adduct and optimised to a reversible potent 330 nM inhibitor using crystal structure-guided design.
12
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
the active site could be used in the rational design of larger more potent binding compounds. Indeed, this approach has been heavily exploited in the NMR field, with small molecule fragment library hits being rationally expanded, or sometimes combined, to generate lead compounds for medicinal chemistry [22–24]. This approach has also been used as a lead finding tool in X-ray crystallography. Specifically, a very small focused fragment libraryscreening approach was used for the generation of a potent inhibitor of the serine/threonine kinase p38 a [25, 26]. The starting fragment set of 327 compounds was selected from available chemicals with ring systems and desired functionalities. A smaller subset of 116 kinase set compounds was then selected based on predicted binding to kinase ATP-binding sites. This kinase set was then screened using cocktails of up to four fragments at 25–200 mM soaked from 1 to 24 h into preformed apo-protein crystals. Screening was performed on a variety of equipment both in-house and at synchrotron units. After the data had been processed and structures solved, an automated method was used whereby the difference in electron density at the active site between soaked and unsoaked protein crystals was compared to ligand structures generated by in silico docking. This was used to identify which fragment from a cocktail bound to the active site (Figure 1.5). The fragments in each cocktail were selected to aid in the electron density identification process. The authors showed how a fragment with an IC50 of
Soak
Compound library cocktail
Protein crystal X-ray
Further lead optimisation chemistry (aided by structure)
Structure-based chemistry
Increase potency & selectivity
Fragment identified & binding mode determined
Binding site electron density solved
Fig. 1.5 Schematic diagram to show the process involved in crystallographic screening of compound fragment cocktails.
M. CHERRY, J. READER AND D. WILLIAMS
13
Cl O
N
Ph
O
NH2
N
Cl
NH2 109 µM
1300 µM
Cl
Cl O
O
O N H N
O
O Ph
N
N H N
30 µM
0.065 µM
F
Fig. 1.6 The increase in potency of a 1.3 mM p38 a protein kinase-binding fragment inhibitor identified by X-ray screening through the major changes made to the chemical series to exploit key binding features within the active site.
1.3 mM could be rationally converted into a compound of 65 nM potency with drug-like properties (Figure 1.6). This process was initiated with an X-ray structure showing the 1.3 mM hit forming a hydrogen bond to the ATP-binding site hinge region, from the pyridyl nitrogen of the fragment to the main chain amide nitrogen of Met-109. In addition, the benzyloxy group of the fragment binds in the lipophilic specificity pocket of the protein kinase. This lipophilic pocket was exploited further by replacing the benzyl group with a 2,6-dichloro substitution to fill this space, resulting in more than a 10-fold increase in potency. Potential movement of the Phe-169 at the start of the activation loop in p38 a leads to exposure of a polar channel formed by residues Asp-168 and Glu-71 stretching from the ATP-binding site to the lipophilic pocket. This movement was exploited by substitution on the 5-position of the fragment phenyl ring with a benzamidine to bring the potency up to 30 mM and then with a large amide, resulting in the 65 nM potency. The inhibitor design was aided both by iterative crystal structures of synthesised compounds and using key information gained from solving structures of other literature-described compounds. The most X-ray intensive screening method was described by Card et al. [8] on the design of phosphodiesterase (PDE) inhibitors (Figure 1.7). The authors initially biochemically screened a 20,000 member library of small molecular weight (120–350 MW) core scaffold compounds against 5-PDE isoforms at 200 mM. Multiple isoforms of PDE were used in order to eliminate the number of false positives obtained from the screen. There were 316
14
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Protein crystal
Biochemical screen (hogh concentration)
or
Protein
Scaffold identified
Scaffold library
Soak or co-crystallise
X-ray Further lead optimisation chemistry (aided by structure)
Scaffold elaboration
Increase potency & selectivity
Scaffold binding mode determined
Binding site electron density solved
Fig. 1.7 Schematic diagram to show the process involved in screening and crystallographic confirmation of scaffold or template libraries.
compounds that gave enzyme inhibition of greater than 30% against three or more enzyme isoforms and these were advanced into co-crystallisation experiments. Successful co-crystallisations were achieved for 269 compounds and 107 co-crystal structures were solved, as traceable ligand electron density was not achieved with all the X-ray data sets. The rationale behind this screening approach was to identify compounds, which could act as scaffolds or templates to further chemical design and so the next step in the process was to validate the compounds as core-binding moieties. This was performed by buying and making substituted versions of the hits, determining their X-ray structures and confirming that the binding mode of the core moiety was identical between the hit and the substituted version. Once the scaffold nature of the hit was confirmed, the core’s chemical elaboration was performed. Compound libraries were first enumerated virtually and then docked in silico, while keeping the scaffold core immobile in the binding site. Compound scoring was then performed on the predicted types of favourable interaction and chemical tractability prior to synthesis. Two rounds of chemical synthesis were performed heavily backed up with co-crystal structure generation. This approach resulted in a 4,000-fold increase in potency against PDE4D for one example shown, from 82 mM as an original carboxyl pyrazole screening hit to 20 nM as a substituted 1-phenyl carboxyl pyrazole (Figure 1.8). The increase in potency was achieved with only a modest increase in molecular weight
M. CHERRY, J. READER AND D. WILLIAMS
EtO2C Me
Me
N
Me
EtO2C
N Me
N
N
H
Ph
82 µM
0.27 µM
15
Me
EtO 2C Me
N
N
Cl
0.019 µM
Fig. 1.8 The increase in potency against PDE4D of a scaffold inhibitor, identified by biochemical screening at high compound concentrations then confirmed by X-ray crystallography, through two iterations of chemistry.
from 168 to 278 Da, meaning that there was still plenty of scope for further lead optimisation to obtain the ideal biological profile. Although this approach was reported on the PDE enzyme family, a similar approach has been successfully performed on protein kinases at Sareum Plc (D. Williams, unpublished results). The use of X-ray crystallography in inhibitor screening has been quite inventive in order to provide valuable data for more rational compound design, given the overall limited throughput of this technique. The last five years have seen many advances that are starting to make the generation of protein–ligand structures much more rapid and commonplace in drug discovery. Advances in both X-ray generator technology [27, 28] and newer concepts in structure determination [29, 30] will lead to further improvements in this field, possibly ultimately resulting in structure generation throughputs only currently enjoyed in the field of high throughput assay screening. SCREENING BY NMR NMR is a valuable tool for studying both the nature and the extent of interactions between ligands and proteins. A key advantage of the method is the fact that an understanding of protein function is not necessary, allowing drug discovery even against orphan proteins. NMR techniques are being increasingly used for the discovery of weak-binding hits and their subsequent optimisation into more potent leads. Furthermore, NMR studies take place in solution, which mimics to a varying extent the natural physiological environment of proteins and allows the examination of dynamic events such as conformational changes in both protein and ligand upon binding. This is in contrast to X-ray crystallography techniques, which necessarily provide a ‘snapshot’ of protein/ligand structure.
16
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Several excellent recent reviews [31–35] describe the varied techniques used for determining protein structure, investigating protein–ligand binding and optimising weak interactions into high-affinity leads. It is beyond the scope of this review to give anything more than an overview of these techniques.
FUNDAMENTALS OF NMR SPECTROSCOPY In a magnetic field, certain magnetic nuclei, such as 15N, 13C or 1H, can exist in nuclear-spin states of different energy and can be induced to flip between these different energy levels by the application of radio-frequency radiation. The frequency of radiation required to effect this energy-level transition is determined by the chemical environment of the magnetic nucleus in a given applied magnetic field. The magnetic environment of a nucleus is affected through chemical bonds (spin–spin coupling) and through space (dipole– dipole coupling), and so the resonance signal for a particular nucleus is directly related to its position within a molecule. When a molecule interacts with another, for example upon ligand binding to a protein, additional intermolecular through-space interactions may become important, affecting the resonance signal for the nuclei involved in the interaction. In theory, any measurable NMR spectroscopic parameter may be used to investigate binding of a ligand to a protein, but in practice they are limited to measurements that can be determined easily and with a sufficient degree of sensitivity. There are two main approaches used in drug discovery today. The first approach examines chemical shift changes of the protein upon binding of a ligand and the second examines the NMR signals of the ligand and their change upon binding to a protein. In addition, there are also two complementary approaches that examine changes in relaxation or diffusion behaviour of a ligand upon binding to a protein [34, 35].
USING CHEMICAL SHIFT CHANGES
Upon binding of a ligand to a protein, the chemical shifts of signals for both protein and ligand will be affected. This effect, in the protein, is greatest for the residues located at the binding site and as protons are the most sensitive nuclei in NMR experiments, it is sometimes possible to detect binding of a ligand to a protein by observation of changes in the chemical shift of wellresolved protein protons. Unfortunately, it is usually extremely difficult to unambiguously assign the chemical shift changes of protein proton signals due to severe overlap, making it impossible to determine the amino acid residues involved in binding.
M. CHERRY, J. READER AND D. WILLIAMS
17
One solution to this problem is to label the target protein with the stable isotopes 15N and/or 13C. Binding of a ligand changes the resonance signals at the binding site, and these changes can be measured using 15N/1H and/or 13 C/1H correlation spectra. The 15N/1H or 13C/1H heteronuclear single quantum correlation (HSQC) spectrum of the labelled protein is acquired as a reference. Upon addition of a binding ligand followed by acquisition of a second HSQC spectrum, changes will be observed between the two spectra, particularly at the protein residues at the binding site. To simply detect binding, it is only necessary to observe changes between the two spectra. However, to determine the residues involved in binding it is necessary to assign the 15N or 13C HSQC signals to the amino acids in the protein. NUCLEAR-SPIN RELAXATION
Magnetic nuclei in a magnetic field can adopt nuclear-spin states of different energy. As a system reaches equilibrium, the population differences between the different nuclear-spin states decays exponentially through relaxation. The intensity of a resonance signal in the NMR spectrum is related to the difference in population between the two energy levels of the different nuclearspin states. This means that the rate at which this difference returns to equilibrium and relaxation has a profound effect on the sensitivity and resolution of an NMR spectrum. Longitudinal magnetisation, Mz, is restored to its equilibrium value Moz by longitudinal relaxation, characterised by the longitudinal relaxation time T1. Transverse magnetisation, Mx and My, decays by transverse relaxation characterised by the transverse relaxation time T2. Nuclear-spin relaxation is mainly modulated via through-space interactions between different nuclear spins and via Brownian rotational tumbling as the orientation of the molecule varies relative to the applied magnetic field. Slowly tumbling large molecules, such as proteins, undergo rapid transverse relaxation, which causes line broadening in the NMR spectrum. This imposes an upper limit on the size of molecules whose structures can be usefully interpreted by NMR. Small molecules tumble at high rates and have much slower relaxation rates, and therefore a sharper well-resolved NMR spectrum. NUCLEAR OVERHAUSER EFFECTS
Nuclear Overhauser effects (NOEs) cause changes in the intensity of NMR signals by through-space dipole–dipole interactions [36]. The magnitude of an observed NOE between two magnetic nuclei gives useful information on the distances between them. The observed NOE is also related to Brownian
18
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
rotational tumbling, with small, rapidly tumbling molecules giving positive NOEs and a maximum relative signal strength of 50%, and large, slowly tumbling molecules giving negative NOEs with a maximum relative signal decrease of 100%. EXCHANGE PHENOMENA
NMR spectra are affected by dynamic processes such as the binding of a ligand to a protein. As a bound ligand will have a different NMR spectrum to the free ligand in solution, the rate constant for formation of the ligand/ protein complex, Kon, and the dissociation rate constant, Koff, will affect the NMR signals for the system at equilibrium. If the exchange process is slow, two distinct sets of signals for the ligand will be observed, but if the exchange process is rapid, a single set of NMR signals will be observed, representing the weighted average chemical shifts of the free and bound signals.
APPLICATIONS OF NMR IN SCREENING Two distinct strategies are used in NMR screening. The first strategy looks for changes in the NMR spectrum of the protein target and the second looks for changes to the NMR spectrum of the ligand. TARGET-BASED SCREENING
When a ligand binds to a protein, there is a change in the magnetic environment at the binding site and at any other residues affected by conformational changes in the protein. This results in measurable changes in the NMR spectrum of the protein and, if the affected residues are mapped onto the protein structure, it is possible to determine the ligand-binding site. There is currently, however, an upper limit on the protein molecular weight of approximately 35 kDa, as such assignments are very resource and time intensive, even for small proteins. This approach has been used in the study of ligand–protein and protein–protein interactions. The group at Abbott Laboratories has developed an extension of this method called ‘SAR by NMR’, which is used to screen collections of small molecules [22]. Using labelled protein, the resonances are assigned as far as possible and the 3D structure of the protein is solved by NMR or by X-ray crystallography. A collection of ligands is screened by comparing the 15N–1H HSQC spectrum of the protein in the absence of, and then in the presence of, a mixture of 10 or more compounds. Changes in the chemical shifts of the amide 15N and/or 1H
M. CHERRY, J. READER AND D. WILLIAMS
19
induced by the binding of a ligand can be detected and if the resonances affected have been assigned, determination of the protein residues involved in binding is straightforward. Any mixture of compounds containing a hit is then deconvoluted to find the active component. Furthermore, measuring the resonance shift changes upon ligand titration enables an estimation of the dissociation-binding constant of that ligand with the protein. 13 C–1H HSQC is based on proteins containing 13C-labelled methyl groups and is increasingly used to complement 15N–1H HSQC experiments [37]. The method is more sensitive due to the higher proton multiplicity and is suitable for screening proteins up to 40 kDa. The key binding site residues of a protein can be identified by using a known inhibitor to identify cross-peaks in the 13C–1H HSQC spectrum [38].
LIGAND-BASED SCREENING
Ligand-based NMR screening examines changes in the NMR spectrum of a ligand or a mixture of ligands in the presence and absence of the target protein or macromolecule. These methods identify which ligand binds to the target, but give no information on the binding site. The techniques require less protein, do not require labelling of protein and have no restriction on the size of the protein being studied, as they do not require assignment of the target’s resonance signals. Some experiments, such as saturation transfer difference (STD) [39] or WaterLOGSY [40] require protein concentrations of 1 mM or less meaning much less protein is required even for screening multiple mixtures of ligands. The transverse relaxation time, T2, of small molecules is usually long compared to that of proteins and therefore the resonance signals for small molecules are generally much narrower than those of proteins. However, upon binding of a ligand to a protein, T2 of the ligand will more closely resemble that of the protein, resulting in line broadening of the ligandassociated signals. Line broadening in the NMR spectrum of a ligand following addition of a macromolecule to the sample is a clear indication of binding. Furthermore, the extent of line broadening, and therefore the sensitivity of the experiment, is related to the size of the protein – with larger structures usually having a more pronounced effect on T2 of the ligand. The longitudinal relaxation time, T1, of small molecules is also altered by binding to proteins, resulting in the observation of negative NOEs for bound ligand resonances [41]. Ligand binding can therefore be detected by measuring a 2D [1H–1H]-NOESY spectrum of the ligand in the presence of a relatively low concentration of protein. Unbound small molecules generally have small, positive NOEs, but on binding to a protein, adopt the
20
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
characteristics of that protein and can display negative (transferred) NOEs, provided that the T1 relaxation time of free ligand is long compared with 1/Koff for the complex. Practically, this means that weak-binding compounds with relatively high dissociation constants will give negative NOEs in the presence of protein, whereas tight-binding molecules may not. There are several ligand-screening techniques that look at the transfer of magnetisation from the protein to the ligand or from ligand to protein. STD NMR spectroscopy [39, 42] has been used in the past to examine tightly bound ligand/protein complexes. If there is slow exchange between the bound state and the free state, the ligand will show a pair of signals and a transfer of saturation between the free and the bound states is possible. By irradiating a signal of the free ligand, the corresponding signal of the bound ligand may be identified following saturation transfer. More common in screening, however, is the transfer of saturation from the protein to a bound ligand, which in turn, by exchange, moves into solution where it is detected. Subtracting a spectrum where the protein is saturated from one without protein saturation generates a different spectrum containing only the signals of a binding ligand. WaterLOGSY [40] is a variant of STD spectroscopy that utilises the bound water at the protein–ligand interface. Negative NOEs between water and ligand are observed due to bound water being present between the protein and the ligand, or by the presence of a shell of water molecules surrounding the ligand. This has allowed the development of experiments that allow the transfer of magnetisation from bulk water to the protein-binding site and on to a bound ligand, allowing the detection of binding of ligands to proteins. Methods based on diffusion filters have also been described by the group at Abbott. Small organic molecules diffuse about 20 times more rapidly than a protein of molecular weight 20 kDa. This difference can be used to distinguish between bound and unbound ligands in the presence of a protein. A diffusion-edited spectrum is obtained for a mixture of ligands in the absence of protein. Following addition of a small concentration of protein, the diffusion-edited spectrum is repeated and comparing the two spectra allows identification of compounds that bind to the target protein [43].
EXAMPLES OF NMR METHODS FOR DISCOVERING KINASE INHIBITORS THE SHAPES STRATEGY
An NMR screening strategy in which a small but diverse set of small molecules is screened against a potential drug target was recently described
M. CHERRY, J. READER AND D. WILLIAMS
21
by the Vertex group [44]. The set of compounds is derived from shapes commonly found in existing drugs. Detection of low-affinity binding is achieved using either differential line broadening or transferred NOE NMR techniques. The utility of this technique has been demonstrated with several enzyme targets including the serine/threonine mitogen-activated protein kinase (MAPK) p38. In selecting an NMR screening library, the objective was to acquire a set of compounds allowing optimisation of a large number of factors (e.g. cost, ease of synthesis, solubility, separation of NMR signals and diversity). The design of the library was based on earlier analyses of drugs and descriptors of their ‘drug likeness’ [45, 46]. In the study, all drug molecules were broken down into their component rings, linkers and side chains. The library was initially chosen from commonly occurring rings and linkers (collectively ‘frameworks’) and side chains from the comprehensive medicinal chemistry (CMC) database, then further filtered by predicted aqueous solubility and synthetic complexity. All library compounds were commercially available, soluble and non-aggregating in water at 1 mM, chemically and isomerically pure and contained no reactive functional groups. The compounds had an average molecular weight of 194 Da and calculated log P range of 2.2–5.5. They were also required to have a wellresolved simple 1H NMR spectrum and contain at least two protons within 5 A˚ of one another. The initially reported library contained 132 compounds from which subsets were screened depending on the pH of the screening solution. A typical protocol for NMR screening involves dissolving the protein in 500 ml of an appropriate aqueous buffer, at a concentration of 50–100 mM. Low volumes of a concentrated stock solution of ligands in deuterated dimethyl sulphoxide (DMSO) are then added, such that the final concentration of each ligand is 1 mM and the total amount of DMSO in solution could be as high as 1%. As the NMR-screening experiment may take place over a number of hours, it is important for the protein to remain stable in solution over this time period. The Vertex group routinely employs the microdrop protein screening method [47] to screen protein samples to ensure their stability under differing concentrations of DMSO, with or without stabilisers and at varying pH. To maximise throughput, it is preferable to screen the SHAPES library as mixtures. However, several problems are raised by this approach. Perhaps the most important is the fact that if the mixture contains a compound with high affinity for the protein, it will successfully compete for the majority of the protein-binding sites in the solution. This may mask the activity of a more weakly binding, but highly optimisable scaffold, resulting in the elimination of an entire compound class from further development. However, due to the inherent weak-binding
22
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
nature of the small molecules in the SHAPES library, this has not been reported as a significant problem to date. The problem of spectral overlap has been largely overcome using automated methods that search the 1D spectra and select combinations of ligands whose spectra are generally easily distinguishable. When examining binding by following line broadening in a 1D spectrum or by analysis of transferred NOE, mixtures of 1–4 compounds are routinely used. However by using 2D tNOE spectroscopy, mixtures of up to 12 compounds have been successfully tested. Once the appropriate mixtures are selected, either the 1D, or both the 1D and 2D tNOE spectra for each mixture are recorded in the absence and presence of protein. Binding of a ligand is identified either via line broadening or by inversion of the NOE cross-peaks. These effects cannot distinguish between specific and non-specific binding, so more rigorous follow-up is needed. Looking for line broadening in the 1D spectra alone is suitable when examining binding to higher molecular weight proteins (>60 kDa) and so screening of the entire library can be completed in several hours. Smaller proteins require the acquisition of both 1D line broadening and 2D NOE spectra and this can take several days. The method has been demonstrated to have utility in hit-finding against a kinase target. It is believed that modulation of serine/threonine kinase JNK3 (c-Jun amino-terminal kinase 3) could provide therapeutic benefits in the treatment of neurodegenerative diseases such as stroke or epilepsy. After an unsuccessful high throughput screen, the SHAPES library was screened versus JNK3 using a 2D transferred nuclear Overhauser effect (tNOESY) experiment and 17 weakly active binders were discovered of which 13 were found to bind specifically in the ATP-binding site [32]. The available chemicals directory (ACD) [48] was then searched using fragment-based and similarity methods to identify analogues of the SHAPES hits, and these analogues were then virtually screened using the X-ray structure of JNK3 before a final selection of 100 high-scoring compounds were chosen. Additionally, 200 compounds from the ACD, which combined features of the SHAPES hits were selected manually. Secondary screening of the follow-up compounds found eight with potencies better than 20 mM. Three of these are shown in Figure 1.9. The thiazole and the uracil classes were found by combining the initial SHAPES hits, whereas the isoxazole was discovered by selecting analogues of the hit from the ACD directly. Four classes of compounds were selected for optimisation, affording 1 mM and 3 nM lead series. Interestingly, none of these classes of compounds had shown activity in the high throughput screen of JNK3. The Vertex group suggests that this may be because the small SHAPES compounds are more likely to bind (albeit weakly) than the more complex compounds typically found in their HTS collection.
M. CHERRY, J. READER AND D. WILLIAMS
23
Follow-up compound
SHAPES hit
O
N
NH
N
N
Scaffold O Ph
Combination
Ph
S
Scaffold
Ph
Ki = 13 µM
O
Ph
N H
HN
Combination
CF3
N H
N
NH
O
N H O
NH
Ph
Ki = 0.72 µM
Ph N
H N
N Analogue
N
N N
NHAc N
Ph N
O
Me
Ki = 0.79 µM
Fig. 1.9 Analogues of JNK3 inhibitors identified using NMR screening. NMR SCREENING BY WATERLOGSY METHOD
Water is known to play a key role in ligand–protein binding, with multiple water molecules being frequently observed at the ligand–protein interface, e.g. a layer of water was detected at the lovastatin/LFA-1 interface [49]. The intermolecular water–ligand NOEs are negative, indicating a residence time of >1 ns. Saturation of water results in magnetisation transfer from bulk water to bound water located in protein cavities and in the magnetisation transfer from bulk water to the layer of water at the protein–ligand interface. The group at Pharmacia developed an NMR technique called Water–Ligand observation with gradient spectroscopy (WaterLOGSY), which is able to detect binding of ligands to proteins via the magnetisation transfer from bulk water. The method was exemplified by the selection of an indole derivative from a mixture of 10 diverse compounds, which was found to bind to cyclin-dependent kinase 2 (cdk2). The compound (Figure 1.10) is reported to have a Ki in the high micromolar range [40].
24
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
CO2 Et CO2 Et N H Fig. 1.10 Cdk2 inhibitor identified using NMR screening by the WaterLOGSY method.
NMR SCREENING OF PROTEIN KINASES BY ATP–STD METHOD
The Schering–Plough group has recently reported on the use of ATP as a site-specific marker in STD–NMR experiments for screening of kinase inhibitors [50]. ATP–STD spectra detect the NMR signals from ATP in the active site of the kinase and reduction of that signal in the presence of competitive inhibitors allows measurement of the inhibitor Ki with respect to the natural substrate. Furthermore, by adding MnCl2 to the sample, ATP is converted into a paramagnetic probe, which can be used to elucidate the distance of non-competitive inhibitors from the ATP-binding site. Four 1D experiments are performed. Initially a 1D spectrum of the kinase, ATP and TSP (trimethylsilylpropane sulfonate – as an internal reference) is recorded. Then an inhibitor (or compound of interest) is added to the sample and an additional spectrum is generated. Any compound degradation or side products are detectable by the NMR method and hydrolysis of ATP can be monitored by measuring chemical shift changes of the purine and sugar protons. In a third experiment, the ATP–STD signal is optimised. A typical STD spectrum of target-bound ATP gives peaks from the purine H8 and H2, and the sugar H10 protons. In the presence of an ATP-competitive binder, these ATP–STD signals are reduced and an inhibitor STD signal appears. This was demonstrated in an experiment in which the ATP–STD peak for the H2 proton of MgATP bound to extracellular signal-regulated kinase 2 (ERK2) was reduced by 54% by the addition of olomoucine. Olomoucine STD peaks were also observed. Competitive inhibitors can be distinguished from non-competitive inhibitors by the addition of a high-affinity inhibitor e.g. staurosporine. As staurosporine is a highly potent inhibitor and competitive with ATP for most serine/threonine kinases, its addition eliminates the STD peaks for ATP and for any other competitive inhibitors. The STD signals of non-competitive inhibitors are not affected by the addition of potent competitive inhibitors. In a fourth experiment, a paramagnetic probe can be used to determine the proximity from the ATP-binding site of non-competitive inhibitors. An MnATP probe is generated by the addition of Mn2+ ions to ATP [51]. The
M. CHERRY, J. READER AND D. WILLIAMS
25
use of the MnATP probe was demonstrated in an NMR-binding study of diarylamines to the serine/threonine kinase MEK1 (Map Erk kinase 1). The diarylamine, PD318088 is a non-ATP-competitive MEK1 inhibitor, known by X-ray crystallographic studies to bind proximally to the ATP in MEK1 [52]. NMR studies with a diarylamine analogue gave strong STD signals, indicating binding. However, these signals were not reduced by the addition of staurosporine suggesting non-competitive binding. The addition of an MnATP probe reduced the STD signals from the diarylamine compound, indicating that it was binding in close proximity to the ATP-binding site. Furthermore, proton signals on the two rings of the analogue were reduced to a different extent, allowing the orientation of the molecule to be deduced. ATP–STD NMR is described as a simple, cost-effective and robust assay that can be used to identify inhibitors of virtually any nucleotide-binding target.
NMR BACKBONE ASSIGNMENT OF A KINASE
The partial backbone assignment of the catalytic domain of protein kinase A (PKA) using a combination of NMR techniques was reported in 2004 [51]. This represented the first reported NMR assignment of any protein kinase catalytic domain. Backbone resonance assignment of the 42 kDa protein was achieved using a combination of triple-labelled (2H, 13C, 15N) protein with classical NMR assignment, back-calculation of chemical shifts from X-ray structures, the use of paramagnetic adenosine derivatives as spin-labels and selective amino acid labelling. PKA is not currently a drug target due to its broad spectrum activity and multiple physiological functions. However, it is considered to be a useful protein for studying other protein kinases [53]. Several X-ray structures of PKA, with and without bound inhibitors, have been published. The structure of the non-phosphorylated, inactive structure was, however, unknown. The authors were keen to emphasise the dynamic nature of proteins, particularly the conformational changes occurring upon activation, and upon binding of substrates and inhibitors, and point out that NMR is an ideal tool for studying motional processes by relaxation analysis. The authors expressed PKA consisting of 353 amino acids, of which eight are prolines. Resonances of 274 backbone amide peaks were visible in the spectrum, of which 191 were assigned. It was possible to assign resonances for the N- and C-terminal sequences, the majority of the N-lobe, including the glycine-rich loop, and most of the solvent-exposed residues of the C-lobe. This enabled a determination of the structure for the more flexible parts of the structure. However, many correlations were missing for the
26
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
more rigid parts of the protein, resulting in incomplete data sets. It was only possible to correlate relatively short stretches of the protein, making it difficult to match on the sequence. To circumvent this difficulty, the authors adopted a novel approach of predicting chemical shifts for the backbone and Cb from known structures [54]. The experimental data from a correlated stretch of amino acids from a known structure was found to provide sufficient information to allow matching to the novel structure. It was possible to unambiguously assign the amino acids near to the ATP-binding site by the use of paramagnetic spin-labelled adenosine (Figure 1.11), leading to a pure distance-dependent line broadening or disappearance for those signals within approximately 20 A˚ of the spin-labelled adenosine. Selective labelling of PKA with 15N-labelled Phe, Tyr, Leu, Asp, Ile and Val was carried out allowing more facile assignment of the peaks due to those residues. For example, it was possible to assign 19 out of the 20 resonances due to valine in the protein using this approach. 13C-labelled Tyr was used in conjunction with 15N-labelled Val allowing the identification of the only Tyr–Val sequence in PKA via a 2D HNCO spectrum. The authors were able to identify the Val-123 transverse relaxation optimised spectroscopy (TROSY) peak, which had no residual correlations in the 3D spectrum. By adding the known kinase inhibitor H7, it was possible to define the binding site by examination of the chemical shift perturbations and to map the interaction surfaces. This experiment confirmed the crystallographically determined position of the ligand [55]. An examination of mutant PKA proteins was undertaken. Phosphorylation of Thr-197 is required to activate PKA and phosphorylation of Ser-338 enhances stability of the protein. Replacement of Thr-197 and/or Ser-338 by Ala was examined to determine any conformational changes in the protein. Both single substitution mutants were expressed in Escherichia coli in similar levels to wild-type protein. However, both mutants were found to be less stable, as had been previously described. The double mutant O Me Me
NH N
N
O
Me Me
N
NH2
O HO
OH
N
N
Fig. 1.11 Structure of spin-labelled adenosine (1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate (5-aminoadenosine)-amide).
M. CHERRY, J. READER AND D. WILLIAMS
27
Thr-197-Ala/Ser-338-Ala could also be expressed but was highly unstable and aggregated readily. To investigate folding of the Thr-197-Ala and Ser-338-Ala mutants, the proteins were 15N-labelled and their TROSY–NMR spectra were recorded. The peak pattern for the Ser-338-Ala mutant closely matched that of the wild-type protein. However, the Thr197-Ala mutant showed significant differences in the peak patterns, thus indicating conformational changes in at least one region of the protein. The ability to assign a significant percentage of the NMR signals from a kinase catalytic domain is an important prerequisite for the study of the conformational changes that the kinase catalytic domain undergoes upon activation, phosphorylation events, ATP binding and inhibitor binding. These experiments also open up the possibility of using techniques such as SAR by NMR with kinases in the future, thus potentially allowing the screening by NMR of compound libraries, and the discovery of novel and selective inhibitors of kinases. DESIGNING NOVEL KINASE INHIBITORS FROM THE NMR-BASED SCREENING OF FRAGMENTS
The Abbott group describes a method in which an existing high-affinity ligand is divided into its constituent fragments and fragments suitable for replacement are identified. The binding affinity and pose of these fragments is then examined by analysing changes in 15N–1H HSQC spectra of the 15 N-labelled protein upon addition of the fragments. NMR-based screening is then used to identify new molecules that bind in the same way as the fragment to be replaced, but which are expected to have more favourable characteristics, for example, an improved protein kinase profile. This approach is depicted in Figure 1.12 below. The method was exemplified by the discovery of novel inhibitors of adenosine kinase (AK) [56]. Compound (1) (Figure 1.13) is a novel inhibitor of AK that has been demonstrated to have potent antinociceptive activity in animal pain models. However, the molecule has solubility and side-effect profiles that could be improved. One fragment deemed suitable for replacement was the bromophenyl moiety and so a suitable core molecule was required that would allow access to the binding site, but reduce undesired binding at other areas in the active site. Core structure (2) most closely resembles the original molecule. However, the proton at the 5th position could interfere with prospective groups binding at the bromophenyl subsite. The acetylene containing compound (4) had been found to be active against AK and was deemed to contain a better core, (5), for these studies. The subset of peaks that can serve as markers for the binding of replacements were identified by comparing the HSQC spectra of 15N–AK
28
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
(a) Summary of the fragment optimisation approach:
• The high affinity lead is divided into constituent (b)
fragments
• A replacement fragment is identified by NMR screening
• The newly identified fragment is incorporated
(c)
back into the original lead.
Fig. 1.12 Fragment optimization approach.
Br
N NH2
NH2 N
N N
N
N (1)
(4)
N
N
N
O
N O
Br NH2
N
NH2
(3)
(6) N
N
N
N
N (2)
N
(5)
N O
N
N O
Fig. 1.13 Adenosine kinase inhibitor designed using fragment optimization approach.
M. CHERRY, J. READER AND D. WILLIAMS
29
complexed to (1) versus (2) and 15N–AK complexed to (4) versus (5). A subset of peaks was observed to change allowing the identification of the binding site of the bromophenyl or pyridyl moieties. Furthermore, these same peaks were observed to move upon the addition of pryridine to a solution of AK and core (5), but no movement was observed on the addition of pyridine to a solution of AK in the presence of (1) or (4). More than 2,000 potential replacements for the bromophenyl or pyridyl groups were then screened using the NMR-screening technique. Several fragments were identified which caused chemical shift changes in the desired binding site of the protein, amongst them indole (7) and 2-phenylimidazole (8) (Figure 1.14). The KDs of the fragments were then measured and found to be 3 mM in both cases. The indole linker was then incorporated back into the original lead molecule via appropriately sized linkers to generate molecules (9) and (10) (Figure 1.15). These molecules were found to have IC50s of 23 and 10 nM, respectively, compared to the 1.7 nM IC50 for (1) in an in vitro cell-free enzyme assay. Compound (10) had good activity in a cell-based assay (IC50 ¼ 370 versus 51 nM for (1)) and demonstrated promising in vivo activity with an ED50 value of 3 mmol/kg in a carrageenan-induced thermal hyperalgesia assay, compared to 0.6 mmol/kg for (1).
H N
H N Ph
N (7)
(8)
Fig. 1.14 Fragments found to cause chemical shift changes in binding site.
NH2 HN
(CH2)n
N
N H N
(9) n = 1
N
(10) n = 2 N
N O
Fig. 1.15 Fragment optimized inhibitors.
30
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION DESIGN OF LIBRARIES FOR USE IN NMR SCREENING
The group at Vernalis describes an approach to selecting a Selection of Experimentally Exploitable Drug Startpoints (SEEDS) library for use in NMR screening [57]. The solubility requirements for the library members were defined as aqueous solubility >2 mM and solubility in DMSO of >200 mM for stock solutions. Stability of the fragments to storage and to the screening conditions in use was required. The size of the library struck a balance between chemical diversity, and the cost and practical considerations involved in handling and screening a large set of compounds. Finally, the compounds were required to contain a range of chemical functionality and to be amenable to further optimisation into drug-like candidates. The objective was to select a kinase-focused fragment library from the 1.62 M compound rCat database [58]. As the majority of known kinase inhibitors interact with at least one of the backbone carbonyls of one residue and/or the backbone NH and/or carbonyl of the residue at the +2-position, the principal constraint in the library design was to target at least one of these interactions. Combinations of pharmacophores were built by considering the conformation of hymenialdisine bound to CDK2 as shown in Figure 1.16. Each of the pharmacophore queries consisted of one donor, one acceptor and one of the two hydrophobic points indicated in Figure 1.16. The directionality of hydrogen bonds was inferred from the X-ray structure and reasonably loose tolerances of 1.5 A˚ were used for donor–acceptor distances and 2–2.5 A˚ to the hydrophobe were chosen to allow for the flexibility seen across kinase structures and to maximise the diversity amongst the identified fragments. Four pharmacophore queries were completed and the results were combined. The chosen fragments were further filtered by molecular weight (between 150 and 250), Slog P (between 2.5 and 2.5) and the presence of
H O
N O
H N
NH N
Br
NH2
Fig. 1.16 The interaction of hymenialdisine with the backbone of a kinase. Arrows mark the location and direction of hydrogen-bonding groups, the filled circles represent the hydrophobic features.
M. CHERRY, J. READER AND D. WILLIAMS
31
suitable functionality for subsequent optimisation. Compounds containing unwanted functionality such as halogens, disulphides, or bridged systems were then removed, yielding a set of 2,042 compounds. These were further analysed for diversity based on Tanimoto similarity and on a 2D, three-point pharmacophoric fingerprint method followed by an in silico solubility cut-off of 2 mM. The sets of compounds derived were pooled and inspected visually for chemical tractability, availability and cost. A total of 204 compounds were purchased, of which 174 passed QC tests. The hit-rate of the library in NMR screening was examined versus two ATP-binding proteins, heat shock protein 90 (HSP90) and cyclin-dependent kinase 2 (CDK2), and compared with other non-kinase-biased fragment libraries. A hit was generally defined as a fragment, which binds to the protein with an affinity of greater than 5 mM. The hit-rate for the kinasebiased library was found to be approximately 8.5% against CDK2, with the next best non-kinase-biased library having a hit-rate of slightly over 5%. Against HSP90, the kinase-biased library had a hit-rate of approximately 5%, with the best library having a hit-rate of 7%. Although HSP90 is an ATP-binding protein, its active site has a number of conserved water molecules that mediate interactions between the protein and active ligands. The lower activity of the kinase-biased fragment library against HSP90 compared to that for CDK2 is therefore expected. Many advances have been made in recent years in NMR instrumentation and in experimental methodology. The role and value of NMR screening has become firmly established, particularly as newer methods have a reduced requirement for protein quantity, allowing screening of fairly large compound libraries. As the capacity for screening increases, so the intelligent design of focused NMR libraries will become more important and can be expected to continually develop. Although this review has treated NMR and X-ray crystallography as two distinct methodologies, recent reviews have emphasized the synergies to be gained by combining the two techniques [59, 60].
IN SILICO METHODS Virtual screening is not a new technology, with database searching using structural fragments as queries introduced as early as the 1970s; there has since been many reviews highlighting developments [61–67]. Today in silico screening encompasses a variety of computational tools and utilizes a broad range of information to formulate a screen. Table 1.1 lists the most commonly used methodologies. At the broadest end of the spectrum, filters based on the calculation of physiochemical properties, the most obvious being the Lipinski’s rule of
32
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION Table 1.1 IN SILICO SCREENING TECHNOLOGIES
Method
Details
High throughput docking
In silico simulation of ligand binding and ranking of datasets using scoring functions Pharmacophore hypotheses generated from the 3D structure of the receptor Pharmacophore hypotheses generated from known inhibitors Quantitative Structure–Activity Relationship–statistical models that relate biological activity to features of a molecule Comparison of molecules using molecular descriptors and a measure of similarity, for example a 2D fingerprint and the Tanimoto coefficient Exact and substructure searching
Receptor-based pharmacophore Ligand-based pharmacophore QSAR models Similarity
Structure-based searching
5 [68] or Veber’s drug-like filter [69], are now routinely used in the selection of compounds from databases and in the design of new molecules. Structure-based, high throughput docking represents the opposite end of the spectrum, where compounds are ranked and selected using 3D information regarding the predicted binding of ligand to receptor. While generating more valuable target-specific information, high throughput docking has, in practice, hit upon similar issues to experimental high throughput screening in terms of speed and accuracy. A mix and match approach can, therefore, be adopted where techniques are used in succession, thus optimizing the speed and efficiency of subsequent steps in the form of a screening cascade. A cascade typically starts with a simple drug-like filter that requires no knowledge of the enzyme structure or of inhibitor compounds. The next step in a cascade is then to incorporate information specific to the target, i.e. protein kinases, whether it is ligand-based or receptor-based data. The present review focuses on structure-based methods, primarily concentrating on high throughput docking.
RECEPTOR-BASED SCREENING The abundance of crystallographic information on the 3D structure of protein kinases, including knowledge of receptor–ligand complexes, has seen protein kinases feature consistently in datasets employed to both develop and evaluate methods for receptor-based screening. Indeed, the vast majority of literature surrounding protein kinases and receptor-based in silico
M. CHERRY, J. READER AND D. WILLIAMS
33
screening concerns development and evaluation, only recently have examples emerged where receptor-based screening was used purely in application. Muegge and Enyedy [70] recently reviewed virtual screening for kinase targets, discussing the many pitfalls and areas of concern. Receptor-based virtual screening can be broken down into several distinct stages; compound database and receptor preparation, protein–ligand docking, post-docking analysis and finally compound prioritization. Recent developments have centred upon docking and scoring, but it should be stressed that each stage is crucial to overall performance and so an overview of each will now be presented.
COMPOUND DATABASE AND RECEPTOR PREPARATION
As stated above, an advantage of virtual screening is that any compound, real or virtual, can be screened and the user is not restricted to those compounds available in corporate or external collections. The technology can also be used to screen proposed libraries and even select monomers for a combinatorial library based on 3D fit to the target structure. The first stage in the preparation of the compound database is to standardize the representation of the compounds, remove additional fragments (for example salts) and fix the protonation state of ionisable groups. Docking tools do not, as yet, consider alternative stereochemistry or tautomerism and so it may also be necessary to enumerate the compounds accordingly. Filters can then be applied such as substructure searching, similarity-based methods, Quantitative Structure–Activity Relationship (QSAR) models and the drug-like filters discussed above. There are many tools available for these tasks and throughput is extremely rapid, easily handling several millions of compounds. These filters can also significantly reduce the size of a compound database as demonstrated by Baurin et al. [58] in the analysis of chemical databases from commercial suppliers. Twenty-three catalogues covering 2.3 M compounds underwent a series of filters based on 1D and 2D molecular descriptors including the Lipinski filter, the Veber filter, an aqueous solubility model and a permeability model. Of 1.6 million unique compounds only 37% passed all the filters, a significant saving in resource if screening such a dataset. Molecular recognition is a 3D event and most, if not all, docking tools call for the compounds in a suitable 3D format. For standalone docking tools there are several well-validated methods for 3D conversion [71]. Where a docking module is part of a suite of modelling tools, there is usually an associated 3D conversion utility. Most docking algorithms incorporate ligand flexibility. For those that do not, an additional stage of conformer
34
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
generation is required, a point discussed in greater detail below. Also, depending on the docking tool there may be other factors that need to be considered including geometric isomerism, ring flips, partial charge assignment and appropriate atomic configuration. The protein kinase model, whether derived from crystallographic data or generated using comparative modelling techniques, should undergo preparation appropriate for the choice of docking algorithm. The process begins with a general evaluation, refining any potential ambiguities in the model. Decisions need to be made regarding the protonation state of ionisable groups, tautomerism, side-chain rotamers, inclusion of water molecules and possibly how to incorporate protein flexibility. The importance of having a full understanding of the application and limitations of X-ray crystallographic data were reviewed by Davis et al. [72].
PROTEIN–LIGAND DOCKING
Protein–ligand docking can be further divided into two phases. First is the sampling of protein–ligand-binding space and second is the selection of the best scoring pose(s) from the sampling process. Both phases have been approached using a variety of methods; the most popular packages are listed in Table 1.2, together with the approach employed. Sampling of the pose space, considering all possible positions, orientations and conformations of a ligand in the protein-binding site, is crucial to the success of a method. Rigid docking programs, for example Fast Rigid Exhaustive Docking (FRED) [73], require a pre-computed conformational database containing an ensemble of conformers for each ligand; these conformers are then rigidly docked into the protein active site. Rigid docking
Table 1.2 HIGH THROUGHPUT DOCKING PROGRAMS Program
Strategy
Vendor
Website
GOLD
Genetic Optimisation of Ligand Docking Incremental build Grid-Based Ligand Docking with Energetics. Flexible, exhaustive docking employing a heuristic screening process Geometric matching of ligand to receptor Fast Rigid Exhaustive Docking
CCDC
www.ccdc.cam.ac.uk
Tripos Schrodinger
www.tripos.com www.schrodinger.com
UCSF
dock.compbio.ucsf.edu
OpenEye
www.eyesopen.com
FlexX GLIDE
DOCK FRED
M. CHERRY, J. READER AND D. WILLIAMS
35
benefits from advantages in speed and, once generated, the database is available for future experiments. Issues surrounding storage are less apparent with current computational resources and generating the conformational database using packages, such as Omega (OpenEye) [74, 75] and Catalyst (Accelrys), is extremely rapid. The protein environment can though favour ligand conformations that would otherwise be rejected by methods operating in the free state. McGann [76] calculated the root mean square deviation (RMSD) for conformers generated by Omega and those observed in protein–ligand complexes, and noted differences >1.5 A˚ for 2% of the ligands. The sampling, therefore, has to be exhaustive to ensure that the ensemble of conformers generated is relevant to the binding of ligand to protein. In addition to an exhaustive search of conformational space for each ligand, FRED (OpenEye) performs an exhaustive, systematic sampling of the position and orientation of each conformer in the active site. Poses are initially rejected based on steric overlap with the protein before ranking and selection, using one or more scoring functions. Grid-Based Ligand Docking with Energetics (GLIDE; Schrodinger) [77, 78] approximates a complete systematic search of the positional and orientational docking space, but incorporates ligand flexibility as part of the docking process. High throughput is attained by first performing a rough dock eliminating low-scoring poses. Surviving candidates are then subjected to an energy optimisation phase allowing full torsional freedom of the ligand before further refinement using Monte Carlo sampling. Monte Carlo and other computationally intensive methods are, at present, unfeasible for large scale screening, hence GLIDE’s approach to first reduce the dataset using a more approximate positioning and scoring phase. Monte Carlo, simulated annealing and molecular dynamics calculations have found use for smaller datasets and in the prediction of binding affinities [79–81]. A large percentage of the binding space sampled through an exhaustive search will be redundant. FRED and GLIDE attempt to circumvent the inefficiency of an exhaustive search by first performing a rough dock, reducing the dataset to a more manageable size for more detailed analysis. Alternatively, the docking phase can be site directed, only sampling binding space pertinent to the system of interest. For example, Dock (UCSF) employs a geometric matching algorithm to superimpose the ligand onto a negative image of the binding pocket. The receptor is represented using an unbiased grid of spheres that characterises the shape of the active site. Ligand atoms are matched to the spheres generating potential binding poses that are then scored using a shape and/or energy-based function. In Genetic Optimisation for Ligand Docking (GOLD; Cambridge Crystallographic Data Centre (CCDC)) [82], sampling is directed by hydrogen bond and hydrophobic fitting points. The position, orientation and conformation of
36
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
each pose form the chromosomes used in a genetic algorithm to select the best pose using either a force field-based or empirically derived scoring function. FRED, GLIDE and GOLD all consider the molecule as a whole. Alternatively, the molecule can be divided into fragments. FlexX (Tripos) [83] employs an incremental growth strategy. First, the molecule is split into fragments, a core fragment is then placed into the active site matching the fragment to interaction sites defined for the target enzyme. The molecule is then reconstructed using knowledge of the connectivity, a database of torsion angles taken from crystallographic studies, and further interactions between ligand and receptor.
SCORING FUNCTIONS
High throughput screening identifies inhibitors of the target enzyme by measuring the change in activity of the protein kinase in the presence of the chemical compound. For an ATP-competitive inhibitor, the stronger the affinity of the molecule for the enzyme-binding site the greater the inhibition. The ultimate goal of high throughput docking is to select inhibitors from the compound dataset through prediction of both binding mode and affinity. As discussed below, the prediction of binding modes has outpaced the prediction of binding affinities. Some success has been described in the use of more computationally intensive algorithms to predict binding affinities based on known experimental data [79–81]. At present, though, there is no fast and reliable method for predicting binding affinities. Considerable resource has therefore been devoted to the development of functions for scoring and ranking the large numbers of poses generated in virtual screening. There are three main types of scoring function; physical, empirical and knowledge-based. Physical, energy-based functions are cutdown versions of atomic forcefields, focusing on the calculation of the intermolecular component of the potential energy of the protein–ligand complex. In empirical functions, a model is generated from experimental observations of binding modes and affinities. Most models can be divided into terms that describe hydrogen bonding interactions, hydrophobic interactions, a ligand intramolecular strain energy and a desolvation term. Knowledge-based functions originate from the prediction of the tertiary structure of proteins. In docking, the functions are derived from a statistical analysis of known protein–ligand complexes. A pairwise potential of mean force is computed from the radial distribution function for each pair of atom types as observed in the protein–ligand complexes. Calculation of knowledge-based functions is fast and their development is facilitated by an ever
M. CHERRY, J. READER AND D. WILLIAMS
37
increasing number of protein–ligand complexes, as compared to the availability of the binding affinities required to derive empirical models.
DEVELOPMENT AND EVALUATION OF DOCKING AND SCORING
There are numerous studies evaluating the performance of docking methods and scoring functions, independently and in a variety of combinations. In most docking studies, the primary measure of success is the ability to reproduce the crystallographically observed binding modes of protein– ligand complexes. As the availability of data increases, studies are also investigating the prediction of binding affinities. A comparison is usually made to other tools typically DOCK, GOLD or FlexX. These commercially available packages have been tested extensively on a wide range of receptor systems and their performances have become the benchmark by which other methods are evaluated. The starting point for any study is the construction of a suitable dataset. GOLD was initially validated on a set of 100 protein–ligand complexes and then tested against an additional 34 complexes. The set has since been expanded to 305 complexes and is available for download from the CCDC website, www.ccdc.cam.ac.uk. This set of 305 complexes was constructed from publicly available complexes taken from the RCSB PDB www.pdb.org. A series of filters was used to select the entries from several thousand complexes available in the PDB. First, an assessment of the involvement of crystallographically related protein units in ligand binding and second, the identification of bad clashes between protein side chains and the ligand, and finally, a check for structural errors and/or inconsistency of ligand placement with crystal structure electron density. The set of 305 complexes contains 10 protein kinase–ligand structures. Similarly, FlexX was validated using a set of 19 protein–ligand complexes and more recently the performance of GLIDE was tested using a dataset of 282 co-crystallized PDB structures. As the primary objective of most docking evaluations is to reproduce the 3D structure of protein–ligand complexes, all that is required is a reliable high-resolution structure. The development of empirical scoring functions, however, requires knowledge of the structure and binding affinity. Roche et al. [84] have taken the concept a step further and compiled a universal world wide web accessible database, the Ligand–Protein DataBase (LPDB), that is specifically designed to facilitate the development and evaluation of empirical scoring functions. The set of 195 complexes corresponds to 51 proteins from 21 classes of receptor. Each complex is a high-resolution structure and has an associated binding affinity for use in the parameterization of empirical functions. In addition, each complex is characterized
38
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
by a set of 1D descriptors describing features of the protein, the ligand and the complex. The properties are commonly observed features in popular scoring functions and allow a statistical analysis of the functions in relation to the protein–ligand complexes. Likewise Wang et al. [85, 86] have sourced the PDB for high-resolution complexes, where binding affinity data were available in the primary reference. They applied a rigorous set of criteria to filter the entries resulting in a set of 1,600 complexes. Of these, 900 were selected to form a refined set of particular use for the development and evaluation of docking and scoring methods. These 900 entries have been organised into a web accessible database, PDBbind, available at www.pdbbind.org. Docking methods rarely perform well across a diverse range of protein–ligand complexes, scoring functions in particular tend to show a bias towards complexes dominated by either hydrogen bonding or hydrophobic interactions. A diverse dataset is essential to ensure a fair evaluation and will also provide a better understanding of the performance of a method towards different systems. Perola et al. [87], in a detailed comparison of current docking and scoring methods, emphasised the need to formulate a test set pertinent to subsequent investigations. Their comparison was based on a highly curated test set of pharmaceutically relevant protein–ligand complexes with known binding affinities. The dataset comprised a diverse set of proteins from multiple classes of interest to drug discovery. Ligands obeyed drug/lead-like rules and the complexes satisfied constraints on resolution (o3.0 A˚) and binding mode. The set included 43 kinase entries, from 12 proteins representing tyrosine, serine/threonine and nucleotide kinases, reflecting the importance of kinases in current discovery efforts and the abundance of structural data. A rigorous procedure was followed in the preparation of the complexes; interestingly tightly bound water molecules were maintained as part of the receptor structure. Earlier studies, in particular, removed water molecules without consideration, although this can have a negative impact, and evidence permitting water molecules should be considered as a feature of the receptor structure. Three programs were tested, GOLD, GLIDE and ICM (MolSoft) with respect to their ability to reproduce crystallographic binding modes, the RMSD (A˚) between predicted and observed pose was used as a measure of success. In internal coordinate mechanics (ICM), docking was performed using stochastic sampling, including pseudo Brownian moves, and energy minimisation of a fully flexible ligand in a rigid receptor. Energy calculations were based on the ECEPP/3 force field and took into consideration the intramolecular strain of the ligand and the intermolecular interaction of the complex. Of the top ranking poses, only 61% were within 2.0 A˚ for GLIDE, 48% for GOLD and 45% for ICM. GLIDE and GOLD, however, correctly sampled the
M. CHERRY, J. READER AND D. WILLIAMS
39
crystallographically observed pose in 79 and 77% of the complexes, respectively. The results highlight one of the main difficulties of docking, that of identifying where possible the correct pose from the sampling phase. GLIDE is thought to outperform GOLD in ranking the poses, as it refines the position of each pose prior to ranking using molecular mechanics-based energy minimisation. A theory supported by the improved performance of GOLD to a level equal to that of GLIDE when an additional step is taken minimising the poses generated through sampling. One rationale for such an improvement lies in the nature of the GOLD fitness function, where a soft repulsive term is used. Soft functions are one approach to accommodating the dynamic nature of the receptor [88], discussed in more detail below, but they also lead to mis-docked molecules and a higher number of false positives. Energy minimisation counteracts the inadequacies of the soft functions, but at the price of additional computational resource. Kontoyianni et al. [89] performed a similar evaluation of docking algorithms investigating the ability of five programs, FlexX, DOCK, GOLD, GLIDE and LigandFit (Accelrys) to reproduce experimental structures of 69 protein–ligand complexes. One of the purposes of the target selection, which included several CDK2 and fibroblast growth factor receptor-1 (FGFR-1) complexes, was to explore the ability of the programs to handle conformational variations in the same receptor. Up to 60 solutions per complex were generated and accuracy was assessed by a combination of visual inspection and calculated RMSD. Applying the subjective visual inspection GOLD correctly sampled the experimental pose for 47 of the 69 complexes, next best was GLIDE with 39 close predictions. Notably, as for the Perola study [87], the close predictions were rarely in the top ranking poses, for GOLD only 10 compared to 17 high-ranking solutions for GLIDE. The results confirm that algorithms are available that can sample the binding space and reproduce experimentally observed binding modes, but scoring and ranking the solutions is altogether a more difficult task. Several studies have separated these tasks and focused solely on gaining an understanding of the capabilities and failings of scoring functions. Perez and Otiz [90] looked in detail at two functions, a molecular mechanics function based on AMBER and a knowledge-based function potentials of mean force (PMF) [91]. First, an exhaustive rigid docking was performed using the experimentally observed ligand conformation. A 7D energy landscape was constructed from the docking energies and coverage error plots (CEPs) were used to quantify the behaviour of the functions. CEPs provide a description of the extent of error incurred in recovering a given percentage of good solutions as defined by the user. The test set comprised 17 types of protein, each receptor complexed with two different, but usually related, ligands. The authors found that the molecular
40
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
mechanics function had a small but significant advantage over the statistical function in reproducing the exact crystal structure, succeeding in 27 of the 34 cases. However, when cross-docking the alternate ligand in the receptor there was no difference in performance between the methods. Three categories of energy landscape were defined; one where the experimental solution existed in a funnel-shaped energy surface; a second, where alternate docking solutions of comparable energy existed; and a third, where the native like pose was not detected on the energy surface. There is an increased probability in finding correct solutions, where a funnel-shaped surface exists and little or no chance of success in the later scenario. Statistical analysis of the results suggested that sterics are critical for both types of potential, neglecting desolvation effects and poorly defined hydrogen bonding terms adversely impact on the molecular mechanics potential, whereas a more comprehensive treatment of dispersive forces may improve the performance of PMF. Similar results were found by Ferrera et al. [92] assessing nine different scoring functions on a set of 189 protein–ligand complexes. Recognition rates up to 80% were achieved when comparing mis-docked decoys to the native pose, performance though deteriorated when crossdecoys formed part of the test set. Steric complementarity was also seen as a more important factor than electrostatics in identifying a near native pose. In a comparative evaluation of 11 scoring functions, Wang et al. [93], in addition to standard RMSD analysis, tested the ability of each function to construct a funnel-shaped energy surface. The concept of funnel-shaped energy surfaces arose from the study of protein folding and Wang postulated that an ideal scoring function would describe the ligand-docking process in such a manner. An ensemble of binding poses was computed for 100 protein–ligand complexes from an exhaustive conformational search using Autodock (Scripps Research Institute). Success rates for correctly ranking the experimental pose within an RMSD of 2.0 A˚ ranged from 76% to as little as 26%. Again, broadening the success criteria and looking at lower ranking solutions increased the probability of observing the true binding mode, but obviously at the expense of increasing the number of false positives. Correlation between RMSD and score was used as an indication of funnel-shaped behaviour. Only one function (X-score) exhibited a significant level of such behaviour, with a correlation coefficient X0.6 for 53% of the complexes and most functions demonstrated rugged energy surfaces with minimal correlation. It is clear from these studies and others that methods have evolved capable of sampling the binding space of a receptor and reproducing experimentally observed structures of protein–ligand complexes. Scoring and ranking, on the other hand, is very much a hit and miss affair dependent on factors including the nature of receptor and ligand. How then do these
M. CHERRY, J. READER AND D. WILLIAMS
41
methods cope with the binding sites of protein kinases and what steps are being taken to improve the reliability of virtual screening? VIRTUAL SCREENING AND PROTEIN KINASES
In an unbiased, unconstrained attempt to find inhibitors of protein kinase B (PKB) (also known as AKT), Forino et al. [94] used FlexX to dock and rank 50,000 compounds into the crystal structure of a ternary complex (106 K) involving AMP–PNP (non-hydrolysable form of ATP). The top 2,000 compounds were then re-scored using CSCORE (Tripos), with the top 100 compounds as defined by Drugscore, the top 200 Goldscore compounds and the top 200 molecules according to Chemscore selected for testing. Only one active compound (11), Figure 1.17, was identified from the screen. The same compound was identified using GOLD when docking the top 4,000 compounds found using FlexX. Further evaluation of the top 4,000 compounds, selecting 200 common to both the Goldscore and Chemscore rankings and a visual inspection of the docked solutions, resulted in a further 100 compounds for biological testing. Of these, two additional micromolar inhibitors were found, also shown in Figure 1.16. A hit-rate of 3 in 50,000 may raise the question, have I missed anything? When presented with a set of hit compounds from an experimental high throughput screen, it is easy to forget that there will also be false negatives. PKB is recognised as a difficult target, indeed it was noted that an experimental strategy screening 270,000 compounds found only two inhibitors. For targets where chemical matter is O
Cl
Ph Me
Cl
N
O
NC
NH
O
H2N
(11)
CO2H
Me
N H CN
(12)
OH
O
O
CO2H
O (13)
Fig. 1.17 PKB inhibitors identified using in silico screening.
42
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
scarce, the complementarity of virtual and experimental techniques may yield better results. Bias, constraints and consensus scoring were employed by Lyne et al. [95] to identify nanomolar inhibitors of checkpoint kinase-1. A knowledge-based strategy involving a generic physical property filter, an undesirable chemical functionality filter and a 3D pharmacophore filter reduced a subset of the AstraZeneca collection to a set of 200,000 compounds for screening. A two point pharmacophore, based on the standard donor–acceptor pair motif observed in many protein kinase inhibitors, was employed. The pharmacophore biased the set towards those compounds capable of mimicking the interactions of adenine in the receptor, thus reducing the computational resource required for the screen. However, without additional directional and spatial constraints, the pharmacophore filter alone is insufficient in generating a target-biased compound set. Docking was performed using the program FlexX-Pharm (Tripos), which allows full flexibility in the ligand while the receptor is kept rigid. Constraints were applied eliminating those compounds that did not make hydrogen bond interactions with the backbone atoms of the linker region, further reinforcing the bias towards conventional protein kinase inhibitors. Constraints are a convenient mechanism for guiding the docking process and include pharmacophore (interaction)based constraints, distance-based constraints, substructure mapping and spatial constraints. Constraints need not be compulsory and partial matches can be defined. Applying constraints does increase the risk of missing a compound acting through an alternate, potentially novel mechanism. Here, two compulsory pharmacophore constraints were applied specifying the need for the ligand to interact through hydrogen bonds with Cys-87(NH) and Glu-85(C ¼ O) of the receptor. In previous protein kinase-docking experiments, the authors had noted a tendency for ligands to be docked in the more polar regions of the ATP-binding site, namely the phosphate groove and the ribose pocket. As the objective of the screen was to identify inhibitors targeting the adenine region of the ATP pocket, the constraints were thought necessary to reduce the occurrence of mis-docked and false positive compounds resulting from the deficiencies in the scoring function. For each ligand, up to 100 poses were saved and subsequently re-scored using a consensus-scoring scheme, an approach discussed in more detail below. Briefly, multiple scoring functions are used to score each of the poses generated from the docking simulation and only those compounds that score well for each of the functions are taken forward for further investigation. There are many functions available and, as stated above, their performance can vary hugely across different receptors. So which combination is best suited to the target of interest? Lyne et al. [95] used a consensus scheme derived from a previous study of Cdk2. A database of 8,000 compounds
M. CHERRY, J. READER AND D. WILLIAMS
43
containing 100 known Cdk2 inhibitors was screened and the top 300 poses for each ligand re-scored using the CSCORE module from Tripos. From an analysis of all possible function combinations, it was determined that a consensus of the FlexX and PMF functions gave the highest enrichment. The scheme was applied to the checkpoint kinase-1 poses and a score assigned to each ligand. The dataset was seeded with known checkpoint kinase-1 inhibitors and the consensus scores for these inhibitors were used as a cut-off for progressing compounds. The resulting 250 compounds were inspected visually to remove any unrealistic poses, leaving 103 compounds, which were tested in a checkpoint kinase-1 assay. Encouragingly, 36 compounds showed activity ranging from 110 nM to 68mM. Vangrevelinghe et al. [96] employed a similar approach to identify a potent and selective inhibitor of the protein kinase CK2 (caesin kinase 2). A subset of a 400,000 compound collection was selected using physical property filters and these compounds were then docked into a homology model of the human variant of CK2 using the program DOCK (UCSF). A previous systematic assessment of docking protocols indicated that the dock energy scoring function, in combination with an all atom model, should give the best possible results. Docking was constrained to the region surrounding the adenine-binding site of the ATP pocket. No other limitations were applied at the docking stage, instead a series of three post-processing treatments were used to filter the results. Compounds not forming a hydrogen bond with the linker region were removed using a pharmacophore style filter. The remaining compounds were then re-scored using an alternate function, with the top 1,592 compounds progressing to the final stage of visual inspection. From the visual inspection, 12 compounds were chosen for testing in a CK2 assay, four of which exhibited >50% inhibition at 10 mM. The indoloquinazoline compound in Figure 1.18 showed 97% inhibition at 10 mM with a resulting IC50 of 0.08 mM. The virtual screening experiment took nearly a month to complete, but with increases in computational power through parallelisation, more recent studies took
O NH N
CH2COOH
Fig. 1.18 Indoloquinazoline inhibitor of CK2.
44
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
less than a week. Short timescales are necessary if the approach is to establish itself as a complementary tool to experimental high throughput screening. The studies discussed above demonstrate the fact that virtual screening has already been successful in selecting subsets of databases for biological testing. Scoring functions, though, are not accurate enough to reliably discriminate active from inactive compounds and so measures, such as constraints, are incorporated into a docking protocol in order to improve the chance of success. There are other measures and methods that have been devised to facilitate the use of virtual screening, the more popular of which will now be discussed.
FAULTS AND FIXES FOR VIRTUAL SCREENING CONSENSUS SCORING
Consensus scoring is a method where molecules docked into a receptor are ranked and scored using two or more different functions, and the combined score used to re-rank the compounds. The method stems from the idea that a pose scoring well across different functions is more likely to be a true positive, rather than an artifact or bias of one particular function. Charifson et al. [97] demonstrated the concept of using intersection-based consensus approach, found to enhance the discriminative power of virtual screening compared to conventional scoring and ranking. They investigated two docking methods and 13 scoring functions, both individually and in combination, on a number of receptors including the MAPK p38. A random, drug-like set of 10,000 compounds (assumed to be inactive) was seeded with approximately 500 active compounds ranging in activity from low nanomolar to 30 mM. was docked into the receptor and the top scoring pose saved for re-scoring using the remaining 12 scoring functions. Enrichment rates, the percentage of active compounds found through screening plotted against the percentage of compounds that would need to be screened, were calculated for the scoring functions individually and for combinations involving up to four functions. Analysis was also broken down into activity bands. Three functions, Chemscore, PLP and DOCK performed well on an individual basis when considering the more active compounds, recovering 50% of the low nanomolar actives in the first 10% of the test set. Performance deteriorates for the less active compounds, with a considerable increase in the false positive rate. Taking the intersection of two of the three functions dramatically reduces the false positive rate and also decreases the total number of compounds that would need to be tested.
M. CHERRY, J. READER AND D. WILLIAMS
45
The intersection of two or more functions is a very simple consensus approach and a more rigorous statistical analysis may increase the robustness of any scoring scheme. Principal components analysis (PCA) was used in the derivation of a model to predict the bioactive conformation of matrix metalloproteinase (MMP) complexes [98]. Forty compounds were docked into three different receptors and the poses re-scored using eight different functions. Three of the functions were found to be of minor importance and their exclusion improved the quality of the model. When compared to a simple combination consensus scheme, the PCA model was found to select the bioactive pose more frequently for the MMP complexes. Performance was comparable on a set of 120 different receptor complexes, suggesting that consensus schemes could be optimised for different receptor families. It should also be noted that where one function performs extremely well, it is likely that the consensus scheme will see a decrease in performance. Without prior knowledge of inhibitors for a receptor it would be impossible to determine such behaviour and it is here that a scheme derived for a related enzyme, as noted in the Lyne study [95], would present the best option. Performance of a consensus scheme is also dependent upon how the top-scoring poses for re-scoring are selected and on any subsequent refinement of these poses. Ideally, each pose should be refined in a manner appropriate to the scoring function, as minor variations in pose can dramatically affect the score as noted in the investigations of energy landscapes. Indeed, simplex minimisation formed part of re-scoring for the three functions, Chemscore, PLP and DOCK score that performed well in the Charifson study [97]. Failing that, an exhaustive enumeration and scoring of the binding poses is required.
KNOWLEDGE-BASED SCREENING
Virtual screening tools are, in general, developed to cover a broad range of receptor types, although as noted previously, performance varies from system to system. What, then, can be learnt from the ever increasing number of protein kinase complexes and how can that information be used to improve the accuracy of virtual screening for protein kinase systems? Wu and Vieth [99] have developed an algorithm, SDOCKER, which can be applied to any system but relies on known protein–ligand complexes. The algorithm is based on a hybrid scoring function, combining force field energy with similarity to a predefined template bound to the receptor. CHARMm is used to calculate the force field component of the function evaluating the protein–ligand interaction energy and the ligand internal energy. The docking is then driven towards solutions where the shape of the ligand in the binding
46
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
site matches the shape of one or more template ligands. Parameters allow the contribution of each term to be varied, ranging from a similarity-based search through to a conventional force field-based docking experiment. The hybrid function resulted in a 10% improvement in the success rate of predicting the observed binding mode for 23 ligands bound to CDK2. In a more constrained methodology, Vieth and Cummins [100] derived a method for statistically determining the Docking Mode that is Consistent with a Structure-Activity Relationship (DoMCoSAR). The method is only applicable to compounds from the same chemical class having a common core substructure, for example a combinatorial library. Two docking runs are preformed, first an unconstrained dock and secondly a constrained dock superposing the core substructure onto the poses most commonly observed in the first run. A set of descriptors is then calculated based on the interaction of each pose with the receptor. The descriptors are used to generate a QSAR model aimed at reproducing the observed SAR. For a series of oxindole compounds docked into vascular endothelial growth factor (VEGF) receptor tyrosine kinase, 11 major binding modes were predicted from the unconstrained docking run. The two most popular modes were taken forward and used to re-dock the compounds. The approach was able to identify the binding mode consistent with crystallographic data of related enzymes, but failed to generate a reliable QSAR model. Chaqui et al. [101] used a measure of similarity to score and rank compounds docked using the program FlexX. The method calculates a fingerprint for each predicted binding mode and compares that structural interaction fingerprint (SIFt) to a precomputed set of SIFts derived from 93 protein kinase complexes [102]. The SIFts essentially encode the patterns of protein–ligand interactions. Docking solutions will exhibit an interaction pattern and when that pattern matches one of the known patterns (SIFts), the docking solution is scored and ranked more highly than those that exhibit alternative interaction profiles. The protein kinases p38 and CDK2 were used as test cases to compare three different post-processing strategies; scoring and ranking using conventional technologies, scoring and ranking using SIFts and a hybrid approach where poses are filtered using the SIFt and survivors ranked using a conventional scoring function. A considerable enhancement in the enrichment curves was observed for p38 using the SIFt scoring and ranking scheme. For CDK2 hybrid schemes using any of the functions PMF, Chemscore, DScore and GScore gave enrichments better than either the SIFt or scoring function alone. The difference in performance is attributed to the different gatekeeper residues in p38 (threonine) and CDK2 (phenylalanine). The gatekeeper residue is known to play an important role in the selectivity profile of protein kinases and will therefore constitute an important feature in the SIFts. It would appear that the
M. CHERRY, J. READER AND D. WILLIAMS
47
compounds docked into p38 share the ability to bind in the hydrophobic pocket and are readily identified from the fingerprint. Compounds inhibiting CDK2 bind in a more general ATP-competitive fashion, the SIFt can then eliminate alternative predictions, but the scoring function is required to discriminate between the remaining good predictions. One advantage of the SIFt scoring scheme is that it can be tailored to an individual target enzyme or the protein family as a whole. The method also provides a non-graphical, automated approach to classifying and comparing the binding modes of protein kinase inhibitors. Statistical analysis has been used in a number of studies to improve the performance of virtual screening. Vigers and Rizzi [103] employed a statistical correction factor to account for the inability of two docking tools, FlexX and GOLD, to match ligands to active sites for a series of complexes. Ligands from 15 different PDB complexes were docked into each of the 15 different receptors. Encouragingly, the 15 native structures were reproduced by both docking tools. However, in the cross-docking experiment, only three of the ligands were correctly identified as the top scoring compounds for that receptor. Certain compounds were found to score well across all the receptors, a result in the main attributed to bias in the scoring functions rather than true biological non-specificity. The authors noted that for GOLD and FlexX, a different set of ligands scored highly across all the receptors adding weight to the rationale that the promiscuity is a reflection of bias in the scoring function. An alternative scoring scheme was constructed, called multiple active site correction (MASC), based on the mean and standard deviation of the scores for each compound across all 15 receptors. The new scoring scheme increased the discriminative power of both docking tools significantly, correctly identifying 11 of the 15 ligands. In any statistical analysis, the question of validation arises. Vigers, therefore, tested the method on an additional 63 complexes taken from the GOLD test set. Results were not as good for the test set but the MASC score still showed a significant advantage over uncorrected scores. It was also found that the number of receptors required in the MASC correction factor could be reduced from the original 15 to 7 and the best results were obtained when the MASC receptors were diverse in nature. A machine-learning method was proposed by Klon et al. [104] as an alternative form of consensus scoring. The method proved unsuccessful for PKB, but showed promise for the phosphatase PTP1B (protein tyrosine phosphatase 1B). In this approach, compounds were first docked into the receptor and scored using conventional means. The top scoring compounds were then assumed to be active and used to build a naı¨ ve Bayes classification model, all compounds were subsequently re-scored and ranked using the model. The method is heavily dependent upon predicting accurate binding
48
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
modes in the docking phase and the results for PKB appeared to be negatively affected by the presence of manganese ions in the receptor site during the docking. All the high scoring compounds for PKB were false positives found to interact with the metal ions. The classification model would then only find similar false-positive compounds. The work does illustrate how preparation is key to achieving good results and it would be interesting to see if the approach improved enrichment using an alternative model without the metal ions.
PROTEIN FLEXIBILITY AND INDUCED FIT
Preparation of the enzyme model is obviously a significant factor in obtaining accurate and reliable results from structure-based design. The evaluations discussed above have highlighted how minor changes can dramatically change results. McGovern and Shoichet [105] investigated the variation in results for virtual screening when using holo, apo and modelled conformations for 10 different enzymes. No protein kinases were included, but the lessons learned are applicable. The MDC drug data report (MDDR) database was prepared and docked into the 30 models, in the knowledge that up to 1% of the database was known to be active against each target. Enrichment factors calculated for the docking experiments showed that for seven of the targets, the holo model gave the highest enrichment, for two the apo model performed best and, finally, one homology model achieved the highest enrichment. Unsurprisingly, the holo models performed best where the active compounds in the database resembled the ligands complexed in the crystal structures, but faired worst when the compounds differed considerably. All of the experiments, though, provided some level of enrichment compared to random screening. How then can virtual screening and structure-based design cope with the conformational changes observed in enzyme structures and factors such as induced fit? Two methods, soft docking and multiple receptor conformations, are compared by Ferrari et al. [106] for their ability to select active compounds from a set of decoys. In soft docking, the steepness of the repulsive term for the scoring function is reduced, allowing greater overlap between the ligand atoms with the receptor. Here the standard 12-6 Lennard–Jones potential was substituted by a more permissive 9-6 potential. Soft functions have the advantage that they incur no additional cost in computational resource to compute, but can only cope with what would be relatively minor conformational changes in the receptor. Multiple receptor conformations involves using two or more structures either experimental or computationally generated and docking the compounds into each. Obviously, the computational
M. CHERRY, J. READER AND D. WILLIAMS
49
resource for multiple receptor conformations scales linearly with the number of docking models, but has the advantage of no limit on the conformational change that can be modelled. An increase in enrichment was found for both methods, on average a 10% improvement for soft docking and 17% for multiple receptor models. Also, as the approach using multiple receptor models allows for greater movement, a wider range of inhibitors was identified compared to soft docking. For protein kinases, the multiple receptor approach would allow the user to screen against models ranging from the inactive through to the active conformation. In theory it would reduce the number of false negatives, but in practice would no doubt lead to more false-positive compounds. Barril and Morley [107] studied the use of multiple receptor models for the protein kinase CDK2. The test set comprised 49 X-ray structures exhibiting reorganisation of side chain atoms, backbone atoms and a variation in the hydration state of the enzyme with respect to the bound ligand. An inhouse docking programme, rDock, was used to independently dock a set of known inhibitors into each receptor model. The method was assessed for its ability to predict binding modes (within an RMSD of 2.0 A˚) for the ligands extracted from the X-ray structures and enrich virtual screening amidst a random set of 1,000 compounds. Two tests were performed to investigate the prediction of binding modes. First, the experimental binding mode was used as a starting point for energy minimisation using the docking function and second, docking from a random starting position. The first test determined whether the experimental pose was close to a minimum in the energy landscape for the docking function. The docking experiment determines whether the experimentally observed pose is the global minimum as defined by the docking function. The performance of the different receptor models varied significantly, ranging from 29 to 100% (average 78%) for the minimisation experiment and from 3 to 68% (average 33%) for the docking runs. The results verify that conformational variations do affect performance and that docking functions have great difficulty in discriminating the true biological pose from alternate solutions. Taking the best scoring pose predicted for each model and combining the results was found to improve performance for the docking experiment. Randomly selecting a model, the average performance for predicting the bioactive conformation was 33%. Using all the models improved the performance to 76%, though it was observed that the optimum gain occurred using 10 models after which there was a diminishing return on performance. Apart from the increased expense on computational resource, several limitations were noted for the method. In the multiple receptor method, the internal energy of the receptor was not accounted for due to uncertainties and errors in making the calculations. The docking scores were then dependent purely on the internal energy of the
50
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
ligand and the interaction between protein and ligand. In practice, the free energy of binding incorporates the internal energy of the receptor, which is dependent on a number of factors including conformation. Another source of error lay in the choice of receptor models, as the selection sometimes had a detrimental effect on the results. A simple example would involve a model conformation, perhaps as a result of induced fit, that excluded the standard ATP-competitive mechanism of inhibition observed for many protein kinase inhibitors. Multiple receptor models can then increase the ability to predict binding poses, but how does it affect enrichment in virtual screening? On average, for CDK2 no advantage was observed when using two or more receptor models to screen a database. Any advantages gained in identifying inhibitors were offset by the inadequacies of the scoring functions, resulting in an equivalent increase in the number of false positives. A similar study investigating protein flexibility in virtual screening did report an overall improvement in enrichment for a series of protein kinases, where results from multiple models are combined using a merge and shrink procedure [108]. In the first phase of the study, 1,000 compounds seeded with co-crystallised kinase inhibitors were docked into four protein kinases cAPK, CDK2, p38 and LCK using the ICM flexible-ligand rigid receptordocking programme. For the 29 structures, all the native ligands were docked with an RMSD o1.5 A˚. As expected, cross docking the native ligands showed a decrease in success with only 70% of the ligands correctly docked. In terms of enrichment, 80% of the known inhibitors were identified in the top 1.5% of the library. The cross-docking results were then combined by extracting the top scoring result for each compound and eliminating all others. Enrichment factors using the reduced dataset showed a 1.8570.65-fold increase. For the enzymes studied here multiple crystal structures are available. This obviously is not always the case. A method, IFREDA, is reported in the study for computationally generating conformers pertinent to the holo protein. Essentially, known inhibitors are docked into the enzyme and then the resulting complex undergoes a global energy minimisation allowing both side chain and backbone atoms to move. Using the computationally generated models, rather than the X-ray structures, was found to give a comparable level of enrichment.
HIGH THROUGHPUT DOCKING AS A VIRTUAL SCREENING TOOL
It is clear from the studies discussed above that there is no universal solution to high throughput docking and methods should be tailored to the target of interest and according to what is expected from the docking experiment. Constraints, consensus scoring, knowledge-based processing and
M. CHERRY, J. READER AND D. WILLIAMS
51
the incorporation of flexibility are all approaches aimed at improving the performance of virtual screening using high throughput docking. Pre- and post-processing are very important aspects of the experiment with the concept of a screening cascade already mentioned. There are also other approaches to searching compound databases for protein kinase inhibitors either as part of a cascade or as stand-alone tools.
ALTERNATIVES TO HIGH THROUGHPUT DOCKING Despite the ever-increasing number of protein kinase crystal structures available in the public domain, still only a small percentage (o10%) of the human kinome is represented. Homology modelling is discussed below as a route to generating a 3D structure of a protein kinase, where a crystal structure is unknown. There are, however, numerous well-tested methods for screening that rely on information regarding known inhibitors of the target protein as an alternative to the receptor structure. There are many reviews discussing the methodologies of ligand-based virtual screening [109–111] and so only examples, where protein kinases are the focuses of attention are presented here. The most popular methods for ligand-based virtual screening can be classified as substructure searching, similarity-based methods, QSAR modelling and pharmacophore methods. Each method requires that the molecules are characterised using a set of descriptors that are generally calculated computationally. Many descriptors have been proposed based on 1D, 2D and 3D characteristics of the molecules. 3D descriptors can be subdivided into those that are dependent on special alignment and those that are independent of the coordinate space. Pirard and Pickett [112] compared the ability of BCUTs, a 2D fingerprint and multi-pharmacophore descriptors, to classify EGFR tyrosine kinase inhibitors. BCUTs are derived from molecular graphs and have been developed to describe the bonding patterns and properties of molecules pertinent to ligand–receptor interactions including charges, polarizabilities, H-bond characteristics and surface areas. First BCUTs were calculated for a total of 770 inhibitors from five different protein kinases. The first six principal components (PCs) from a PC analysis could, for the most part, discriminate between inhibitors of the different enzymes, though overlap was found between p38 and spleen tyrosine kinase (SYK) inhibitors. Clustering using the first six PCs verified the relative separation of the different inhibitor sets. A success rate greater than 70% was obtained for all enzymes except Cdk1, in classifying the inhibitors using a five-component partial least squares discriminate analysis model (PLS DA) . On a separate test set of 52 endothelial growth factor receptor tyrosine
52
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
kinase (EGFR TK) inhibitors, the partial least squares discriminant analysis (PLS DA) model successfully classified 48 compounds. How then did the performance of the BCUTs compare to the Daylight fingerprint and the pharmacophore analysis? The success rate in classifying the 52 novel EGFR inhibitors was low for the Daylight fingerprint, whereas the multipharmacophore analysis gave comparable classification rates to the BCUTs. The BCUTs are thought to encode more information than the 2D descriptors and are also fast to calculate, not requiring the generation of 3D databases. One downside of BCUTs is in interpretation, as for many descriptors it is not easy to place a chemical rationale behind the classification of compounds. Methods such as pharmacophore models and 3D comparative molecular field analysis (COMFA) [113] require the generation and superposition of 3D representations of molecules. Putta et al. [114] have formulated an algorithm for efficiently mining the 3D conformational space of compounds and finding alignments likely to be biologically relevant. Molecules are first superposed using subshape matching, which allows the alignment of multiple conformers of each molecule and the matching of different sized molecules. Feature maps are used to score the alignment where a high score would result from the close overlay of many, equivalent features in an alignment; typical features being hydrophobic centres and hydrogen bonding groups. The matching algorithm was validated using a set of CDK2 compounds, comparing predicted conformations of each ligand with the crystallographic observations. One of the alignments closely matched the observed binding modes, correctly identifying the standard donor–acceptor sites of interaction. The method was also able to map out other regions of the ATP-binding site, though some error was noted with regard to functionality lying near solvent space. The program CATALYST (Accelrys) generates pharmacophore models based on the superposition of inhibitors molecules. Bhattacharjee et al. [115] used CATALYST to build 3D QSAR pharmacophore models capable of identifying inhibitors of the cyclindependent kinase Pfmrk. The models were constructed by overlaying 15 structurally diverse kinase inhibitors having a range of activities. A model comprising two hydrogen bond acceptor points, an aliphatic and an aromatic pharmacophore point gave a correlation of 0.9 for the training set when calculating the activities. Cross validation using an additional 15 compounds saw a reduction in the correlation to 0.7. A further test was performed using the model to select potential inhibitors from a database of 29,000 compounds. Steric factors for the binding site were introduced through a shape-based restriction on the compounds. There are several methods for restricting the molecules in a pharmacophore screen based on sterics. Exclusion volumes prohibit any atom in the specified volume of
M. CHERRY, J. READER AND D. WILLIAMS
53
space, inclusion volumes state that one atom must occupy the specified space and shape constraints state that all the atoms must fall within the defined volume. The pharmacophore screen helped to generate a shortlist of 16 compounds subsequently found to have an IC50 o25 mM. COMPARATIVE HOMOLOGY MODELLING Of the 517 protein kinases in the human kinome [116], structures are publicly available for o10% of the different enzymes. In the absence of experimental data, construction of homology models based on known structures has proven a reliable method for generating 3D information. How, then, are the models built and what are the limitations of the models especially as applied to the family of protein kinases? There are several stages to the construction of the homology model, probably the most crucial being the identification of a suitable template (or templates) and the alignment of the sequences. Template recognition is usually undertaken with programs like FASTA or BLAST, methods readily capable of identifying templates having a sequence identity >25%. Confidence in any model falls rapidly as sequence identity falls below 25% and will at best lead to an approximate reproduction of the tertiary structure. At the opposite end of the scale, errors in models built using templates where the identity >90% can be as low as the errors in the experimental crystallographic structure. Within the family of protein kinases, homology across the subfamilies generally lies in the region 25–35% ID. Homology of the residues defining the ATP-binding site is higher, as there are clusters of conserved residues that are involved in the catalytic mechanism of the enzymes. At this point, it is important to assess the template(s) that have been identified considering, among other things, the quality of the data; the activation state of the kinase structure and ligand induced conformational changes. Following the selection of one or more templates, a detailed alignment is performed based on maximising a scorings or exchange matrix and more often than not involving manual correction. A model can now be constructed, first building the backbone, then the loop regions and finally adding the side chains. There are many programs available for building homology models. Most, if not all, also incorporate the means to evaluate and refine the model after it has been constructed. Further details of the methods are presented at the CMBI website (www.cmbi.ru.nl/gvteach/ hommod/index). There are very few reported studies outlining the use of homology modelling in protein kinases. Panigrahi and Desiraju [117] performed a simple comparison of a model of the EGFR kinase domain to an experimental
54
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
X-ray structure, citing a C-a RMSD of 1.96 A˚. McGovern and Shoichet [15] came to a number of conclusions, stating that the performance of the docking experiment is affected by the particular representation of the receptor. Perhaps, the most telling remark is that the majority of the structures including the models gave some degree of enrichment compared to random screening. Diller and Li [118] have also assessed the use of homology models in high throughput docking. Models for six protein kinases (PDGFRb, VEGFR1, EGFR, p38, SRC and FGFR-1) were built from a variety of templates using the Modeler package (Accelrys). A database of 32,000 compounds seeded with known inhibitors for each kinase was then docked into each model using the program LibDock (Accelrys) and scored with the Piecewise Linear Potential 2 (PLP2) function. A solvation term was added to the function to correct for any correlation between score and size for the molecules, a consequence of the function being based on interaction counts. Enrichment factors were calculated for each simulation and the models were also assessed for their ability to discriminate between the inhibitors, a key point of concern when building a model based on an alternative enzyme. Crystallographic data are available for four of the enzymes, allowing for a direct comparison of the docking results between experimental and computergenerated structures. The homology model of EGFR was compared to the apo crystal structure of EGFR (1M14) and achieved similar enrichment factors versus the random compounds of 4–5 and 5–6, respectively. The model for p38 performed poorly, enrichments of 1.5–2.6, compared to the crystal structure, enrichments of 7–11, mainly attributed to the fact that the crystal structure used (1A9U) is a complex containing the well-known pyridinyl-imidazole inhibitors. The situation was reversed for Src kinase, where the model achieved higher enrichments than the crystal structure. The model was based on an apo form of the related enzyme lymphocyte-specific kinase Lck, sequence identity of 66%, whereas the crystal structure was solved from protein crystals initially seeded with the ATP analogue AMP–PNP. Structures complexed with ATP or alike adopt a more closed binding site, thereby restricting access to larger ligands. For FGFR-1, neither the model nor the crystal structure performed well, again a consequence of induced fit. A second more open model built using an apo template structure faired better. The results can be summarised as follows; the variation in conformation between a model and X-ray structure can be no more than that observed between the different forms of a single protein kinase. Success is very much dependent on the conformation of the template structure and the end objective of the model. If screening for novel chemotypes, an open apo template provides the best starting point, though this will no doubt lead to an increase in false positives.
M. CHERRY, J. READER AND D. WILLIAMS
55
Virtual screening formed the basis of comparison for Oshiro et al. [119] looking at enrichment factors of homology models of CDK2 versus X-ray data. MOE (Chemical Computing Group) was used to build four models of CDK2 based on templates ranging in sequence identity (ATP site residues only) from 43 to 60%. A set of 17,000 compounds containing 367 actives from 15 different scaffolds was then docked into the X-ray structure and each of the models. Compounds were docked, scored and ranked using the DOCK program. All of the screening experiments exhibited enrichment compared to random screening, with models constructed from templates greater than 50% identity consistently achieving enrichment factors equivalent to using the crystallographic structure. Fifty per cent identity was noted as a threshold value above which the C-a RMSD of model versus crystal structure was found to be, on average, of the same order as the error in the X-ray data, roughly 2 A˚, hence the comparable performance in the docking experiments. Enrichment values decreased to a 2-fold low as the sequence identity of the model templates decreased. The study further reinforces the value of homology models where crystallographic data are unavailable, provided due care and attention is paid to the generation of the model, in particular the choice of template. In an ideal scenario, crystallographic data would form part of the hit verification process, but, as noted in many of the studies discussed in this review, it is rarely the case. Selectivity is also an issue of many of the medicinal chemistry programmes, where homology modelling could play a vital role in providing comparisons between the structures of different enzymes. Homology modelling provides a rapid and cheap alternative to the significant investment required for protein crystallography. This, coupled with the fact that not all protein kinases are amenable to crystallography, means that there will always be a need to generate 3D information using alternative methods. The uncertainties of using the homology model are then often outweighed by the desire to have a degree of structural insight into the development of hit compounds.
DE NOVO DESIGN Both X-ray crystallographic and NMR methods have been discussed as approaches to finding lead compounds starting with the discovery of lower molecular weight fragments or templates. Computational de novo design methods have been in existence for some time, with the two main approaches mirroring the experimental fragment evolution and fragment linking strategies discussed by Rees et al. [120]. Fragment evolution, also referred to as seed and grow, involves docking a set of small fragments or
56
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
templates into the active site and expanding upon the hit fragments to yield a more potent lead-like compound. Fragment linking entails joining together multiple fragment hits that are sited in proximal regions of the binding site. Initial attempts at de novo design met with limited success, as deficiencies in the methods, for example the chemical intractability of proposed compounds, limited the effectiveness of the approach. More recently, with a greater understanding of the components that constitute most drug molecules, more chemically aware strategies have evolved. Schneider et al. [121] compiled a set of 25,000 building blocks through retro-synthetic fragmentation of 36,000 known drugs. Fragmentation involved a series of chemically intelligent rules for breaking down the known drugs in a manner amenable to subsequent re-linking as part of the de novo design strategy. A ligand focused evolutionary design algorithm, TOPAS, constructs molecules from the building blocks that are similar to known inhibitors, defined by either a 2D fingerprint or 2D topological pharmacophore description of the molecules. The program Skelgen (DeNovo Design), developed by Dean and co-workers, pieces together molecules within the confines of an active site taking into account physio-chemical properties such as hydrogen-bonding, lipophilicity, electrostatic and steric parameters. The fragments that are pieced together in a dock and link approach are derived from the World Drug Index. In an investigation focused on protein kinases, Hare et al. [122] reviewed the binding modes of known kinase inhibitors extracting common molecular frameworks for guiding the generation of protein–ligand complexes. The frameworks are used as constraints in an automated docking procedure, significantly increasing the accuracy of docking and reducing the time required. Aronov and Bemis [123], in a related study, developed a novel methodology that integrates fragment-based design with virtual screening techniques. Using a previous analysis of the frameworks [45] and side chains [46] of known drugs, a set of 119 kinase inhibitors was fragmented into rings and linkers. Fragments frequently observed to form key interactions with the linker region of the enzymes were designated as scaffolds, four ring systems and eight linkers formed the remainder of the fragment set. A virtual library was constructed through an exhaustive enumeration adding the rings and linkers to the scaffold templates. The library was then docked into a test set of protein kinases comprised of Bcr–Abl (Abelson kinase), Cdk2 and tyrosine kinase Src using a constrained docking process matching the scaffold fragments to observed poses from crystallographic data. The use of experimental X-ray data to guide the docking significantly reduced the falsepositive rates associated with free docking experiments. The method, termed a minimalist approach to scaffold library design, is geared towards optimising the affinity and selectivity of ligand–receptor interactions. Knowledge
M. CHERRY, J. READER AND D. WILLIAMS
57
of the interactions important to each receptor can then be extended to more novel compounds, either through adding diversity to the building blocks or more radically, designing new scaffolds. Four classes of Cdk4 inhibitor were identified by Honma et al. [124] employing the use of the homology model and a de novo design strategy. A model of Cdk4 was constructed from a crystal structure of the active form of the related enzyme Cdk2. An analysis of the ATP site and the binding of several different Cdk2 inhibitors identified a number of residues conserved in Cdk4 important to the development of small molecule inhibitors. An in-house atomistic de novo design program LEGEND identified a large number of proposed inhibitors based on the analysis of the active site of Cdk4. However, initial propositions were found to be synthetically unfeasible, a shortcoming noted previously for chemically ignorant sequential construction algorithms. Therefore an additional step comparing the core fragment of each suggested compound to known structures was introduced to ensure chemical tractability. The overall process is as follows; first, key interaction points in the enzyme are identified, a sequential growth algorithm then adds atoms in a complementary fashion to meet predefined growth criteria, finally the key components of the proposed molecule form the queries to search commercial databases. Eighteen low potency (micromolar) hits were identified from an in vitro assay after screening 382 commercially available compounds proposed by the de novo design strategy. An informer library, a target-guided library designed to probe the features of the binding site, was synthesised for one class of hit, a series of diarylurea compounds. The library yielded a 100 nM compound which was further investigated using a more detailed docking analysis taking into account the SAR derived from the library. Additional gains in potency and optimisation of the physio-chemical characteristics resulted in several low nano-molar compounds, one of which was soaked into a crystal of Cdk2 (see Figure 1.19). The predicted binding mode was in close agreement with the observed binding mode for these compounds.
O N
HN N H
O
Fig. 1.19 Inhibitor of Cdk4 designed using de novo methods.
58
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Honma et al. [125] extended their investigation of the Cdk4 inhibitors by designing libraries to interact with residues in the binding site. An analysis of the binding mode of the lead compound, determined crystallographically, identified potential sites of substitution and the scope for substituents at each point. Two de novo programs, LUDI (Accelrys) and LEAPFROG, suggested possible additions to the scaffold based on optimising interactions with the enzyme, synthetically accessible additions were then chosen that mimicked these suggestions. The site analysis also included a comparison of the Cdk4 sequence versus other protein kinases, providing a guide to developing more selective compounds. In particular non-conserved residues in Cdk1/2 were targeted, increasing the selectivity of the inhibitors against these enzymes 100-fold. Target-focused libraries are an important application of de novo design tools, as they provide one possible resolution to the difficulties in predicting binding affinities and effects such as induced fit. Knowledge of the structure, coupled with a known scaffold, allows for an efficient exploration of the binding site mapping out key interactions and also investigating the conformational changes. Careful selection of reagents used in the library design also ensures that what is suggested computationally has a greater chance of success in the laboratory.
SUMMARY Hit identification is a crucially important stage gate in the drug discovery process. As the development candidate that emerges from pre-clinical research invariably resembles the initial hit, it is important to make as wellinformed a choice as possible when selecting which hits to progress and which to shelve. Decisions made during the hit identification process determine the chemistry direction in which a project proceeds, usually taking into account the potency of the hit, any SAR generated during the hitfinding exercise, the potential scope for generating novel and patentable chemical matter, and the synthetic tractability of the series. Over the last decade, a huge amount of financial and intellectual investment has been made in HTS to identify compounds with low micromolar IC50s, leading to major advances in combinatorial chemistry, high throughput analysis and purification, and compound handling and storage. HTS is constantly improving as the processes are refined and compound collections are improved, but overall results have been disappointing. Recently, structure-guided approaches have been used much more frequently at the hit-finding stage of drug discovery and, as this review seeks to demonstrate, these approaches have had a major impact on a number of kinase targets. The closer integration of these tools, combined with ongoing
M. CHERRY, J. READER AND D. WILLIAMS
59
technological advances in computational chemistry, X-ray crystallography and NMR spectroscopy will inevitably lead to an even greater use of structural techniques for hit generation to complement or replace HTS.
REFERENCES [1] Parang, K. and Sun, G. (2004) Curr. Opin. Drug Discov. Devel. 7, 617–629. [2] Gill, A. (2004) Mini Rev. Med. Chem. 4, 301–311. [3] Knighton, D.R., Zheng, J.H., Eyck, L.F.T., Ashford, V.A., Xuong, N.H., Taylor, S.S. and Sowadski, J.M. (1991) Science (Washington DC) 253, 407. [4] Petsko, G.A. (1975) J. Mol. Biol. 96, 381–392. [5] Muchmore, S.W., Olson, J., Jones, R., Pan, J., Blum, M., Greer, J., Merrick, S.M., Magdalinos, P. and Nienaber, V.L. (2000) Struct. Fold Des. 8, R243–R246. [6] Stewart, L., Clark, R. and Behnke, C. (2002) Drug Discov. Today 7, 187–196. [7] Sharff, A. and Jhoti, H. (2003) Curr. Opin. Chem. Biol. 7, 340–345. [8] Card, G.L., Blasdel, L., England, B.P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P.N., Artis, D.R., Bollag, G., Milburn, M.V., Kim, S.H., Schlessinger, J. and Zhang, K.Y. (2005) Nat. Biotechnol. 23, 201–207. [9] Broach, J.R. and Thorner, J. (1996) Nature (London) 384(Suppl.), 14–16. [10] Nienaber, V.L., Richardson, P.L., Klighofer, V., Bouska, J.J., Giranda, V.L. and Greer, J. (2000) Nat. Biotechnol. 18, 1105–1108. [11] Boehm, H.J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N. and Mueller, F. (2000) J. Med. Chem. 43, 2664–2674. [12] Carr, R. and Jhoti, H. (2002) Drug Discov. Today 7, 522–527. [13] Hann, M.M., Leach, A.R. and Harper, G. (2001) J. Chem. Inf. Comput. Sci. 41, 856–864. [14] McGovern, S.L., Caselli, E., Grigorieff, N. and Shoichet, B.K. (2002) J. Med. Chem. 45, 1712–1722. [15] McGovern, S.L. and Shoichet, B.K. (2003) J. Med. Chem. 46, 1478–1483. [16] Ryan, A.J., Gray, N.M., Lowe, P.N. and Chung, C.W. (2003) J. Med. Chem. 46, 3448–3451. [17] McGovern, S.L., Helfand, B.T., Feng, B. and Shoichet, B.K. (2003) J. Med. Chem. 46, 4265–4272. [18] Erlanson, D.A., Braisted, A.C., Raphael, D.R., Randal, M., Stroud, R.M., Gordon, E.M. and Wells, J.A. (2000) Proc. Natl. Acad. Sci. USA 97, 9367–9372. [19] Fry, D.W., Bridges, A.J., Denny, W.A., Doherty, A., Greis, K.D., Hicks, J.L., Hook, K.E., Keller, P.R., Leopold, W.R., Loo, J.A., McNamara, D.J., Nelson, J.M., Sherwood, V., Smaill, J.B., Trumpp-Kallmeyer, S. and Dobrusin, E.M. (1998) Proc. Natl. Acad. Sci. USA 95, 12022–12027. [20] Singh, J., Dobrusin, E.M., Fry, D.W., Haske, T., Whitty, A. and McNamara, D.J. (1997) J. Med. Chem. 40, 1130–1135. [21] Mattos, C. and Ringe, D. (1996) Nat. Biotechnol. 14, 595–599. [22] Shuker, S.B., Hajduk, P.J., Meadows, R.P. and Fesik, S.W. (1996) Science (Washington DC) 274, 1531–1534. [23] Szczepankiewicz, B.G., Liu, G., Hajduk, P.J., Abad-Zapatero, C., Pei, Z., Xin, Z., Lubben, T.H., Trevillyan, J.M., Stashko, M.A., Ballaron, S.J., Liang, H., Huang, F.,
60
[24]
[25]
[26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50]
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Hutchins, C.W., Fesik, S.W. and Jirousek, M.R. (2003) J. Am. Chem. Soc. 125, 4087–4096. Liu, G., Xin, Z., Pei, Z., Hajduk, P.J., Abad-Zapatero, C., Hutchins, C.W., Zhao, H., Lubben, T.H., Ballaron, S.J., Haasch, D.L., Kaszubska, W., Rondinone, C.M., Trevillyan, J.M. and Jirousek, M.R. (2003) J. Med. Chem. 46, 4232–4235. Gill, A.L., Frederickson, M., Cleasby, A., Woodhead, S.J., Carr, M.G., Woodhead, A.J., Walker, M.T., Congreve, M.S., Devine, L.A., Tisi, D., O’Reilly, M., Seavers, L.C., Davis, D.J., Curry, J., Anthony, R., Padova, A., Murray, C.W., Carr, R.A. and Jhoti, H. (2005) J. Med. Chem. 48, 414–426. Hartshorn, M.J., Murray, C.W., Cleasby, A., Frederickson, M., Tickle, I.J. and Jhoti, H. (2005) J. Med. Chem. 48, 403–413. Glinec, Y., Faure, J., Dain, L.L., Darbon, S., Hosokai, T., Santos, J.J., Lefebvre, E., Rousseau, J.P., Burgy, F., Mercier, B. and Malka, V. (2005) Phys. Rev. Lett. 94, 025003. Faure, J., Glinec, Y., Pukhov, A., Kiselev, S., Gordienko, S., Lefebvre, E., Rousseau, J.P., Burgy, F. and Malka, V. (2004) Nature (London) 431, 541–544. Miao, J., Hodgson, K.O. and Sayre, D. (2001) Proc. Natl. Acad. Sci. USA 98, 6641–6645. Miao, J., Chapman, H.N., Kirz, J., Sayre, D. and Hodgson, K.O. (2004) Annu. Rev. Biophys. Biomol. Struct. 33, 157–176. Pellechia, M., Sem, D.S. and Wu¨thrich, K. (2002) Nat. Rev.: Drug Discov. 1(March), 211–219. Fejzo, J., Lepre, C. and Xie, X. (2003) Curr. Top. Med. Chem. 3, 81–97. Meyer, B. and Peters, T. (2003) Angew. Chem. Int. Ed. 42(8), 864–890. Van de Ven, F.J.M. (1995) In ‘‘Multidimensional NMR in Liquids: Basic Principles and Experimental Methods’’. Wiley, UK. Cavanagh, J., Skelton, N.J. and Fairbrother, W. (1995) In ‘‘Protein NMR Spectroscopy: Principles and Practice’’. Academic Press, New York, NY, USA. Neuhaus, D. and Williamson, M.P. (2000) In ‘‘The Nuclear Overhauser Effect in Structural and Conformational Analysis’’. Wiley-VCH, New York, NY, USA. Hajduk, P.J., Augeri, D.J., Mack, J., Mendoza, R., Yang, J., Betz, S.F. and Fesik, S.W. (2000) J. Am. Chem. Soc. 122, 7898–7904. Pellechia, M., Meininger, D., Dong, Q., Chang, E., Jack, R. and Sem, D.S. (2002) J. Biomol. NMR 22, 165–173. Mayer, M. and Meyer, B. (1999) Angew. Chem. Int. Ed. 38, 1784–1788. Dalvit, C., Pevarello, P., Tato`, M., Veronesi, M., Vulpetti, A. and Sundstro¨m, M. (2000) J. Biomol. NMR 18, 65–68. Ni, F. (1994) Prog. NMR Spectrosc. 26, 517–606. Klein, J., Meinecke, R., Mayer, M. and Meyer, B. (1999) J. Am. Chem. Soc. 121, 5336–5337. Hajduk, P.J., Olejniczak, E.T. and Fesik, S.W. (1997) J. Am. Chem. Soc. 119, 12257–12261. Fejzo, J., Lepre, C.A., Peng, J.W., Bemis, G.W., Ajay, Murcko, M.A. and Moore, J.M. (1999) Chem. Biol. 6, 755–769. Bemis, G.W. and Murcko, M.A. (1996) J. Med. Chem. 39, 2887–2893. Bemis, G.W. and Murcko, M.A. (1999) J. Med. Chem. 42, 5095–5099. Lepre, C.A. and Moore, J.M. (1998) J. Biomol. NMR 12, 493–499. Integrated Scientific Information Systems (ISIS); MDL Information Systems Inc., San Leandro, USA. Dalvit, C., Cottens, S., Ramage, P. and Hommel, U. (1999) J. Biomol. NMR 13, 43–50. McCoy, M.A., Senior, M.M. and Wyss, D.F. (2005) J. Am. Chem. Soc. 127, 7978–7979.
M. CHERRY, J. READER AND D. WILLIAMS
61
[51] Langer, T., Vogtherr, M., Elshorst, B., Betz, M., Schieborr, U., Saxena, K. and Schwalbe, H. (2004) Chembiochemistry 5, 1508–1516. [52] Chen, H., Delaney, A.M., Dudley, D.T., Hasemann, C.A., Kuffa, P., McConnell, P.C., Ohren, J.F., Pavlovsky, A.G., Tecle, H., Whitehead, C.E., Yan, C., Zhang, E. (2003) EPA 1321518; (2003) Chem. Abstr. 137 488644. [53] Shabb, J.B. (2001) Chem. Rev. 101, 2381–2411. [54] Neal, S., Nip, A.M., Zhang, H. and Wishart, D.S. (2003) J. Biomol. NMR 26, 215–240. [55] Engh, R.A., Girod, A., Kinzel, V., Huber, R. and Bossemeyer, D. (1996) J. Biol. Chem. 271, 26157–26164. [56] Hajduk, P.J., Gomtsyan, A., Didomenico, S., Cowart, M., Bayburt, E.K., Solomon, L., Severin, J., Smith, R., Walter, K., Holzman, T.F., Stewart, A., McGaraughty, S., Jarvis, M.F., Kowaluk, E.A. and Fesik, S.W. (2000) J. Med. Chem. 43, 4781–4786. [57] Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., Finch, H., Fromont, C., Richardson, C., Simmonite, H. and Hubbard, R.E. (2004) J. Chem. Inf. Comput. Sci. 44, 2157–2166. [58] Baurin, N., Baker, R., Richardson, C., Chen, I., Foloppe, N., Potter, A., Jordan, A., Roughley, S., Parratt, M., Greaney, P., Morley, D. and Hubbard, R.E. (2004) J. Chem. Inf. Comput. Sci. 44, 643–651. [59] Muchmore, S.W. and Hajduk, P.J. (2003) Curr. Opin. Drug Discov. Devel. 6, 544–549. [60] Moore, J., Abdul-Manan, N., Fejzo, J., Jacobs, M., Lepre, C., Peng, J. and Xie, X. (2004) J. Synchrotron Radiat. 11, 97–110. [61] Walters, W.P., Stahl, M.T. and Murcko, M.A. (1998) Drug Discov. Today 3, 160–178. [62] Bajorath, J. (2002) Curr. Drug Discov., March, 24–28. [63] Schneider, G. and Bohm, H.-J. (2002) Drug Discov. Today 7(1), 64–70. [64] Lyne, P.D. (2002) Drug Discov. Today 7(20), 1047–1055. [65] Lengauer, T., Lemmen, C., Rarey, M. and Zimmermann, M. (2004) Drug Discov. Today 9(1), 27–34. [66] Jain, A.N. (2004) Curr. Opin. Drug Discov. Devel. (2004) 7(4), 396–403. [67] Xu, H. and Agrafiotis, D.K. (2002) Curr. Top. Med. Chem. 2, 1305–1320. [68] Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Adv. Drug Del. Rev. 23, 3–25. [69] Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) J. Med. Chem. 45, 2615–2623. [70] Muegge, I. and Enyedy, I.J. (2004) Curr. Med. Chem. 11(6), 693–707. [71] Sadowski, J., Gasteiger, J. and Klebe, G. (1994) J. Chem. Inf. Comput. Sci. 34, 1000–1008. [72] Davis, A.M., Teague, S.J. and Kleywegt, G.J. (2003) Angew. Chem. Int. Ed. 42, 2718–2736. [73] FRED, Openeye Scientific Software Inc., Santa Fe, NM, USA, www.eyesopen.com, 2005. [74] Bostrom, J., Greenwood, J.R. and Gottfries, J. (2003) J. Mol. Graph. Model 21, 449–462. [75] Klebe, G. and Mietzner, T. (1994) J. Comput.-Aided Mol. Des. 8, 583–606. [76] McGann, M. (2005) SMI Drug Design Conference, London, UK (February 28–March 1). [77] Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shaw, D.E., Shelley, M., Perry, J.K., Sander, L.C. and Shenkin, P.S. (2004) J. Med. Chem. 47, 1739–1749. [78] Halgren, T.A., Murphy, R.B., Friesner, R.A., Beard, H.S., Frye, L.L., Pollard, W.T. and Banks, J.L. (2004) J. Med. Chem. 47, 1750–1759. [79] Juhn, B., Gerber, P., Schulz-Gasch, T. and Stahl, M. (2005) J. Med. Chem. 48, 4040–4048. [80] Pearlman, D.A. and Charifson, P.S. (2001) J. Med. Chem. 44, 3417–3423.
62
[81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118]
FINDING PROTEIN KINASE HITS USING STRUCTURAL INFORMATION
Tominaga, Y. and Jorgensen, W.L. (2004) J. Med. Chem. 47, 2534–2549. Jones, G., Willet, P. and Glen, R.C. (1995) J. Mol. Biol. 245, 43–53. Rarey, M., Kramer, B., Lengauer, T. and Klebe, G. (1996) J. Mol. Biol. 261, 470–489. Roche, O., Kiyama, R. and Brooks, C.L. (2001) J. Med. Chem. 44, 3592–3598. Wang, R., Fang, X., Lu, Y. and Wang, S. (2004) J. Med. Chem. 47, 2977–2980. Wang, R., Fang, X., Lu, Y., Yang, C.-Y. and Wang, S. (2005) J. Med. Chem. 48, 4111–4119. Perola, E., Walters, W.P. and Charifson, P.S. (2004) Proteins 56, 235–249. Carlson, H.A. and McCammon, J.A. (2000) Mol. Pharmacol. 57, 213–218. Kontoyianni, M., McClellan, L.M. and Sokol, G.S. (2004) J. Med. Chem. 47, 558–565. Perez, C. and Ortiz, A.R. (2001) J. Med. Chem. 44, 3768–3785. Muegge, I. and Martin, Y.C. (1999) J. Med. Chem. 42, 791–804. Ferrara, P., Gohlke, H., Price, D.J., Klebe, G. and Brooks, C.L. (2004) J. Med. Chem. 47, 3032–3047. Wang, R., Lu, Y. and Wang, S. (2003) J. Med. Chem. 46, 2287–2303. Forino, M., Jung, D., Easton, J.B., Houghton, P.J. and Pellecchia, M. (2005) J. Med. Chem. 48, 2278–2281. Lyne, P.D., Kenny, P.W., Cosgrove, D.A., Deng, C., Zabludoff, S., Wendoloski, J.J. and Ashwell, S. (2004) J. Med. Chem. 47, 1962–1968. Vangrevelinghe, E., Zimmermann, K., Schoepfer, J., Portmann, R., Fabbro, D. and Furet, P. (2003) J. Med. Chem. 46, 2656–2662. Charifson, P.S., Corkery, J.J., Murcko, M.A. and Walters, W.P. (1999) J. Med. Chem. 42, 5100–5109. Terp, G.E., Johansen, B.N., Christensen, I.T. and Jorgensen, F.S. (2001) J. Med. Chem. 44, 2333–2343. Wu, G. and Vieth, M. (2004) J. Med. Chem. 47, 3142–3148. Vieth, M. and Cummins, D.J. (2000) J. Med. Chem. 43, 3020–3032. Chuaqui, C., Deng, Z. and Sing, J. (2005) J. Med. Chem. 48, 121–133. Deng, Z., Chuaqui, C. and Singh, J. (2004) J. Med. Chem. 47, 337–344. Vigers, G.P.A. and Rizzi, J.P. (2004) J. Med. Chem. 47, 80–89. Klon, A.E., Thoma, M.G.M., Acklin, P. and Davies, J.W. (2004) J. Med. Chem. 47, 2743–2749. McGovern, S.L. and Shoichet, B.K. (2003) J. Med. Chem. 46, 2895–2907. Ferrari, A.M., Wei, B.Q., Costantino, L. and Shoichet, B.K. (2004) J. Med. Chem. 47, 5076–5084. Barril, X. and Morley, S.D. (2005) J. Med. Chem. 48, 4432–4443. Cavasotto, C.N. and Abagyab, R.A. (2004) J. Mol. Biol. 337, 209–225. Sathura, F.L. and Bajorath, J. (2005) Curr. Pharm. Des. 11, 1189–1202. Sheridan, R.P. and Kearsley, S.K. (2002) Drug Discov. Today 7, 903–911. Xu, H. and Agrafiotis, D.K. (2002) Curr. Top. Med. Chem. 2, 1305–1320. Pirard, B. and Pickett, S.D. (2000) J. Chem. Inf. Comput. Sci. 40, 1431–1440. Naumann, T. and Matter, H. (2002) J. Med. Chem. 45, 2366–2378. Putta, S., Landrum, G.A. and Penzotti, J.E. (2005) J. Med. Chem. 48, 3313–3318. Bhattacharjee, A.K., Geyer, J.A., Woodard, C.L., Kathcart, A.K., Nichols, D.A., Prigge, S.T., Li, Z., Mott, B.T. and Water, N.C. (2004) J. Med. Chem. 47, 5418–5426. Kostich, M., English, J., Madison, V., Gheyas, F., Wang, L., Qiu, P., Greene, J. and Laz, T.M. (2002) Genome Biol. 3(9), 1–12. Panigrahi, S.K. and Desiraju, G.R. (2003) Nat. Acad. Sci. Lett. (India) 27, 1–11. Diller, D.J. and Li, R. (2003) J. Med. Chem. 46, 4638–4647.
M. CHERRY, J. READER AND D. WILLIAMS
63
[119] Oshiro, C., Bradley, E.K., Eksterowicz, J., Evensen, E., Lamb, M.L., Lanctot, J.K., Putta, S., Stanton, R. and Grootenhuis, P.D.J. (2004) J. Med. Chem. 47, 764–767. [120] Rees, D.C., Congreve, M., Murray, C.W. and Carr, R. (2004) Nature Rev. Drug Discov. 3, 660–672. [121] Schneider, G., Lee, M.-L., Stahl, M. and Schneider, P. (2000) J. Comp.-Aided Mol. Des. 14, 487–494. [122] Hare, B.J., Walters, P., Caron, P.R. and Bemis, G.W. (2004) J. Med. Chem. 47, 4731–4740. [123] Aronov, A.M. and Bemis, G.W. (2004) Proteins: Struct. Func. Bioinform. 57, 36–50. [124] Honma, T., Hayashi, K., Aoyama, T., Hashimoto, N., Machida, T., Fukasawa, K., Iwama, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., Iwasawa, Y., Hayama, T., Nishimura, S. and Morishima, H. (2001) J. Med. Chem. 44, 4615. [125] Honma, T., Yoshizumi, T., Hashimoto, N., Hayashi, K., Kawanishi, N., Fukasawa, K., Takaki, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., Hayama, T., Nishimura, S. and Morishima, H. (2001) J. Med. Chem. 44, 4628–4640.
This page intentionally left blank
64
Progress in Medicinal Chemistry – Vol. 44, Edited by F.D. King and G. Lawton r 2006 Elsevier B.V. All rights reserved.
2 Blunting the Swiss Army Knife of Hepatitis C Virus: Inhibitors of NS3/4A Protease$ PETER W. WHITE, MONTSE LLINAS-BRUNET and MICHAEL BO¨S Boehringer Ingelheim (Canada) Ltd, 2100 Cunard St., Laval, QC H7S 2G5, Canada Dedicated to Professor Dr. Dieter Seebach
HEPATITIS C INFECTION Introduction The Hepatitis C Virus Current Therapies for the Treatment of HCV Infections The HCV NS3/4A Protease
66 66 67 69 70
TOOLS TO STUDY NS3/4A PROTEASE INHIBITORS Enzymatic Assays Viral Replication
73 73 74
INHIBITORS OF THE NS3/4A SERINE PROTEASE Non-covalent Peptidic Inhibitors Covalent Reversible Peptidic Inhibitors Non-peptidic Inhibitors
78 78 90 97
SUMMARY AND OUTLOOK
98
REFERENCES
100
$
The title was adapted from a phrase coined by Prof. James McKerrow (University of California, San Francisco), as quoted by P. Frost in the American Chemical Society newspaper Chemistry (Spring 1999, 15–19). DOI: 10.1016/S0079-6468(05)44402-1
65
66
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
HEPATITIS C INFECTION INTRODUCTION
Liver disease resulting from Hepatitis C Virus (HCV) infection is a serious, worldwide health problem. HCV is endemic to central Africa and Southeast Asia and has probably existed for over 100,000 years in these locations [1]. However, during the 20th century it became a worldwide epidemic, currently infecting an estimated 170 million people or 3% of the world’s population [2]. HCV is a blood-borne virus, and its increased prevalence in modern times results from the increased use of blood transfusions, or the use of improperly sterilized needles, either for medical procedures such as vaccination, or for the intravenous administration of illicit drugs. However, HCV was only identified, and its genome sequenced, in the late 1980s [3]. Since that time, diagnostic tests have essentially eliminated the virus from the blood supply [4]. Furthermore, awareness of HCV, as well as of HIV, has led to decreased transmission through unsterilized needles. Intravenous drug use remains the major mode of Hepatitis C transmission, still occurring with significant frequency in certain populations, for example in prisons [5]. Acute infection by HCV is usually asymptomatic and passes unnoticed [6, 7]. The immune system brings this initial infection under control, and in some cases is able to completely eliminate the virus. However, the virus possesses several mechanisms to evade the immune response, so that approximately 80% of people become chronically infected [8]. Further progression of the disease is slow, but most chronically infected individuals eventually develop liver fibrosis, which can then lead to cirrhosis with or without progression to hepatocellular carcinoma. End-stage liver disease and liver failure resulting from HCV infection are currently the major indications for liver transplant in the U.S. and Europe [9].The progression from chronic infection to cirrhosis is poorly understood, and the extent to which pathology is caused, either directly by the virus or as a consequence of the body’s immune response, is the subject of some debate. Current therapies for HCV, as described below, work by stimulating the immune system. They are poorly tolerated and only partially effective. There is a significant need for new forms of treatment, and it has long been recognized that drugs specific for viral targets will play a critical role in combating the disease. The NS3 serine protease in particular was recognized as a prime target for intervention 12 years ago [10]. However, to this day no drugs directed against any viral target have reached the market or late-stage clinical trials. For reasons outlined below, development of anti-HCV drugs, and protease drugs in particular, has been slow and difficult. Progress against this target was last reviewed in this series in 2002 [11]. Here we will focus primarily on recently
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
67
reported results. The last few years have seen a number of exciting developments in this field, holding out the hope that highly effective drugs directed against this target will be available in the not-too-distant future.
THE HEPATITIS C VIRUS
HCV is a small enveloped single-stranded RNA virus belonging to the Flaviviridae family and Hepacivirus genus [12]. Other Flaviviridae members include the flaviviruses such as yellow fever virus, and pestiviruses, which are responsible, for example, for bovine viral diarrhea [13]. The most closely related virus identified to date is GBV-B, which infects the tamarind, a new world monkey. GBV-B has also been tentatively classified as a Hepacivirus [12]. The HCV genome consists of approximately 9,600 bases, encoding a single polyprotein of approximately 3,000 amino acids, flanked by conserved 50 - and 30 -untranslated regions essential for replication and translation (Figure 2.1A). The genome is replicated in the cytoplasm by a virally encoded polymerase and translated by cellular machinery directed to the viral RNA by a highly structured internal ribosomal entry sequence (IRES) [13] (Figure 2.1B). The viral polyprotein comprises four structural proteins followed by six non-structural proteins. The structural proteins are: envelope glycoproteins E1 and E2, Core, and the small P7 ion channel [14, 15]. Another putative protein, F, is also encoded by an alternate reading frame in the structural protein region, but no function for the protein has been identified [16]. The non-structural proteins are designated NS2-N5B. NS2/3 possesses an essential autoprotease activity, but it is still not clear whether NS2 itself has an independent function. The bifunctional NS3 protein consists of an N-terminal 5’-UTR C E1 (IRES)
P NS2 7
NS3
NS4 A B
A
5’-UTR r EM NS2 (IRES) Neo -CV
NS3
NS4 A B
A
E2
NS5 B
3’-UTR
(A) NS5 B
3’-UTR
(B) Fig. 2.1 (A) Structure of the HCV genome, with 50 - and 30 -untranslated regions and individual proteins of the polyprotein indicated. Regions of the genome (approximately 3,000 bases) are drawn to scale. Structural protein regions are in light gray, nonstructural proteins in white, and untranslated regions in dark gray. (B) Structure of a typical replicon sequence, with the antibiotic resistance gene (Neor) in place of the structural region and the second IRES (EMCV) inserted. The NS2 sequence is often not present in the replicon.
68
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
protease domain and a C-terminal helicase. NS4A is an essential component of the NS3 protease. The functions of NS4B and NS5A are not wellunderstood, though NS4B possesses a putative NTPase motif, which appears to play an important, though still uncharacterized, role in replication [17]. NS5A is a phospho-protein, which has been shown to interact with several host proteins and seems to play a role in subverting the host immune response. NS5B encodes the viral polymerase [13]. The junctions between structural proteins are cleaved in the lumen of the endoplasmic reticulum by cellular signal peptidases, whereas the nonstructural proteins are processed by the virally encoded proteases. The NS3 protease–NS4A cofactor complex (vide infra), cleaves all the non-structural junctions except NS2–NS3 [13]. The NS3 protease and helicase, as well as the NS5B polymerase, have significant homology to other known enzymes and were recognized early-on as potential targets for anti-viral drugs. Other possible targets include the poorly characterized NS2/3 protease activity and the interactions of the IRES or other viral proteins with host cell factors. Like most viral RNA polymerases, NS5B does not possess 30 –50 exonuclease editing capability and is relatively error prone. This results in a mutation rate of approximately 1.4 10 3 nucleotide changes per site per year [18, 19]. Combined with the estimated production of up to 1012 virions per day in an infected individual [20], HCV sequences clearly have the potential to evolve rapidly. This results in the appearance of multiple sequence variants or quasi-species in each infected individual [21]. Sequence evolution is balanced, however, by the need to maintain simultaneously both the functions of the viral proteins and also the highly ordered RNA structure found in many regions of the genome [1]. Thus longterm evolution of the virus has occurred at a much slower rate. Globally, HCV sequences have been divided into six major genotypes (1–6), which differ by 30–35% in nucleotide sequence. Within these genotypes are found over 60 subtypes, which differ from each other by 20–25% [22]. Most genotypes and subtypes are confined to the regions of Africa and Asia in which the virus has existed longest, or to recent immigrants from these regions. The worldwide outbreak of the virus has been caused almost entirely by subtypes 1a and b, 2a, b and c, and 3a. Of these the most predominant are 1a and 1b, which are responsible for approximately 70% of the infections in the Americas, Europe, and Japan [23]. Sequence variation could in principle result in differences in disease pathology, but no such link has been proven to date and the progression of the disease is generally independent of genotype. There is a strong association of particular subtypes with different modes of transmission. The high prevalence genotype 1b infection in the developed world is attributed mostly to the use of contaminated blood in transfusions. Subtypes 1a and 3a currently
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
69
account for most new infections, which are being spread by intravenous drug use [23]. The infection of approximately 20% of the population of Egypt with the otherwise rare genotype 4 has been traced to the mass inoculation of the population with a parenteral treatment for schistosomiasis in the 1950s and 1960s, carried out with inadequately sterilized equipment [24]. It is not clear whether the predominant genotypes are in some way more efficiently transmitted, or if they owe their primary importance simply to chance, with the spread of these viruses beginning only recently with a very small number of individuals who just happened to be infected with these specific subtypes. As described below, viral genotype is an important factor in determining the effectiveness of drugs directed either at stimulating the immune system or directly against viral targets.
CURRENT THERAPIES FOR THE TREATMENT OF HCV INFECTIONS
The primary therapy for HCV infection is the intravenous administration of type-I interferon. Interferons are a group of endogenous proteins, which form part of the innate immune response [25]. Use of type I interferon-a was approved in 1990 and can reduce viral load and in some cases eliminate the virus completely. Many individuals do not respond, however, and many of those who respond initially do not clear their infections completely. The prolonged (up to 48–96 weeks) treatment course also has numerous side effects, including flu-like symptoms and psychiatric disorders [26]. Thus, in addition to those who fail to respond to treatment, many individuals are forced to discontinue therapy due to these side effects. Subsequent years have seen significant developments in interferon therapy. The most important have been the use of pegylated interferons, which have increased stability, and the introduction of combination therapy with the nucleoside analogue ribavirin [27]. Ribavirin is a broad-spectrum antiviral. The mechanism by which it acts against HCV is still controversial. However, in combination with interferon it both accelerates the initial drop in viral load and increases the probability of sustained response [28]. Ribavirin also has its own significant side effects, most importantly anemia [26]. The combination with pegylated interferon yields a sustained viral response rate of 50–60% [27]. The success rate is higher for genotypes 2 and 3 (approximately 80%) but is still less than 50% against the predominant genotype 1 [27]. Standard treatment times have been shortened to 24 or 48 weeks for genotypes 2 and 3 or genotype 1, respectively, and it may be possible to shorten treatment times even further [29]. Further improvements in immune system-boosting therapies have been described recently, including type II interferon-g or alternative forms of type I interferon, better tolerated derivatives of
70
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
ribavirin, and other small molecules acting against a variety of host targets [30], but it remains to be seen if any of these non-virus-specific agents will have an impact on the overall effectiveness of HCV therapy. Together, these options are expected to further increase the number of individuals who can be successfully treated. However, major breakthroughs in therapy are expected only with the introduction of drugs directed specifically against viral targets such as the NS3 protease and NS5B polymerase.
THE HCV NS3/4A PROTEASE
NS3 is a 631 amino acid protein, and its first 180 amino acids encode a serine protease of the chymotrypsin family (Figure 2.2A). It has a typical chymotrypsin-family fold consisting of two b-barrels, with catalytic triad residues at the interface. His-57 and Asp-81 are contributed by the N-terminal b-barrel and Ser-139 from the C-terminal b-barrel. NS3 and closely related viral proteases are significantly smaller than other members of the chymotrypsin family, and many of the loops normally found between adjacent b-strands in trypsin proteases are truncated in NS3 [31]. Probably
Fig. 2.2 (A) Structure of full-length NS3 including the N-terminal protease domain (bottom) and C-terminal helicase domain (top). The NS4A peptide (purple) is covalently attached to the N-terminus of NS3 (see text). Within the protease domain the N- and C-terminal b-barrels are at the right and left, respectively. The zinc atom is visible at the bottom left. [98]. (B) Surface view of the NS3 protease domain showing compound (1) bound at the relatively shallow active site (See also Fig. 2.6) [42].
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
71
as a result of its small size, in the absence of zinc, the NS3 protease is not structurally stable and requires the binding of a structural zinc, chelated by Cys-97, Cys-99, and Cys-145 and His-149, to maintain its tertiary structure [32]. The NS3 protease–Zn complex does have enzymatic activity, but full activity requires association with the 54 amino acid NS4A protein, or at least a peptide containing its central 14 amino acids [33, 34]. This peptide adopts a b-strand conformation and forms part of the N-terminal b-barrel. Only subtle changes in the positions of the protein backbone occur upon binding of the NS4A peptide, but several side chains move; in particular Asp-81 adopts an altered conformation to form a hydrogen bond to His-57 necessary for efficient catalysis [31, 35, 36]. Extensive work on the struc ture and catalytic properties of this protease has been reported over the last several years [37, 38], and only a few more recent studies will be described here. The small size of NS3, with only short interstrand loops, yields a very flat, open binding active site (Figure 2.2B). Indeed, this is the major challenge for the discovery of potent ligands for this enzyme. Early SAR studies of hexapeptide inhibitors based on C-terminal cleavage products (vide infra) identified acidic P5 and P6 residues, as well as a free acid at the C-terminus, as important for high affinity binding [39, 40]. Crystal structures with such inhibitors bound have not been reported, but modelling suggests that acidic residues at P5 and P6 could possibly form electrostatic interactions with several different positively charged residues found on the surface of the active site, including Arg-123, Arg-155, Arg-161, and Lys-165 [41]. Recently reported work using both enzymes with mutations in these positively charged residues as well as substrates with both neutral and acidic residues at P5 and P6 has revealed that charge complementarity improves affinity due to an increased on-rate, rather than a decreased off-rate. The cluster of positive charges on the active site surface accelerates binding by attracting negatively charged residues and thus increasing the initial collision rate of the protein and the inhibitor [41]. Modelling studies showed that specific ion-pairing interactions were not necessary for high affinity, and in fact were detrimental due to the high cost of desolvation. The relevance of these findings in vivo is not clear, since the affinity imparted by these acidic residues is significant only at low salt concentrations and is largely absent in physiological salt conditions [41]. In contrast, the C-terminal carboxylic acid of product-derived inhibitors plays an important role even at high ionic strength, suggesting that this group forms an ion-pair interaction with catalytic triad residues. The role of individual active site residues in inhibitor binding was investigated by using fluorescence polarization [42] or fluorescence resonance energy transfer [43] to study the binding of fluorescent inhibitors to wild-type (WT) and mutant
72
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
enzymes. Interestingly, binding was not affected by substitution S139A, but significantly weaker binding was observed to the H57A mutant. The crystal structure of a more optimized peptidic inhibitor has confirmed that a strong hydrogen bond forms to His-57 rather than to Ser-139 (vide infra) [42]. All early work was performed with genotype 1a and 1b enzymes. Recent reports have described the catalytic and inhibitor-binding properties of sequence variants, including genotype 1 enzymes encoding resistance mutations (vide infra) and also genotype 2 and 3 proteases. Compared to genotype 1, the genotype 2 and 3 protease domains have approximately 50 and 40 amino acid differences, respectively, but only a small number of these are close to the active site. Specific differences are Val-78, Asp-79, Gln-80, and Ser-122 in genotype 1 compared to Ala, Glu, Gly, and Arg, respectively, in genotype 2, as well as Arg-123 and Asp-168 to Thr and Gln in genotype 3. In addition, residue 132 is Val in some genotype 1b sequences, Ile in genotype 1a and other 1b, and Leu in genotypes 2 and 3. This is the only active site residue not conserved between genotype 1a and 1b, and does not appear to have a significant effect on substrate or inhibitor binding. One report comparing genotype 1a, 1b, and 3a proteases found that they had almost identical catalytic efficiencies, and nearly identical affinities for hexapeptide inhibitors based on natural substrates [44]. However, introduction of unnatural amino acids at positions P4 or P5 was found to improve affinity only for genotype 1, such that these inhibitors bound five-fold more tightly to genotype 1 enzymes than to genotype 3. Mutagenesis was used to show that the sequence difference at amino acid 123 was responsible for this difference in affinity [44]. In another report the activities of both full-length NS3/4A proteins and NS3 protease domains were compared for enzymes of genotype 1, 2, and 3 [45]. This work also demonstrated that protease catalytic activity was only slightly affected by genotype differences, either in the kcat or Km parameter. The inhibitor BILN 2061, however, which was highly optimized for binding to the genotype 1 enzyme (vide infra), had 50–60-fold lower affinity for the genotype 2 and 3 enzymes. Mutagenesis studies confirmed that the active site residue differences noted above were primarily responsible for the loss of binding affinity. In contrast to the hexapeptide inhibitor study above, the single residue difference contributing most significantly to the loss of affinity for genotype 3 was at position 168 rather than at 123 [45]. A recent report has demonstrated that the proteolytic activity of NS3 plays an additional role in viral infection, beyond polyprotein processing. An important mediator of the cellular immune response is the transcription factor interferon regulatory factor 3 (IRF-3), which becomes activated on infection and then stimulates production of type-1 interferon and other antiviral genes [46]. It was found that expression of heterodimeric NS3/4A
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
73
in cells abrogated this response [47]. Furthermore, protease activity appeared to be necessary, since the interferon response was not reduced by expression of NS3 without NS4A or a mutated NS3, and addition of a protease inhibitor also reactivated the IRF-3 response [47]. The specific molecular target of the NS3 proteolytic activity has not yet been confirmed, but the existence of this additional role for the viral protease suggests there might also be an additional advantage to treatment of HCV with protease inhibitors (or other HCV agents which inhibit viral replication and thus reduce the concentration of protease in infected cells).
TOOLS TO STUDY NS3/4A PROTEASE INHIBITORS ENZYMATIC ASSAYS
Biochemical assays to measure the activity of NS3 protease inhibitors can be performed with either the isolated protease domain or the full-length bifunctional protein. Both forms are frequently reported in the scientific and patent literature. Typically the full-length protein is expressed as a fusion with full-length NS4A, which cleaves itself during expression to yield the authentic NS3/4A heterodimer. Assays with the protease domain are carried out using an NS4A peptide of about 17 amino acids having charged residues appended at each terminus to improve solubility. The full-length heterodimeric complex is quite stable, and dissociation of the NS4A protein is not observed even at subnanomolar concentrations. In contrast, the NS4A peptide binds to the protease domain with only micromolar affinity, and it is necessary to perform assays with a large excess of the peptide as well as high concentrations of glycerol (30–50%) to stabilize the complex [48, 49]. The weakness of the peptide–protease complex is surprising, given that once bound the peptide is completely surrounded by NS3 residues [35]. However, the on-rate for binding has been found to be very slow, probably due to the significant conformational changes required in both the protein and peptide [48]. Stable complexes of the NS4A peptide with NS3 (protease domain or full-length) can be obtained by fusion of the peptide sequence to the N-terminus of NS3 [50, 51]. The design of these covalent complexes followed from the observation that the C-terminus of the NS4A peptide lies close to the N-terminus of NS3 in crystal structures [35]. The most active substrates for enzymatic assays are modelled on the NS5A/5B cleavage site spanning positions P6–P40 , and are often depsipeptides containing an ester rather than an amide at the cleavage site. Cleavage can be detected by high-performance liquid chromatography (HPLC) separation or by using substrates with a radiolabel at one end and a biotin at
74
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
the other, so that biotinylated substrate can be separated from the radiolabelled but non-biotinylated product after the reaction [52]. However, one of the simplest assay formats uses a substrate with a fluorescent group at one end and a quencher at the other, so fluorescence increases significantly after cleavage [53]. In this case, no physical separation of substrate and product is needed. Another homogeneous format uses substrate peptides modelled on the P-side of the NS5A/5B cleavage site and modified at the C-terminus by acylation of a chromophoric alcohol such as nitrophenol [54]. Enzymatic cleavage of this ester bond yields a significant increase in absorbance. Both the fluorogenic and colorimetric formats are amenable to high-throughput, and also allow continuous monitoring of activity, making them suitable for kinetic studies. Binding assays have also been described. One method uses NS3, which is biotinylated during expression in Escherichia coli and a radiolabeled peptide pseudo substrate with a proline at P10 to prevent cleavage. The peptide–protein interaction is detected by binding the protein to streptavidincoated scintillation proximity beads [55]. In another binding assay format, interaction of a fluorescently labeled hexapeptide inhibitor with NS3 is detected by changes in fluorescence polarization [42] or fluorescence resonance energy transfer [43]. These binding assays are useful for certain mechanistic studies but have not been widely used for routine testing of inhibitors.
VIRAL REPLICATION
Cell culture models Once potent ligands for a viral protein are identified, further advancement depends on demonstrating activity in cells. Unfortunately, reproducible in vitro viral replication assays for HCV have not been reported. There are scattered reports that a very low level of genome replication, or even virus production, can be observed under certain circumstances [56]. However, recently specific sequences yielding relatively reproducible replication, at consistently detectable levels have been reported [57]. In the coming years these may allow routine assays suitable for compound evaluation to be developed, but to date drug discovery must rely on other cell culture models. The protease is uniquely suited for the development of surrogate cellular assays. Several variations of these assays have been developed in which the protease cleaves a fusion protein at an engineered NS3-specific cleavage site, directly activating a reporter gene such as secreted alkaline phosphatase (SEAP) or releasing a transcription factor which can subsequently direct reporter gene expression [58–61]. Detection of engineered target proteins by
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
75
Western blot has also been reported [62, 63]. These assays have been widely used over the last several years but have recently been largely supplanted by the subgenomic replicon.
The replicon An important advance in HCV research was the report in 1999 that subgenomic constructs encoding only the nonstructural proteins together with an antibiotic resistance gene, flanked by authentic 50 and 30 sequences (Figure 2.1B), could replicate stably in the Huh-7 cell line isolated from human liver [64]. While monocistronic systems do exist, most replicons are bicistronic; that is, they encode two protein chains, with translation of the resistance gene directed by the HCV IRES and translation of the HCV non-structural region directed by the encephalomyocarditis virus (EMCV) IRES [56]. Replicon cell lines are typically generated by transfection of the subgenomic RNA into Huh-7 human liver cells and selection for colonies, which are able to grow in the presence of the antibiotic neomycin. The first replicons were generated using a consensus genotype 1b sequence [64] or a genotype 1a strain [65, 66]. Isolation of stable replicon cell lines was at first a long and very inefficient process, but it was soon found that the HCV sequences in stable replicon-containing cell lines had mutations, which significantly improved efficiency of replication [56, 66]. Fresh cells transfected with adapted sequences yield colonies at a frequency of 0.2–10%, whereas the original genotype 1b sequence yielded only 0.0005% [67]. The adaptive mutations map principally to the NS3 helicase domain and the NS5A sequence [56], but the mechanism by which they improve replication efficiency is still being investigated. With adapted replicons, replication efficiency is high enough so that assays do not need to be performed with stable replicon cell lines. Huh-7 cells can be transfected and the level of replication in the cell population evaluated after 24–96 h [67, 68]. Interestingly, it has been found that although a full-length genome containing the original genotype 1b replicon sequence was infectious in chimpanzees, sequences containing the adaptive mutations were not [69]. Thus, although the subgenomic replicon is believed to carry out many authentic functions of the HCV life cycle, there are significant differences in the constraints on sequences for the cell culture model and authentic infections. Very recently, a genotype 2a replicon was reported [70]. Since genotype 2 differs significantly in sequence from genotype 1, comparing the properties of this new replicon to the established genotype 1 replicons should yield new insights into HCV replication.
76
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
Academic research using the replicon has yielded a number of insights into the biology of HCV, but it has also been widely adopted for pharmaceutical research. Compounds can by tested in 96- or 384-well plate format. RNA copy numbers can be accurately quantified using real-time polymerase chain reaction (PCR). This procedure requires that RNA be isolated from cells at the completion of the assay, and is time-consuming and expensive. Alternative detection procedures have been described in which the level of NS3 protease activity is detected after compound incubation and cell lysis [71], or in which the concentration of the neomycin resistance protein is quantified by (ELISA) [72]. Recently, replicons further engineered to contain a luciferase reporter gene in the first reading frame have been developed [68]. These allow the level of replication to be determined using a simple luminescence readout, significantly increasing throughput of the assay. With these improvements the replicon is not only used as the cell culture assay for inhibitors of defined enzymatic targets, but can also be the subject of highthroughput screening, to yield compounds which appear to target proteins of poorly understood function such as NS5A [73].
Animal models Besides humans, the only known host for HCV is the chimpanzee. A critical early development in HCV research was the discovery that specific cloned RNA genomes could be used to infect chimpanzees [74, 75]. Genomes containing point mutations in nonstructural proteins, including the NS3 protease, which abrogated activity were noninfectious, validating these proteins as essential viral targets [76]. However, for ethical as well as practical reasons the chimpanzee cannot be used routinely to test candidate drugs. To overcome this limitation, two quite elaborate animal models have been developed which use infected human liver cells grafted into severe combined immunodeficiency (SCID) mice. In the Trimera model, mice first receive lethal doses of radiation and are then given bone marrow transplants and grafts of infected human liver tissue [77]. The KMT Hepatech model uses SCID mice which express a urokinase-type plasminogen activator transgene in the liver, resulting in death of most mouse liver cells [78]. Their survival then depends on engrafted human liver cells. Replicating virus can be detected in both models, and they have further been validated using candidate antivirals: a small molecule directed against the IRES and an antibody directed against E2 in the case of the Trimera model [77] and interferon-a [79] and the protease inhibitor BILN 2061 [80] in the KMT model. However, both models use immunodeficient animals, and the duration and severity of infection is not well controlled. Thus many questions regarding the kinetics
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
77
of viral infection or the interaction of the virus and immune system cannot be addressed. In the future, these models may prove useful in helping to validate agents directed against non-traditional targets, such as the poorly understood NS4B or NS5A, but they are not believed to be critical for the advancement of protease or polymerase inhibitors. In some cases, candidate HCV drugs have been tested in primates infected with related viruses such as GVB-B [81]. A protease-specific model has also been reported in which a replicationdefective adenovirus encoding an NS3 protease–SEAP fusion protein is injected into mouse tail veins, resulting in expression of the fusion protein in the liver [82, 83]. Protease activity can be detected both by measuring activity of liberated SEAP or by protease-induced liver damage. Protease activity was found to be reduced by administration of protease inhibitors. This model can be used to show that candidate inhibitors have adequate pharmacokinetic properties in mice to function in the intended target organ, but it is not a true disease model. A possible limitation of these mouse models is suggested by the recently recognized fact that, in addition to the liver, HCV does replicate in other cell types, including peripheral blood mononuclear cells (PBMCs) and dendritic cells [84–87]. In fact, the quasispecies distribution in non-liver cells is different, suggesting that the virus evolves distinct populations for each cell type [23, 88]. Elimination of virus from these non-liver ‘‘reservoirs’’ could possibly be the key to achieving a sustained viral response. In the long-term, full understanding of HCV will require a model in which the full virus life cycle can be studied in an immuno-competent animal. Alternatively, more intensive study of related animal viruses such as GBV-B may yield insights into the viral life cycle, which could be applied to HCV.
Resistance studies As has been observed with inhibitors of HIV, resistance to anti-HCV drugs is expected when these agents are tested in the clinic. The replicon can be used to identify and characterize potential resistance mutations. Assays to measure inhibition of replication are normally run for 24–72 h, but if cells are cultured for a longer time in the presence of high concentrations of inhibitor, colonies eventually emerge which can grow efficiently. RNA isolated from these colonies will usually contain mutations in the gene for the targeted protein. For example, several independent studies with the protease inhibitor BILN 2061, or a close analogue, have identified resistance mutations in the protease active site (vide infra). Since each isolated sequence usually contains additional mutations due to natural drift of the sequence
78
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
on long-term culture, resistance is confirmed by engineering the specific resistance mutation into the initial sequence and confirming the decreased sensitivity to the inhibitor for the resulting replicon, as well as for the isolated enzyme containing the same mutation. However, the replicon is under fewer constraints than the full virus sequence, since it only models a part of the viral life cycle. Viruses encoding replicon resistance mutations may not be viable. Sequences encoding resistance mutations have not yet been used to infect chimpanzees, and it will probably be only after long-term clinical trials that authentic resistance mutations can be identified and compared to those that arise in replicon studies. It is encouraging that treatment with sufficiently high concentrations of protease inhibitors or interferon [89] appears to completely suppress the emergence of resistance and in fact results in ‘‘curing’’ cells of the replicon, such that no HCV replication can be detected even after removal of the drug. The replicon can also be used to evaluate combinations of inhibitors. Additivity or slight synergies have been reported for interferon–protease inhibitor [90–92], interferon–polymerase inhibitor [93], and protease– polymerase inhibitor [94] combinations. Additional advantages are found on longer-term treatment with drug combinations, since as found for HIV these combinations very effectively prevent the emergence of resistance [91, 92]. Any colonies that do form must have sequences encoding separate mutations for both drugs in the combination [94].
INHIBITORS OF THE NS3/4A SERINE PROTEASE NON-COVALENT PEPTIDIC INHIBITORS
A rather unusual feature of the NS3 protease is the presence of product inhibition [39, 95]. The initial discovery of N-terminal product inhibition of peptide substrates has been exploited in the design of potent and specific inhibitors of this protease [42, 96]. The observation that a carboxylic acid can interact very efficiently with the catalytic triad via ionic interactions, producing very potent and specific inhibitors, has led to significant research into non-covalent inhibitors [97]. The binding mode of the C-terminus of the helicase domain in the active site of the protease was revealed by the first crystal structure of the full-length NS3 protein with its N-terminus covalently linked to the NS4A peptide cofactor (Figure 2.2A) [98]. This X-ray crystal structure of a C-terminal carboxylate bound to the active site of the NS3/NS4A complex provided an atomic view of the interactions between the protease domain and the P-side product of the cis cleavage reaction. The carboxylate in the active site is stabilized via several hydrogen bonds.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
79
Several classes of non-covalent substrate based inhibitors have been reported, and are grouped below based on the nature of the C-terminal group interacting with the catalytic triad of the enzyme. The majority of the reported inhibitors are based on the N-terminal product of a modified substrate of the NS5A/5B cleavage side or to a lesser extent of the NS4A/4B substrate peptide. Carboxylic acid containing inhibitors After the discovery of weak inhibition by the N-terminal products of substrate peptides, researchers at Boehringer Ingelheim reported potent and specific hexapeptides providing up to a 106-fold increase in potency (Figure 2.3) [89]. Crucial to this class of inhibitors was the discovery of (1R,2S)-1-amino-2vinylcyclopropane carboxylic acid (vinyl-ACCA) as a P1 residue [99]. Initially, several reports appeared describing chemically stable replacements for the cysteine residue at the P1 position of all trans-cleaved substrates. An aliphatic side chain with two (aminobutanoic acid) or three (nor-valine) carbon atoms seemed to be an acceptable replacement, with only a moderate loss in potency and improved chemical stability [96, 100]. An improved P1 COOH O H2N
H N
N H
O
COOH
O N H
SH
N
Ki = 79,000 nM O
O
OH
N H
O
Ph
N COOH O H N O
O
H N
N H COOH
O
O N H
N O
O
N H
OH O
Fig. 2.3 Hexapeptide inhibitors of the NS3 protease.
Ki = 0.074 nM
80
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
residue designed using a model of the cysteine bound to the S1 pocket of the NS3 protease resulted in the identification of 4,4-difluoro-aminobutanoic acid, which is an equivalent replacement for the cysteine [101]. However, Rancourt, et al. [99] reported recently SAR studies on tetrapeptide inhibitors and demonstrated that the introduction of vinyl-ACCA produces inhibitors that are 14 times more potent than those containing cysteine (Table 2.1). Vinyl-ACCA containing inhibitors are chemically stable and very specific for the NS3 protease, over other serine or cysteine proteases. Another crucial finding for these inhibitors was the discovery of the 2phenyl-4-oxoquinoline as a substituent at the 4-proline of the P2 residue (Figure 2.4) [102]. This novel substituent was designed based on NMR studies of two series of inhibitors [103]. Figure 2.4 displays a superposition of the P2 bound conformations of the two analogues. The A rings of these two inhibitors adopt very similar bound conformations, whereas their second aromatic rings (B rings) explore different regions of the conformational space and therefore occupy different binding areas. Combination of these residues led to tricyclic derivatives with an approximately 10-fold increase in inhibitory activity. Further optimization of the tetrapeptide series led to very potent inhibitors allowing for size reduction to tripeptides (Figure 2.5) [104]. Further structural studies revealed that macrocyclization can improve potency by constraining the vinyl-ACCA into the correct conformation for binding [42, 105]. In this series of macrocyclic inhibitors, the cyclopropyl P1 moiety is Table 2.1 VINYL–ACCA IN COMPARISON WITH VARIUOS P1 RESIDUES
IC50 (µM)
R SH
140 O
Ph
N H
CO2H
N H
CO2H
O H N
530
N N H
O
O
O
H
R
9.7 N H
CO2H
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
Fig. 2.4 Superposition of the P2 bound conformation of two analogues.
81
82
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
O
O AcHN
OMe
N
Ph
N
N H
O
IC50 = 0.002 µM
O
OH
N H
O OMe
N
Ph
IC50 = 0.025 µM O
O tBuO
N H
N O
MeO
O
N H
OH O
MeO
N
N Ph
H N
N O
O
O
S
O
O O O
N
O (1)
O OH
O
O
tBuO
H N
N OH
H N
N
N H
BILN 2061
Fig. 2.5 From tetrapeptide inhibitors to BILN 2061.
essential for potency with 2,000-fold loss in potency versus the cyclic norvaline analogue. Macrocyclic inhibitor (1) [42] is a selective inhibitor of HCV RNA replication in the replicon assay with an EC50 of 77 nM. The crystal structure of compound (1) bound to the NS3/NS4A-peptide enzyme
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
83
Arg 155
Asp Arg Asp155 Arg 168 123 Ala 156 Val 158 Ala Cys 157 Phe 159 Val 154 132
Asp 81
His His 57
Ser
Ala 156 Ser 139
E2 strand Lys 136
S1
Ala 157
Gly 137
Ser 138
C2 strand
Fig. 2.6 X-ray structure of Compound (1) bound to the NS3 protease. Residues of the enzyme that are in contact with the inhibitor are highlighted.
shows that the inhibitor binds in close proximity to the catalytic residues and at the interface between the N- and C-terminal subdomains (Figure 2.6). Overall, the complex can be characterized as a surface interaction with only a single, relatively shallow pocket at S1. The complex structure suggested extensive hydrogen bonding between the C-terminal carboxylate and the oxyanion hole, consisting of the amide NH’s of Ser-139, Ser-138, and Gly137. The carboxylate also appeared to hydrogen bond to the eH of His-57, whereas the side-chain of the catalytic residue Ser-139 rotated away from the P1 carboxylate (Figure 2.6) [42]. Compound (1) suffered from an unfavorable pharmacokinetic profile when studied in rats. It is cleared very rapidly from rat plasma (half-life, t1=2 ¼ 0:4 h) and is poorly bioavailable (F ¼ 2%), as reflected by the low plasma concentration (area under the plasma concentration-time curve, AUC0 N ¼ 0.2 mM h) following a single oral dose of 25 mg/kg in rats [42]. The main challenge was to further optimize this series to obtain NS3 protease inhibitors with low-nanomolar cell-based potency (EC50o10 nM) and with an adequate pharmacokinetic profile for oral absorption. BILN 2061 Structure activity studies on compound (1), focusing on optimization at the 2-position of the quinoline and at the capping group, resulted in the
84
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
identification of BILN 2061 [106], the first HCV-specific antiviral with proven antiviral effect in man [107]. Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels (up to 3 log10 copies/mL in a substantial proportion of patients) and established proof-of-concept in humans for an HCV NS3 protease inhibitor. Virological responses were similar in interferon-a nonresponders and treatment naı¨ ve patients, as well as in patients with both high and low baseline viral RNA concentrations (Figure 2.7) [108]. In a separate clinical investigation, administration of BILN 2061 to patients infected with genotype 2 or 3 viruses yielded significant but less dramatic reductions in viral load over the course of the twoday study [109]. This result is consistent with the somewhat reduced activity of this compound against the genotype 2 and 3 proteases [45]. These short proof-of-principle clinical studies have confirmed the tremendous potential of antivirals, particularly NS3 protease inhibitors, for the treatment of HCV infection. They have also justified the general approach to compound advancement for HCV agents, in which the decision to initiate clinical trials is based on results from the replicon in combination with CMC and DMPK data. In recent toxicology studies in animals receiving high doses of BILN
Course of Virus Load / Hours, Drug naive patients vs. Non responders BILN 2061 ZW 200mg 10,000,000 Administration
Non Resp
Non Resp
Drug naive
Drug naive
Drug naive
Non Resp
Non Resp
Non Resp
Limit of linear range
Drug naive
Non Resp
Limit of linear range
Virus Load: copies RNA / m
1,000,000
100,000
10,000
1,000 0
20
40
60
80
100
120
140
160
Hours
Fig. 2.7 Virologic response of BILN 2061 (200 mg, twice a day) in pretreated and drug naı¨ve patients with minimal fibrosis. Upper and lower yellow lines represent the limits of detection of the Amplicor assay. Upper black triangles represent administration of BILN 2061.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
85
2061 for 4 weeks, cardiac toxicity was identified [108]. As a consequence, no new clinical trials with BILN 2061 will be considered until the animal toxicological findings have been further investigated. Longer-term clinical trials might have resulted in the emergence of resistance to BILN 2061. Several independent reports have described resistance mutations obtained in the replicon system for BILN 2061 [91, 92, 110], or an earlier tripeptide from this series [111]. Predominant mutations were at Asp-168, as well as Arg-155 and Ala-156 [92, 110]. Mutations selected at these positions reduce the potency of BILN 2061 several hundred fold. Furthermore, activity of BILN 2061 [91, 92] or its analogue [111] against purified enzymes encoding the resistance mutations is reduced to a similar extent compared to the WT enzyme. A low level of resistance is also obtained by mutation of Gln-80 [92]. Enzymes encoding any of these mutations have similar catalytic parameters to WT NS3 [91, 92, 111], but the replication capacity of some of these mutants is reduced in transient assays [110]. As discussed above, the fitness of viruses encoding these mutations, and thus their relevance for patients, will only be determined by future longer term clinical studies. The four reported resistance mutations are clustered near the inhibitorbinding site, between the P2 side chain and the capping group (Figure 2.8). Mutation of Gln-80 or Ala-156 seems to directly affect the surface of the active site, which interacts with the P2 quinoline [42, 92]. The mutation of Arg-155 to glutamine appears to disrupt a salt bridge to the quinoline methoxy group [42, 92]. Asp-168 does not interact directly with the inhibitor, but removal of the negative charge would disrupt a network of hydrogen bonds between charged residues including Asp-168 and Arg-155, as well as Arg123. Thus mutation of this residue indirectly affects the interaction of other active site residues with the P2 quinoline [91, 92, 111]. Several different Asp168 mutants have been identified (Val, Tyr, Ala, Gly). D168 V has been most frequently identified and gives the largest level of resistance, about 500-fold. The potency of BILN 2061 is shifted 20-fold less by D168G, indicating that the size, as well as the charge, does have an effect on inhibitor binding [92]. A highly convergent route for the synthesis of BILN 2061 has also been reported [112]. The synthesis is based on the assembly of four key fragments with an overall yield of 10–15% as shown in Scheme 2.1. The crucial step is a ring closing metathesis of an acyclic precursor.
Phenethyl amide containing inhibitors In search of a replacement of the C-terminal carboxylic acid, the IRBM/ Merck group discovered that a phenethylamide group extends into the
86
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
Fig. 2.8 Active site of NS3 protease with the inhibitor BILN 2061 added through molecular modelling [92], highlighting residues found to be mutated in resistance studies (Ala-156 and Asp-168, yellow; Arg-155, green; Gln-80, magenta).
prime side of the protein and interacts with Lys-136 of the enzyme surface (Figure 2.9). Mutation studies identified a lipophilic interaction between the phenyl ring and the aliphatic side chain of the Lys-136 [113]. The optimal amide was found to be 2,6-difluoro-4-carboxyl-phenethylamide [114]. Hexapeptides in this series are very potent and reversible inhibitors of the protease. Reduction in size to tripeptides, however, resulted in substantial reduction in potency (Figure 2.9). Compound (2), also displaying interesting pharmacokinetic properties in rats, is the best compound reported. Not surprisingly this additional binding is dependent on the P1 residue employed in the inhibitor backbone. In contrast to cysteine and the cysteine mimetic 2amino-4,4-difluoro-butyric acid containing inhibitors, vinyl-ACCA derived compounds are inactive [115]. Non-covalent aza-peptide inhibitors Another series of non-covalent competitive inhibitors reaching toward the P0 side has been reported by Boehringer Ingelheim researchers. Bailey, et al. [116]
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
2R
H2N
HO 4S a) TBTU, DIPEA, DMF
COOMe HO 4R
H 3S
+
a) HCl / dioxane
H N
N COOH b) PNBA, DEAD, N PPh3, THF Boc Boc c) LiOH (1.25 eq.), THF, water
COOMe
O
COOH
Cl
O
N O
Cl
OMe
Ru
CH2Cl2 (0.01 M) BocHN 28 h (5.5 mol%)
BocHN
OH OMe
O
DIAD, PPh3, 0 °C, to RT
MeO
MeO a) NaOH (1 eq.), THF-MeOH-water b) i-BuOCOCl, Et3N, then CH2N2 / Et2O
N COOMe O H N
N O BocHN
COOMe
O
H N
N
PCy3
O
O
N
OH
O
H N
b) TBTU, DIPEA, CH2Cl2 NHBoc
MeO OH
87
O
O OMe
c) HBr, THF d) i-PrNHCSNH2, i-PrOH, 70 °C, 1 h d) HCl / dioxane e) c-pentylOCOCl, Et3N, THF f)LiOH, THF-MeOH-water
N
S
O H N
N O O O
H N
N
O OH
O N H
Scheme 2.1 Synthesis of BILN 2061.
reported an inhibitor series that incorporates an aza-amino acyl fragment at the P1/P10 position (Table 2.2). The best compound identified contains a benzyl derivative. The choice of P1 side chain was important for providing specificity against other serine proteases. A four-carbon P1 side chain was found to be optimal (Compound (3)). NMR and SAR studies on this series of inhibitors demonstrated that they bind reversibly and non-covalently to the enzyme [116]. C-terminal acyl sulfonamide containing inhibitors The uniqueness of the non-covalent product-based inhibitors containing C-terminal carboxylic acid prompted the exploration of bioisosteric
88
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
COOH
COOH O AcHN
O
H N
N H
O
COOH
H N
N H
Ph
CHF2
O
H N
N H
O
Ph
O
Ph IC50 = 2 nM
COOH SH O O
O
H N
N H
N H
O
Cl
H N O
COOH
Ki = 700 nM
O O
N H
N O
O
CHF2 N H
F
H N O
F
(2) Ki = 100 nM
N NH N N
Fig. 2.9 Phenethyl amide containing inhibitors.
replacements of this critical group [117, 118]. Initial reports on hexa- and pentapeptide derivatives concluded that bioisosteric replacement of the C-terminal carboxylic acid of the product-based inhibitors with tetrazoles, and especially with acyl sulfonamide residues, produced product-based inhibitors up to 20-fold more potent than the corresponding carboxylates (Table 2.3). The aryl acyl sulfonamide group also allows for elongation into the P0 region, as well as other structural modifications. After the initial reports of the antiviral efficacy of BILN 2061 a large number of reports disclosing macrocyclic (Figure 2.10) [71, 119–124] and acyclic (Figure 2.11) [125–135] analogues have appeared. For some of these compounds an acyl sulfonamide has been also reported at the C-terminus.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
89
Table 2.2 NON-COVALENT AZAPEPTIDE INHIBITORS
IC50 (µ M)
COOH
NS3
HLE
0.60
> 1000
17.5
ND
0.099
414
Ph O
O AcHN
O
H N
N H
O
COOH
N
N H
O
O
OH
N H
O Ph
COOH O O AcHN
O
H N
N H COOH
N
N H
O
O
N H
O
N
NH2 O
COOH
Ph O
O AcHN
N H COOH
H N O
O N H
N O
O
N H
H N
N
Ph
O
(3)
Prime-side inhibitors The IRBM group combined characteristic elements of the product-based inhibitors with decapeptide inhibitors to yield inhibitors binding solely to the prime side and active site of the protease [136]. Thus, the P1 acarboxylate of the product-based inhibitors is now at the N-terminal cyclohexyl moiety, as illustrated in Figure 2.12. The peptidomimetic
90
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS Table 2.3 BIOISOSTERIC REPLACEMENTS OF THE C-TERMINAL CARBOXYLIC ACID
COOH
O HOOC
N H
H N
O
H N
N H
O
O P1
N H
O
O
COOH Ki (µM)
OH
H2 N 0. 22
0. 091
O
0. 16
OH O
NH
H N
H2 N
N N
O
H2 N
N
H2N
H2N
NH
0. 19
Ph
O O
0. 014
H N
N N N
S
H2 N O
S
Ph
O O 0. 004
inhibitor (4) is the result of an elegant evolution of the initial leads. However, the potencies of these prime-side inhibitors are moderate. COVALENT REVERSIBLE PEPTIDIC INHIBITORS
As an alternative to peptidic inhibitors, which display electrostatic interactions with the active site, covalent inhibitors have also been described recently. Such peptides bear a functional group that can react reversibly with the catalytic serine of the protease. These include aldehydes, a-ketoacid derivates, lactams and boronates. Research groups at Vertex and Lilly optimized inhibitors starting from pyrazinoyl capped tetrapeptidic aldehydes (Table 2.4) [137]. The main SAR
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
91
R N
R'
N O
S O
H N
N O
1
R
O
O O
N H
R1 = OH or Acyl sulfonamide
N H
O
N H N
N O
O
O O O S N R H
O tBuO
N H
N
S
Ph
Ph
O
N
N H N
N O
O
O tBuO
N H
O
R1
O
H N
N
O
1
R
O
O tBuO
N H R1 = OH or Acyl sulfonamide
Fig. 2.10 Recent macrocyclic tripeptide inhibitors.
work comprised substitution of the P2 proline as well as modification of the P1 residue (Table 2.5) [138–143]. These studies culminated in the development of VX-950, a a-keto-amide, which is currently undergoing clinical testing [144]. The compound binds slowly and reversibly to the protease. It
92
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
R'
N
MeO
O O tBuO
MeO
N
N H
O
H N N H
O
S
R
N
O O
O
O O
R = Alkyl or Aryl R' = Heterocycle
tBuO
N
N H
H N
O
N H
O
1
R N
O
O
S
R
O O
2
R
O O tBuO
N H
Rc = OH or Acyl sulfonamide
N C
O
R O
N H
O
H N R' N
R
S
N
Rc
= OH or Acyl sulfonamide O O tBuY
N
X
Y = NH, X = C Y= O, X = NH
C
O
R O
N H
O
Fig. 2.11 Recent acyclic tripeptide inhibitors.
shows moderate replicon potency (EC50 ¼ 400 nM), good oral bioavailability and excellent liver exposure [145]. The replicon system was also used to obtain resistance mutations for this compound. The amino acid substitutions A156S [91] or A156 T [146] significantly weaken binding. Interestingly, A156S does not significantly affect the binding of the tripeptide BILN
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
H N HO
O
O
COOH
O N H
H N
O NH2 HO
O
Ph
O
H N
O
93
Ph
N
O COOH Br (4) IC50 = 2 µM
Fig. 2.12 Prime-side inhibitors.
Table 2.4 PEPTIDIC ALDEHYDES AS COVALENT INHIBITORS OR N O H N N N N H R' O O N O H R0
R
Ki (mM)
Benzyl
12
O
(L)
1-Naphthyl
2.1
O (D,L)
0.9
O (D,L)
N O Benzyl
O
3.1
(D,L)
F3C Benzyl (L)
O
3.8
2061, whereas the primary resistance mutations for BILN 2061, at Asp-168, do not significantly affect the potency of VX-950 [91]. The crystal structure of the inhibitory complex shows only partial overlap with the protein regions covered by BILN 2061 providing an explanation for the activity of
94
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS Table 2.5 PEPTIDIC KETO-AMIDES AS COVALENT INHIBITORS
Ki (µM) N O N H N
N
O
O
O
0.4
N
N H
O
O
NH
O
N H O
N
O
H N
N
N
N H
O
O
0.15
O
NH
O
N H O
N
O
H N
N
N
N H
O
O
N N
N H
H N O
O N H
(5)
0.003 N H
VX-950
O
O
NH
O
O
H N O F2 C
O
H N O
COOH
IC50=0.06
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
95
VX-950 against NS3 mutants that are insensitive to BILN 2061, and vice versa [91]. Scientists at Bristol-Myers Squibb used the a-ketoamide functionality to extend binding to the prime side [147]. The glycine carboxylic acid (Compound (5), Table 2.5) was identified as the most effective extension. Modelling studies, coupled with SAR, suggested that there is either hydrogen bonding or a charge complex of the acid with Lys-136 and Arg-109. The synthesis of aldehydes and ketoamides was performed on solid phase as well as in solution (Scheme 2.2). A semicarbazone linker (6) was employed for the assembly of the aldehydes on solid phase whereas the corresponding aminoalcohol was coupled in solution to the tripeptide and oxidized to the aldehyde, which produced epimeric mixtures [137]. For the synthesis of the ketoamides, hydroxyester THP resins were used as solid support ((7), Scheme 2.2) [138]. In solution the peptide bond was formed using an aminohydroxycarboxylic acid building block [138, 147]. Oxidation of the free hydroxyl group yielded the final inhibitors ((8), Scheme 2.2). The pyrrolidine-5,5-trans-lactam ring system, developed by the Glaxo group as a serine trap for a number of proteases, was applied to the NS3 protease [148, 149] (Scheme 2.3). As shown by X-ray structure analysis, the serine hydroxyl attacks the lactam carbonyl, which is activated by ring strain as well as by the N-acyl group to form a hemiketal [150]. The challenge is to find compounds, which display reasonable chemical stability and consequently favorable in vivo pharmacokinetic properties and good biochemical potency. GW0014 (Scheme 2.3) was identified as such an inhibitor and was tested in the GBV-B infected marmoset, showing a three-log virus titer reduction in this surrogate animal model [81]. The ring system is synthetically accessible via acyliminium coupling to ketene acetals followed by ring closure with tBuMgCl (Scheme 2.3) [148, 151]. Boronic acid derivatives are known to inhibit serine proteases through the formation of a reversible tight B–O bond. Bristol–Myers Squibb published a series of peptidic [152] as well as peptidomimetic (+)-pinanediol boronates [153, 154] targeting the NS3 protease (Scheme 2.4). The latter feature a bicyclic pyrimidone and pyrazinone core replacing the P2–P3 dipeptide. These heterocyclic scaffolds allow the formation of the necessary b-sheet hydrogen bonds between the carbonyl and NH of the ring system and the enzyme backbone, as well as extension into the S2 binding pocket. Inhibitors derived from these structural motifs, such as compound (9), display high enzymatic potency, but no replicon data are available. The heterocyclic scaffolds are prepared from pyroglutamic acid [154, 155]. 1-aminoalkyl boronic acid pinanediol esters are readily available through a diastereoselective homologation with dichloromethyllithium, providing (S)-a-chloroboronic esters. Aminolysis of the chloride yielded
96
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS O HO N
H N
N
H N
N H
H N O
(6)
O
N O N N
O
O
H N
O N
N H
O
O
O
H2N
O
O
+
OH
O
(7) N O N H N
N O
O
O N H
N O
NH
O
O O O O
N O
N H N
N O
O
O N H
N O
O
NH
O NHR
(8) O
Scheme 2.2 Synthesis of peptidic covalent inhibitors.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
97
O O
H N
H N
N
N
O
O GW 0014 IC50=1µM
R TMSO
R
OEt CBZ N
CBZ
NHCOCF3
+
N
OEt
NHCOCF3
BF3.OEt2
R CBZ
R
R
COOEt K2CO3
N
NHCOCF3 EtOH
CBZ
N
R
R R
COOEt tBuMgCl NH2
CBZ THF
N
O NH
Scheme 2.3 Synthesis of pyrrolidine-5,5-trans-lactams.
(R)-aminoboronic esters, which are coupled to the pentapeptides or to the bicyclic peptidomimetics (Scheme 2.4) [152]. NON-PEPTIDIC INHIBITORS
The identification of non-peptidic lead structures remains a challenge. Screening of natural product extracts led to the identification of two polyhydroxylated biphenyls ((10a) and (10b), Figure 2.13) that show submicromolar inhibition of the viral protease [156]. A recent report discloses polyesters of glucose (11) and gallic acid (12) as micromolar inhibitors of the NS3 protease [157]. Fragment screening by NMR was applied recently in the search of nonpeptidic small molecule inhibitors. Two scaffolds (13) and (14), which bind the enzyme at the S1–S3 and the S20 binding site respectively, as shown by chemical shift perturbation, were linked together to yield competitive inhibitors such as (15) with micromolar IC50 values [158]. There have been no reports of non-peptidic inhibitors with potency and pharmacokinetics similar to the peptidic or peptidomimetic inhibitors described above.
98
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
HAspGluValValPro
H N
O B O NHR
O N CF3
N H
H N
N
CF3
O
O B O
O
Cl N CF3
N H
H N
N O
O B O
O
(9) IC50=0.06µM
O B O R
Cl2CHLi
O B O
R
a)LiN(SiMe3)2 b) 4N HCl
Cl
R
O B O NH2
Scheme 2.4 Synthesis of boronates.
SUMMARY AND OUTLOOK HCV infection continues to be a serious disease with a large unmet clinical need. There has been substantial progress in HCV virology and in the development of HCV protease inhibitors, in particular, since this topic was last reviewed in this series. The replicon has become a standard tool for the evaluation of inhibitor efficacy in cells, and reports of reproducible in vitro viral replication and useful transgenic animal models for HCV disease are beginning to emerge. We must recognize, however, that progress in the
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
99
OH HO
OH O
O O
HO HO
O
R= O
O O
HO
R
O
Ph
OH
HO
(10a)
OH OH O
(10)
Ph OH OH
OR1 O
R5O R4O
(10b)
HO OR2
HO
OR3
O (12)
(11a), (11b) (R3,4=H,), (11c) (R4=H)
I HO
O
O
HO
I
COOH
MeO (13)
(14)
I HO
O HO
COOH
O O
I
N H
O
O (15)
Fig. 2.13 Non-peptidic inhibitors.
development of HCV protease inhibitors has been difficult and slow. Since the first crystal structures were published almost 10 years ago, it is clear that the active site, a shallow dent on the surface of the enzyme, was not an easy target for small molecule inhibitor design. Indeed, even today no effective inhibitors of this target have been reported based on high-throughput screening or de novo design approaches.
100
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
The most promising inhibitors are peptidic compounds designed to bind at the active site and compete with the substrate. To date, three compounds have been reported to enter clinical trials, one by Schering Plough [159], VX-950 from Vertex, and BILN 2061 from Boehringer Ingelheim. The impressive reduction of HCV RNA plasma levels observed in a two-day proof-of-concept clinical trial with BILN 2061 illustrates the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics and in particular it demonstrates the potential of a potent and specific HCV NS3 protease inhibitor. REFERENCES [1] Simmonds, P., Tuplin, A. and Evans, D.J. (2004) RNA 10, 1337–1351. [2] Lauer, G.M. and Walker, B.D. (2001) N. Engl. J. Med. 345, 41–52. [3] Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. and Houghton, M. (1989) Science (Washington, DC) 244, 359–362. [4] Kuo, G., Choo, Q.L., Alter, H.J., Gitnick, G.L., Redeker, A.G., Purcell, R.H., Miyamura, T., Dienstag, J.L., Alter, M.J., Stevens, C.E. and. (1989) Science (Washington, DC) 244, 362–364. [5] Spaulding, A., Greene, C., Davidson, K., Schneidermann, M. and Rich, J. (1999) Prev. Med. 28, 92–100. [6] Aach, R.D., Stevens, C.E., Hollinger, F.B., Mosley, J.W., Peterson, D.A., Taylor, P.E., Johnson, R.G., Barbosa, L.H. and Nemo, G.J. (1991) N. Engl. J. Med. 325, 1325–1329. [7] Koretz, R.L., Brezina, M., Polito, A.J., Quan, S., Wilber, J., Dinello, R. and Gitnick, G. (1993) Hepatology 17, 361–365. [8] Heydtmann, M., Shields, P., McCaughan, G. and Adams, D. (2001) Curr. Opin. Infect. Dis. 14, 279–287. [9] Willems, M., Metselaar, J., Tilanus, W., Schalm, W. and de Man, A. (2002) Transpl. Int. 15, 61–72. [10] Bartenschlager, R., Ahlborn-Laake, L., Mous, J. and Jacobsen, H. (1993) J. Virol. 67, 3835–3844. [11] Perni, R.B. and Kwong, A.D. (2002) Prog. Med. Chem. 39, 215–255. [12] Simmonds, P. (2004) J. Gen. Virol. 85, 3173–3188. [13] Lindenbach, B.D. and Rice, C.M. (2001) In ‘‘Fields’ Virology’’. Knipe, D.M. and Howley, P.M. (eds), pp. 991–1041. Lippincott Williams & Wilkins, Philadelphia. [14] Pavlovic, D., Neville, D.C., Argaud, O., Blumberg, B., Dwek, R.A., Fischer, W.B. and Zitzmann, N. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 6104–6108. [15] Sakai, A., Claire, M.S., Faulk, K., Govindarajan, S., Emerson, S.U., Purcell, R.H. and Bukh, J. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 11646–11651. [16] Walewski, J.L., Keller, T.R., Stump, D.D. and Branch, A.D. (2001) RNA 7, 710–721. [17] Einav, S., Elazar, M., Danieli, T. and Glenn, J.S. (2004) J. Virol. 78, 11288–11295. [18] Okamoto, H., Kojima, M., Okada, S., Yoshizawa, H., Iizuka, H., Tanaka, T., Muchmore, E.E., Peterson, D.A., Ito, Y. and Mishiro, S. (1992) Virology 190, 894–899. [19] Smith, D.B., Pathirana, S., Davidson, F., Lawlor, E., Power, J., Yap, P.L. and Simmonds, P. (1997) J. Gen. Virol. 78(Pt. 2), 321–328. [20] Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. and Perelson, A.S. (1998) Science (Washington, DC) 282, 103–107.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
101
[21] Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J. and Gomez, J. (1992) J. Virol. 66, 3225–3229. [22] Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M., Nainan, O., Netesov, S., Nishioka, K., Shin-i, T., Simmonds, P., Smith, D., Stuyver, L. and Weiner, A. (1998) Arch. Virol. 143, 2493–2503. [23] Pawlotsky, J.M. (2003) Clin. Liver. Dis. 7, 45–66. [24] Frank, C., Mohamed, M.K., Strickland, G.T., Lavanchy, D., Arthur, R.R., Magder, L.S., El Khoby, T., Abdel-Wahab, Y., Aly Ohn, E.S., Anwar, W. and Sallam, I. (2000) Lancet 355, 887–891. [25] Pestka, S., Krause, C.D. and Walter, M.R. (2004) Immunol. Rev. 202, 8–32. [26] Fried, M.W. (2002) Hepatology 36, S237–S244. [27] Strader, D.B., Wright, T., Thomas, D.L. and Seeff, L.B. (2004) Hepatology 39, 1147–1171. [28] Dixit, N.M., Layden-Almer, J.E., Layden, T.J. and Perelson, A.S. (2004) Nature (London) 432, 922–924. [29] Zekry, A., Patel, K., Muir, A. and McHutchison, J.G. (2004) Hepatology 40, 1249–1251. [30] Foster, G.R. (2004) Semin. Liver Dis. 24(Suppl. 2), 97–104. [31] Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T. and Hostomska, Z. (1996) Cell 87, 331–342. [32] De Francesco, R., Urbani, A., Nardi, M.C., Tomei, L., Steinkuhler, C. and Tramontano, A. (1996) Biochemistry 35, 13282–13287. [33] Lin, C., Thomson, J.A. and Rice, C.M. (1995) J. Virol. 69, 4373–4380. [34] Bartenschlager, R., Lohmann, V., Wilkinson, T. and Koch, J.O. (1995) J. Virol. 69, 7519–7528. [35] Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O’Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R. and Thomson, J.A. (1996) Cell 87, 343–355. [36] Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J.L., Sardana, M., Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L.C. and Chen, Z. (1998) Protein Sci. 7, 837–847. [37] De Francesco, R. and Steinkuhler, C. (2000) Curr. Top. Microbiol. Immunol. 242, 149–169. [38] Bartenschlager, R. (1999) J. Viral Hepat. 6, 165–181. [39] Llinas-Brunet, M., Bailey, M., Fazal, G., Goulet, S., Halmos, T., Laplante, S., Maurice, R., Poirier, M., Poupart, M.A., Thibeault, D., Wernic, D. and Lamarre, D. (1998) Bioorg. Med. Chem. Lett. 8, 1713–1718. [40] Ingallinella, P., Altamura, S., Bianchi, E., Taliani, M., Ingenito, R., Cortese, R., De Francesco, R., Steinkuhler, C. and Pessi, A. (1998) Biochemistry 37, 8906–8914. [41] Koch, U., Biasiol, G., Brunetti, M., Fattori, D., Pallaoro, M. and Steinkuhler, C. (2001) Biochemistry 40, 631–640. [42] Tsantrizos, Y.S., Bolger, G., Bonneau, P., Cameron, D.R., Goudreau, N., Kukolj, G., LaPlante, S.R., Llinas-Brunet, M., Nar, H. and Lamarre, D. (2003) Angew. Chem. Int. Ed. Engl. 42, 1356–1360. [43] Fattori, D., Urbani, A., Brunetti, M., Ingenito, R., Pessi, A., Prendergast, K., Narjes, F., Matassa, V.G., De Francesco, R. and Steinkuhler, C. (2000) J. Biol. Chem. 275, 15106–15113. [44] Beyer, B.M., Zhang, R., Hong, Z., Madison, V. and Malcolm, B.A. (2001) Proteins 43, 82–88. [45] Thibeault, D., Bousquet, C., Gingras, R., Lagace, L., Maurice, R., White, P.W. and Lamarre, D. (2004) J. Virol. 78, 7352–7359.
102
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
[46] Mamane, Y., Heylbroeck, C., Genin, P., Algarte, M., Servant, M.J., LePage, C., DeLuca, C., Kwon, H., Lin, R. and Hiscott, J. (1999) Gene 237, 1–14. [47] Foy, E., Li, K., Wang, C., Sumpter, R., Jr., Ikeda, M., Lemon, S.M. and Gale, M., Jr. (2003) Science (Washington, DC) 300, 1145–1148. [48] Bianchi, E., Urbani, A., Biasiol, G., Brunetti, M., Pessi, A., De Francesco, R. and Steinkuhler, C. (1997) Biochemistry 36, 7890–7897. [49] Urbani, A., Biasiol, G., Brunetti, M., Volpari, C., Di Marco, S., Sollazzo, M., Orru, S., Piaz, F.D., Casbarra, A., Pucci, P., Nardi, C., Gallinari, P., De Francesco, R. and Steinkuhler, C. (1999) Biochemistry 38, 5206–5215. [50] Taremi, S.S., Beyer, B., Maher, M., Yao, N., Prosise, W., Weber, P.C. and Malcolm, B.A. (1998) Protein Sci. 7, 2143–2149. [51] Pasquo, A., Nardi, M.C., Dimasi, N., Tomei, L., Steinkuhler, C., Delmastro, P., Tramontano, A. and De Francesco, R. (1998) Fold. Des. 3, 433–441. [52] Fowler, A., Price-Jones, M., Hughes, K., Anson, J., Lingham, R. and Schulman, M. (2000) J. Biomol. Screen. 5, 153–158. [53] Taliani, M., Bianchi, E., Narjes, F., Fossatelli, M., Urbani, A., Steinkuhler, C., De Francesco, R. and Pessi, A. (1996) Anal. Biochem. 240, 60–67. [54] Zhang, R., Beyer, B.M., Durkin, J., Ingram, R., Njoroge, F.G., Windsor, W.T. and Malcolm, B.A. (1999) Anal. Biochem. 270, 268–275. [55] Steinkuhler, C., Biasiol, G., Cerretani, M., Di Renzo, L., Brunetti, M., Ingallinella, P., Francesco, R.D. and Altamura, S. (2002) Anal. Biochem. 307, 99–104. [56] Bartenschlager, R., Kaul, A. and Sparacio, S. (2003) Antiviral Res. 60, 91–102. [57] Wakita, T. (2004) 11th International Symposium on Hepatitis C Virus and Related Viruses, Heidelberg, Germany, Abst. O-33. [58] Hirowatari, Y., Hijikata, M. and Shimotohno, K. (1995) Anal. Biochem. 225, 113–120. [59] Cho, Y.G., Yang, S.H. and Sung, Y.C. (1998) J. Virol. Methods 72, 109–115. [60] Potts, K.E., Jackson, R.L. and Patick, A.K. (1999) PCT Int. Appl. US 6280940; (1999) Chem. Abstr. 135, 191340. [61] Pellerin, C. and Lamarre, D. (2000) PCT Int. Appl. WO 2000066623; (2000) Chem. Abstr. 133, 344597. [62] Arasappan, A., Chen, K.X., Ganguly, A., Girijavallabhan, V.M., Gu, H., Jao, E., Madison, V.S., Njoroge, F.G., Parekh, T.N., Prongay, A.J., Saksena, A., Venkatraman, S., Vibulbhan, B. and Yao, N.H. (2001) PCT Int. Appl. WO200177113 A2; (2001) Chem. Abstr. 135, 318715. [63] Kettner, C.A., Jagannathan, S. and Forsyth, T.P. (2001) PCT Int. Appl. WO 01 002424; (2001) Chem. Abstr. 134, 101193. [64] Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L. and Bartenschlager, R. (1999) Science (Washington, DC) 85, 110–113. [65] Gu, B., Gates, A.T., Isken, O., Behrens, S.E. and Sarisky, R.T. (2003) J. Virol. 77, 5352–5359. [66] Yi, M. and Lemon, S.M. (2004) J. Virol. 78, 7904–7915. [67] Blight, K.J., Kolykhalov, A.A. and Rice, C.M. (2000) Science (Washington, DC) 290, 1972–1974. [68] Krieger, N., Lohmann, V. and Bartenschlager, R. (2001) J. Virol. 75, 4614–4624. [69] Bukh, J., Pietschmann, T., Lohmann, V., Krieger, N., Faulk, K., Engle, R.E., Govindarajan, S., Shapiro, M., St Claire, M. and Bartenschlager, R. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 14416–14421. [70] Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M. and Wakita, T. (2003) Gastroenterology 125, 1808–1817.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
103
[71] McPhee, F., Campbell, J.A., Li, W., D’Andrea, S., Zheng, Z.B., Good, A.C., Carini, D.J., Barry, L. and Scola, P.M. (2004) PCT Int. Appl. WO 2004 094452; (2004) Chem. Abstr. 141, 395807. [72] Tan, H., Hong, J., Seiwert, S. and Blatt, L.M. (2004) Hepatology 40, 407A. [73] Bartholomew, L. (2004) 11th International Symposium on Hepatitis C virus and related viruses, Heidelberg, Germany, Abst. O–19. [74] Yanagi, M., Purcell, R.H., Emerson, S.U. and Bukh, J. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 8738–8743. [75] Kolykhalov, A.A., Agapov, E.V., Blight, K.J., Mihalik, K., Feinstone, S.M. and Rice, C.M. (1997) Science (Washington, DC) 277, 570–574. [76] Kolykhalov, A.A., Mihalik, K., Feinstone, S.M. and Rice, C.M. (2000) J. Virol. 74, 2046–2051. [77] Ilan, E., Arazi, J., Nussbaum, O., Zauberman, A., Eren, R., Lubin, I., Neville, L., Ben Moshe, O., Kischitzky, A., Litchi, A., Margalit, I., Gopher, J., Mounir, S., Cai, W.Z., Daudi, N., Eid, A., Jurim, O., Czerniak, A., Galun, E. and Dagan, S. (2002) J. Infect. Dis. 185, 153–161. [78] Mercer, D.F., Schiller, D.E., Elliott, J.F., Douglas, D.N., Hao, C., Rinfret, A., Addison, W.R., Fischer, K.P., Churchill, T.A., Lakey, J.R., Tyrrell, D.L. and Kneteman, N.M. (2001) Nat. Med. 7, 927–933. [79] Schiller, D. (2001) 8th International Symposium on Hepatitis C Virus & Related Viruses, Paris, France, Abst. P-142. [80] Kneteman, N., Gao, T.J., Schiller, D., Douglas, D., Addison, B. and Tyrrell, D.L.J. (2003) 10th International Symposium on Hepatitis C virus and related viruses, Kyoto, Japan, Abst. P-187. [81] Andrews, D.M., Barnes, M.C., Dowle, M.D., Hind, S.L., Johnson, M.R., Jones, P.S., Mills, G., Patikis, A., Pateman, T.J., Redfern, T.J., Robinson, J.E., Slater, M.J. and Trivedi, N. (2003) Org. Lett. 5, 4631–4634. [82] Kalkeri, G., Almquist, S., Perni, R. and Kwong, A. (2004) Hepatology 40, 402A. [83] Kalkeri, G., Almquist, S., Bhan, A., Reid, L., Chung, R.T. and Kwong, A.D. (2004) Hepatology 40, 281A. [84] Lerat, H., Rumin, S., Habersetzer, F., Berby, F., Trabaud, M.A., Trepo, C. and Inchauspe, G. (1998) Blood 91, 3841–3849. [85] Negro, F. and Levrero, M. (1998) Hepatology 28, 261–264. [86] Laskus, T., Radkowski, M., Bednarska, A., Wilkinson, J., Adair, D., Nowicki, M., Nikolopoulou, G.B., Vargas, H. and Rakela, J. (2002) J. Virol. 76, 10064–10068. [87] Goutagny, N., Fatmi, A., Ledinghen, V.D., Penin, F., Couzigou, P., Inchauspe, G. and Bain, C. (2003) J. Infect. Dis. 187, 1951–1958. [88] Forton, D.M., Karayiannis, P., Mahmud, N., Taylor-Robinson, S.D. and Thomas, H.C. (2004) J. Virol. 78, 5170–5183. [89] Pause, A., Kukolj, G., Bailey, M., Brault, M., Do, F., Halmos, T., Lagace, L., Maurice, R., Marquis, M., McKercher, G., Pellerin, C., Pilote, L., Thibeault, D. and Lamarre, D. (2003) J. Biol. Chem. 278, 20374–20380. [90] Babine, R.E., Chen, S.H., Lamar, J.E., Snyder, N., Sun, X.D., Tebbe, M.J., Victor, F., Wang, Q., Yip, Y.Y.M., Collado, I., Garcia-Paredes, C., Parker, R.S., III, Jin, L., Guo, D. and Glass, J.I. (2002) PCT Int. Appl. WO 02 018369; (2002) Chem. Abstr. 136, 232547. [91] Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A. and Kwong, A.D. (2004) J. Biol. Chem. 279, 17508–17514.
104
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
[92] Lagace´, L., Marquis, M., Bousquet, C., Doˆ, F., Gingras, R., Lamarre, D., Lamarre, L., Maurice, R., Pause, A., Pellerin, C., Spickler, C., Thibeault, D. and Kukolj, G. (2006) In ‘‘Framing the knowledge of Viral Hepatitis’’. Schinazi, R.F. and Schiff, E.R. (eds), 263–278. IHL Press, College Park, GA, USA. [93] Johnston, V.K., Maley, D., Gagnon, R.C., Grassmann, C.W., Behrens, S.E. and Sarisky, R.T. (2003) Biochem. Biophys. Res. Commun. 311, 672–677. [94] Pratt, J.K., Beno, D., Donner, P., Jiang, W., Kati, W., Kempf, D., Koev, G., Liu, D., Liu, Y., Maring, C., Masse, S., Middleton, T., Mo, H.M., Molla, A., Montgomery, D. and Xie, Q. (2004) Hepatology 40, 697A. [95] Steinkuhler, C., Biasiol, G., Brunetti, M., Urbani, A., Koch, U., Cortese, R., Pessi, A. and De Francesco, R. (1998) Biochemistry 37, 8899–8905. [96] Llinas-Brunet, M., Bailey, M., Fazal, G., Ghiro, E., Gorys, V., Goulet, S., Halmos, T., Maurice, R., Poirier, M., Poupart, M.A., Rancourt, J., Thibeault, D., Wernic, D. and Lamarre, D. (2000) Bioorg. Med. Chem. Lett. 10, 2267–2270. [97] Beaulieu, P.L. and Llinas-Brunet, M. (2002) Curr. Med. Chem. Anti-Infect. Agents 1, 163–176. [98] Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W. and Weber, P.C. (1999) Structure Fold. Des. 7, 1353–1363. [99] Rancourt, J., Cameron, D.R., Gorys, V., Lamarre, D., Poirier, M., Thibeault, D. and Llinas-Brunet, M. (2004) J. Med. Chem. 47, 2511–2522. [100] Llinas-Brunet, M., Bailey, M., Deziel, R., Fazal, G., Gorys, V., Goulet, S., Halmos, T., Maurice, R., Poirier, M., Poupart, M.A., Rancourt, J., Thibeault, D., Wernic, D. and Lamarre, D. (1998) Bioorg. Med. Chem. Lett. 8, 2719–2724. [101] Narjes, F., Koehler, K.F., Koch, U., Gerlach, B., Colarusso, S., Steinkuhler, C., Brunetti, M., Altamura, S., De Francesco, R. and Matassa, V.G. (2002) Bioorg. Med. Chem. Lett. 12, 701–704. [102] Goudreau, N., Cameron, D.R., Bonneau, P., Gorys, V., Plouffe, C., Poirier, M., Lamarre, D. and Llinas-Brunet, M. (2004) J. Med. Chem. 47, 123–132. [103] Poupart, M.A., Cameron, D.R., Chabot, C., Ghiro, E., Goudreau, N., Goulet, S., Poirier, M. and Tsantrizos, Y.S. (2001) J. Org. Chem. 66, 4743–4751. [104] Llinas-Brunet, M., Bailey, M.D., Ghiro, E., Gorys, V., Halmos, T., Poirier, M., Rancourt, J. and Goudreau, N. (2004) J. Med. Chem. 47, 6584–6594. [105] Goudreau, N., Brochu, C., Cameron, D.R., Duceppe, J.S., Faucher, A.M., Ferland, J.M., Grand-Maitre, C., Poirier, M., Simoneau, B. and Tsantrizos, Y.S. (2004) J. Org. Chem. 69, 6185–6201. [106] Llinas-Brunet, M., Bailey, M.D., Bolger, G., Brochu, C., Faucher, A.M., Ferland, J.M., Garneau, M., Ghiro, E., Gorys, V., Grand-Maitre, C., Halmos, T., Lapeyre-Paquette, N., Liard, F., Poirier, M., Rheaume, M., Tsantrizos, Y.S. and Lamarre, D. (2004) J. Med. Chem. 47, 1605–1608. [107] Lamarre, D., Anderson, P.C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bos, M., Cameron, D.R., Cartier, M., Cordingley, M.G., Faucher, A.M., Goudreau, N., Kawai, S.H., Kukolj, G., Lagace´, L., LaPlante, S.R., Narjes, H., Poupart, M.A., Rancourt, J., Sentjens, R.E., St George, R., Simoneau, B., Steinmann, G., Thibeault, D., Tsantrizos, Y.S., Weldon, S.M., Yong, C.L. and Llinas-Brunet, M. (2003) Nature (London) 426, 186–189. [108] Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R.E., Calleja, J.L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R.L., Yong, C.L., Nehmiz, G. and Steinmann, G.G. (2004) Gastroenterology 127, 1347–1355. [109] Reiser, R., Benhamou, Y. and Sentjens, R. (2003) Hepatology 38, 221A.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
105
[110] Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H. and Molla, A. (2004) Antimicrob. Agents Chemother. 48, 2260–2266. [111] Trozzi, C., Bartholomew, L., Ceccacci, A., Biasiol, G., Pacini, L., Altamura, S., Narjes, F., Muraglia, E., Paonessa, G., Koch, U., De Francesco, R., Steinkuhler, C. and Migliaccio, G. (2003) J. Virol. 77, 3669–3679. [112] Faucher, A.M., Bailey, M.D., Beaulieu, P.L., Brochu, C., Duceppe, J.S., Ferland, J.M., Ghiro, E., Gorys, V., Halmos, T., Kawai, S.H., Poirier, M., Simoneau, B., Tsantrizos, Y.S. and Llinas-Brunet, M. (2004) Org. Lett. 6, 2901–2904. [113] Colarusso, S., Koch, U., Gerlach, B., Steinkuhler, C., De Francesco, R., Altamura, S., Matassa, V.G. and Narjes, F. (2003) J. Med. Chem. 46, 345–348. [114] Malancona, S., Colarusso, S., Ontoria, J.M., Marchetti, A., Poma, M., Stansfield, I., Laufer, R., Di Marco, A., Taliani, M., Verdirame, M., Gonzalez-Paz, O., Matassa, V.G. and Narjes, F. (2004) Bioorg. Med. Chem. Lett. 14, 4575–4579. [115] Orvieto, F., Koch, U., Matassa, V.G. and Muraglia, E. (2003) Bioorg. Med. Chem. Lett. 13, 2745–2748. [116] Bailey, M.D., Halmos, T., Goudreau, N., Lescop, E. and Llinas-Brunet, M. (2004) J. Med. Chem. 47, 3788–3799. [117] Johansson, A., Poliakov, A., Akerblom, E., Wiklund, K., Lindeberg, G., Winiwarter, S., Danielson, U.H., Samuelsson, B. and Hallberg, A. (2003) Bioorg. Med. Chem. 11, 2551–2568. [118] Poliakov, A., Johansson, A., Akerblom, E., Oscarsson, K., Samuelsson, B., Hallberg, A. and Danielson, U.H. (2004) Biochim. Biophys. Acta 1672, 51–59. [119] Campbell, J.A. and Good, A.C. (2003) PCT Int. Appl. WO 03 053349; (2003) Chem. Abstr. 139, 69527. [120] Nakajima, S., Sun, Y., Tang, D., Xu, G., Porter, B., Yat, S., Wang, Z. and Miao, Z. (2004) PCT Int. Appl. WO 2004 093798; (2004) Chem. Abstr. 141, 395806. [121] Wu, F.X.H., Nakajima, S., Or, Y.S., Lu, Z.h., Sun, Y., Miao, Z. and Wang, Z. (2005) PCT Int. Appl. WO 2005 010029; (2005) Chem. Abstr. 142, 198355. [122] Miao, Z., Sun, Y., Wu, F., Nakajima, S., Xu, G., Or, Y. and Wang, Z. (2004) PCT Int. Appl. WO 2004 072243; (2004) Chem. Abstr. 141, 220883. [123] Llinas-Brunet, M. and Gorys, V.J. (2003) PCT Int. Appl. WO 03 064455; (2003) Chem. Abstr. 139, 164979. [124] Llinas-Brunet, M. and Bailey, M.D. (2004) PCT Int. Appl. WO 2004 037855; (2004) Chem. Abstr. 140, 357673. [125] Campbell, J.A. and Good, A. (2002) PCT Int. Appl. WO 2002 060926 A2; (2002) Chem. Abstr. 137, 155180. [126] Campbell, J.A. and Good, A.C. (2003) PCT Int. Appl. WO 03 099316; (2003) Chem. Abstr. 140, 16976. [127] Wang, X.A., Sun, L.Q., Sit, S.Y., Sin, N., Scola, P., Hewawasam, P., Good, A.C., Chen, Y. and Campbell, J.A. (2003) PCT Int. Appl. WO 03 099274; (2003) Chem. Abstr. 140, 16975. [128] Ripka, A., Campbell, J.A., Good, A.C., Scola, P., Sin, N. and Venables, B. (2004) PCT Int. Appl. WO 2004 032827; (2004) Chem. Abstr. 140, 253912. [129] Campbell, J.A., D’Andrea, S., Good, A., Li, J., McPhee, F., Ripka, A., Scola, P.M. and Tu, Y. (2004) PCT Int. Appl. WO 2004 043339; (2004) Chem. Abstr. 140, 357668. [130] Llinas-Brunet, M., Bailey, M.D., Bhardwaj, P., Bordeleau, J., Forgione, P., Ghiro, E., Gorys, V., Goudreau, N., Goulet, S., Halmos, T. and Rancourt, J. (2004) PCT Int. Appl. WO 2004 103996; (2004) Chem. Abstr. 142, 38535.
106
BLUNTING THE SWISS ARMY KNIFE OF HEPATITIS C VIRUS
[131] Bailey, M.D. and Llinas-Brunet, M. (2004) PCT Int. Appl. WO 2004 101602; (2004) Chem. Abstr. 141, 395810. [132] Llinas-Brunet, M. (2004) PCT Int. Appl. WO 2004 101605; (2004) Chem. Abstr. 142, 6826. [133] Llinas-Brunet, M., Bailey, M.D. and Ghiro, E. (2004) PCT Int. Appl. WO 03 064416; (2004) Chem. Abstr. 139, 164978. [134] Llinas-Brunet, M. and Gorys, V.J. (2004) PCT Int. Appl. WO 03 064456; (2004) Chem. Abstr. 139, 164980. [135] Miao, Z., Sun, Y., Nakajima, S., Tang, D., Wang, Z. and Yat, S. (2004) PCT Int. Appl. WO 2004 113365; (2004) Chem. Abstr. 142, 94137. [136] Ingallinella, P., Fattori, D., Altamura, S., Steinkuhler, C., Koch, U., Cicero, D., Bazzo, R., Cortese, R., Bianchi, E. and Pessi, A. (2002) Biochemistry 41, 5483–5492. [137] Perni, R.B., Britt, S.D., Court, J.C., Courtney, L.F., Deininger, D.D., Farmer, L.J., Gates, C.A., Harbeson, S.L., Kim, J.L., Landro, J.A., Levin, R.B., Luong, Y.P., O’Malley, E.T., Pitlik, J., Rao, B.G., Schairer, W.C., Thomson, J.A., Tung, R.D., Van Drie, J.H. and Wei, Y. (2003) Bioorg. Med. Chem. Lett. 13, 4059–4063. [138] Perni, R.B., Pitlik, J., Britt, S.D., Court, J.J., Courtney, L.F., Deininger, D.D., Farmer, L.J., Gates, C.A., Harbeson, S.L., Levin, R.B., Lin, C., Lin, K., Moon, Y.C., Luong, Y.P., O’Malley, E.T., Rao, B.G., Thomson, J.A., Tung, R.D., Van Drie, J.H. and Wei, Y. (2004) Bioorg. Med. Chem. Lett. 14, 1441–1446. [139] Perni, R.B., Farmer, L.J., Cottrell, K.M., Court, J.J., Courtney, L.F., Deininger, D.D., Gates, C.A., Harbeson, S.L., Kim, J.L., Lin, C., Lin, K., Luong, Y.P., Maxwell, J.P., Murcko, M.A., Pitlik, J., Rao, B.G., Schairer, W.C., Tung, R.D., Van Drie, J.H., Wilson, K. and Thomson, J.A. (2004) Bioorg. Med. Chem. Lett. 14, 1939–1942. [140] Yip, Y., Victor, F., Lamar, J., Johnson, R., Wang, Q.M., Barket, D., Glass, J., Jin, L., Liu, L., Venable, D., Wakulchik, M., Xie, C., Heinz, B., Villarreal, E., Colacino, J., Yumibe, N., Tebbe, M., Munroe, J. and Chen, S.H. (2004) Bioorg. Med. Chem. Lett. 14, 251–256. [141] Victor, F., Lamar, J., Snyder, N., Yip, Y., Guo, D., Yumibe, N., Johnson, R.B., Wang, Q.M., Glass, J.I. and Chen, S.H. (2004) Bioorg. Med. Chem. Lett. 14, 257–261. [142] Lamar, J., Victor, F., Snyder, N., Johnson, R.B., Wang, Q.M., Glass, J.I. and Chen, S.H. (2004) Bioorg. Med. Chem. Lett. 14, 263–266. [143] Yip, Y., Victor, F., Lamar, J., Johnson, R., Wang, Q.M., Glass, J.I., Yumibe, N., Wakulchik, M., Munroe, J. and Chen, S.H. (2004) Bioorg. Med. Chem. Lett. 14, 5007–5011. [144] Chu, H.M., McNair, L. and Purdy, S. (2004) 55th Annual meeting of the Americal Association for the Study of Liver Diseases, Boston, MA, Abst. LB20. [145] Perni, R.B., Chandorkar, G., Chaturvedi, P.R., Courtney, L.F., Decker, C.J., Gates, C.A., Harbeson, S.L., Kwong, A.D., Lin, C., Lin, K., Luong, Y.P., Markland, W., Rao, B.G., Tung, R.D. and Thomson, J.A. (2003) Hepatology 238, 624A. [146] Lin, C., Govinda, R.B., Luong, Y.P., Fulghum, J.R., Brennan, D.L., Wei, Y.Y., Frantz, J.D., Lippke, J., Hsiao, H.M., Ma, S., Lin, K., Maxwell, J.P., Cottrell, K.M., Gates, C.A., Perni, R.B. and Kwong, A.D. (2004) Hepatology 40, 404A. [147] Han, W., Hu, Z., Jiang, X., Wasserman, Z.R. and Decicco, C.P. (2003) Bioorg. Med. Chem. Lett. 13, 1111–1114. [148] Andrews, D.M., Carey, S.J., Chaignot, H., Coomber, B.A., Gray, N.M., Hind, S.L., Jones, P.S., Mills, G., Robinson, J.E. and Slater, M.J. (2002) Org. Lett. 4, 4475–4478. [149] Andrews, D.M., Chaignot, H.M., Coomber, B.A., Dowle, M.D., Lucy, H.S., Johnson, M.R., Jones, P.S., Mills, G., Patikis, A., Pateman, T.J., Robinson, J.E., Slater, M.J. and Trivedi, N. (2003) Eur. J. Med. Chem. 38, 339–343.
P.W. WHITE, M. LLINAS-BRUNET AND M. BO¨S
107
[150] Andrews, D.M., Chaignot, H., Coomber, B.A., Good, A.C., Hind, S.L., Johnson, M.R., Jones, P.S., Mills, G., Robinson, J.E., Skarzynski, T., Slater, M.J. and Somers, D.O. (2002) Org. Lett. 4, 4479–4482. [151] Slater, M.J., Andrews, D.M., Baker, G., Bethell, S.S., Carey, S., Chaignot, H., Clarke, B., Coomber, B., Ellis, M., Good, A., Gray, N., Hardy, G., Jones, P., Mills, G. and Robinson, E. (2002) Bioorg. Med. Chem. Lett. 12, 3359–3362. [152] Priestley, E., De Lucca, I., Ghavimi, B., Erickson-Viitanen, S. and Decicco, C. (2002) Bioorg. Med. Chem. Lett. 12, 3199. [153] Glunz, P.W., Douty, B.D. and Decicco, C.P. (2003) Bioorg. Med. Chem. Lett. 13, 785–788. [154] Zhang, X., Schmitt, A.C., Jiang, W., Wasserman, Z. and Decicco, C.P. (2003) Bioorg. Med. Chem. Lett. 13, 1157–1160. [155] Webber, S.E., Dragovich, P.S., Prins, T.J., Littlefield, E.S., Marakovits, J.T. and Babine, R.E. (1999) PCT Int. Appl. WO 9931122; (1999) Chem. Abstr. 131, 45107. [156] Hegde, V.R., Pu, H., Patel, M., Das, P.R., Butkiewicz, N., Arreaza, G., Gullo, V.P. and Chan, T.M. (2003) Bioorg. Med. Chem. Lett. 13, 2925–2928. [157] Duan, D., Li, Z., Luo, H., Zhang, W., Chen, L. and Xu, X. (2004) Bioorg. Med. Chem. Lett. 14, 6041–6044. [158] Wyss, D.F., Arasappan, A., Senior, M.M., Wang, Y.S., Beyer, B.M., Njoroge, F.G. and McCoy, M.A. (2004) J. Med. Chem. 47, 2486–2498. [159] Zeuzem, S., Sarrazin, C., Rouzier, R., Tarral, A., Brion, N., Forestier, N., Gupta, S., Deckman, D., Fellows, K., Hussain, M., Cutler, D.L. and Zhang, J. (2005) Hepatology 42, 233A–234A.
This page intentionally left blank
108
Progress in Medicinal Chemistry – Vol. 44, Edited by F.D. King and G. Lawton r 2006 Elsevier B.V. All rights reserved.
3 Peptide Deformylase Inhibitors KELLY AUBART and MAGDALENA ZALACAIN Microbial, Musculoskeletal, and Proliferative Diseases CEDD, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA
INTRODUCTION
110
PEPTIDE DEFORMYLASE AS A NOVEL ANTIBACTERIAL TARGET Function Essentiality Spectrum Selectivity
110 111 112 112 113
PROTEIN STRUCTURE OF PEPTIDE DEFORMYLASES Three-dimensional Structure Metal-binding Site Comparison with other Metalloproteases Substrate-binding Pockets
113 113 114 115 115
DESIGN AND SAR OF PEPTIDE DEFORMYLASE INHIBITORS Early Substrate-based Inhibitors Pseudopeptidic Hydroxamic Acids and N-formyl-N-hydroxylamines Non-peptidic Templates
117 117 121 127
CLINICAL CANDIDATES BB-83698 LBM-415
135 135 136
SUMMARY AND PERSPECTIVES
136
ACKNOWLEDGEMENTS
137
REFERENCES
138
DOI: 10.1016/S0079-6468(05)44403-3
109
110
PEPTIDE DEFORMYLASE INHIBITORS
INTRODUCTION The successful development of numerous antibiotics in the 1930s–1960s [1] created the complacent feeling in the medical and scientific communities that bacterial infections had been defeated, resulting in a decrease in academic and industrial research in the antimicrobial area. Unfortunately, bacteria adapted to their hostile new environment by developing or acquiring resistance mechanisms that eventually rendered many of these antibiotics ineffective. Currently, infectious diseases are still a leading cause of death in the world [2], while the approval of new antibacterial agents has been steadily decreasing over the last 20 years [3]. Although the development of second- and third-generation antibiotics from existing classes has improved their activity and safety, bacterial resistance to these drugs continues to increase. In order to directly address this issue, antimicrobial agents with novel mechanisms of action are needed. However, of the 11 new antibiotics approved by the Food and Drug Administration (FDA) in the last 7 years, only two act through a novel mechanism: linezolid, an oxazolidinone, and daptomycin, a cyclic lipopeptide, both of which have been approved for the treatment of Gram-positive bacterial infections only. While considerable effort is underway to develop next generation oxazolidinones covering a broader spectrum of community and hospital infections [4–6], the identification of new drugs that target previously untapped bacterial pathways will play a critical role in the development of antibiotics active against resistant pathogens. This article summarises the general characteristics of a novel antibacterial target, peptide deformylase (PDF) and reviews the design, structure–activity relationships (SAR) and properties of known PDF inhibitors, including pre-clinical and clinical data for the most advanced members of this class.
PEPTIDE DEFORMYLASE AS A NOVEL ANTIBACTERIAL TARGET A broad-spectrum antimicrobial target must be conserved across all pathogens of interest within a therapeutic product profile, essential for bacterial growth, and either absent, substantially different or non-essential in humans. PDF meets all of these criteria and is one of the most promising unexploited bacterial targets in the search for new antibiotics with a novel mode of action.
K. AUBART AND M. ZALACAIN
111
FUNCTION
Bacterial protein synthesis initiates with formyl-methionyl-tRNA and, consequently, all newly synthesised polypeptides contain an N-formyl-methionine terminus. The N-formyl group and, in most cases, the methionine, need to be removed to provide a mature protein and these reactions are part of the methionine cycle [7] (Figure 3.1). PDF (EC 3.5.1.88) is a metalloprotease that removes the N-formyl group of the polypeptides as they emerge from the ribosome during or immediately after completion of the elongation process [8–10]. Methionine aminopeptidase (MAP; EC 3.4.11.18) then removes the N-terminal methionine depending on the nature of the second amino acid in the peptide chain [7]. Thus, deformylation plays an indispensable role in protein maturation as MAP, an essential protein for bacterial growth, cannot hydrolyse N-blocked peptides [11]. The production of N-formylated proteins is a characteristic specific to bacteria and, therefore, an obvious target for the human immune system. It has been shown that professional phagocytes, the first line of defence against invading microorganisms, express receptors that recognise N-formylated peptides [12], and that activation of these receptors mediates migration of
tRNAi Polypeptide
Met Methionyl tRNA Synthetase
Methionine Aminopeptidase
Met-tRNA
Met-polypeptide
Formyl Methionyl Transferase
Peptide Deformylase
f-Met-polypeptide
f-Met-tRNA
aa-tRNAe
tRNAe tRNAi
Ribosome Fig. 3.1 The methionine cycle.
112
PEPTIDE DEFORMYLASE INHIBITORS
phagocytes to the site of infection as well as the release of antimicrobial peptides and oxidants [13]. Theoretically, inhibition of PDF would increase production of bacterial N-formylated polypeptides, possibly triggering an enhanced immune response. In fact, Fu et al. [14] have shown that exposure of Escherichia coli to subinhibitory concentrations of a PDF inhibitor increases the production of peptides that mediate chemotactic migration and activation of human neutrophils. These results indicate that PDF inhibitors could have an additional advantageous effect, potentially amplifying the human immune response to bacterial infections.
ESSENTIALITY
Deformylation of nascent polypeptides has been shown to be a function essential for growth in E. coli, Staphylococcus aureus and Streptococcus pneumoniae [15–18]. Moreover, antibacterial mode of action studies, using S. pneumoniae or S. aureus strains in which the expression of PDF is controlled by regulatable promoters, have shown that the antibacterial activity of PDF inhibitors is due to their inhibition of the PDF enzyme, as the susceptibility of the strains to these compounds is dependent on the amount of protein present in the cell [19–21]. These results further validate PDF as a target for novel antibiotics.
SPECTRUM
PDF is a ubiquitous bacterial enzyme, with at least one pdf gene present in all bacterial genomes sequenced to date [22]. Based on phylogenetic and structural analysis, PDF proteins can be subdivided into two classes that differ significantly at the C-terminus: type I, found in Gramnegative and some Gram-positive bacteria, and type II, found only in Gram-positive bacteria [22]. The active sites of both type I and type II PDFs are highly conserved, indicating that it should be possible to obtain broad-spectrum inhibitors of this enzyme [22, 23]. In fact, PDF inhibitors have been reported to have activity against a wide range of pathogens including, among others, those involved in community respiratory tract infections (S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis) [24–28], including atypical organisms (Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae) [28–33], Gram-positive infections (S. aureus, enterococci, viridans group streptococci) [28, 34, 35], tuberculosis (Mycobacterium tuberculosis) [36], and even malaria (Plasmodium falciparum) [37].
K. AUBART AND M. ZALACAIN
113
SELECTIVITY
As eukaryotic cytoplasmic protein synthesis does not involve N-formylation, it was generally accepted that eukaryotes did not require PDF activity. However, the recent sequencing of eukaryotic genomes has revealed the presence of PDF-like sequences in the nuclear chromosomes of parasites, plants and mammals, including humans [38]. These eukaryotic PDF enzymes contain an N-terminal exportation sequence and are located in plastids and mitochondria [39–41]. Genomes of plant and parasite organelles encode for a number of proteins that require deformylation for activity [23] and, therefore, it is not surprising to find that PDF is essential in these organisms [37, 40]. On the other hand, there is no evidence to support that this is the case in animals. In fact, it has been shown that proteins synthesised in bovine and rat mitochondria either retain their N-formyl groups or have their N-terminal signal sequences removed [23, 42], indicating that PDF is not active in mammalian mitochondria. In addition, characterisation of human mitochondrial PDF has shown that it is much less active than its bacterial counterpart [41, 43] even when N-formylated peptides corresponding to the N-terminal sequence of human mitochondrial proteins are used as substrates [41]. Finally, known PDF inhibitors are active against this enzyme in vitro, but have no effect on the growth of normal human cell lines [41]. These data suggest that PDF does not play a functional role in human mitochondria and validates PDF inhibitors as selective antibacterial agents.
PROTEIN STRUCTURE OF PEPTIDE DEFORMYLASES THREE-DIMENSIONAL STRUCTURE
X-ray crystallography data are available for numerous PDFs, including E. coli, H. influenzae, Pseudomonas aeruginosa, Thermotoga maritima and P. falciparium (type I) [44–49], and S. aureus, S. pneumoniae, Bacillus stearothermophilus and B. cereus (type II) [22, 46, 48, 50]. The sequence identity between type I and II forms of PDF is low, for example, the homology between the E. coli and S. aureus proteins is only 23% [22]. Consequently, significant tertiary structural differences are observed between the two classes (Figure 3.2). Generally, type II PDFs are larger in size due to differences at either the N- or C-termini, as well as internal insertions. In type I PDFs, the C-terminus is helical, but in type II PDFs, the C-terminus consists of a b-strand that can fold back against the enzyme to form a b-sheet. However, these differences do not significantly affect
114
PEPTIDE DEFORMYLASE INHIBITORS
Fig. 3.2 Superposition of E. coli and S. aureus PDF. Comparison of the overall structure of E. coli PDF (Blue, PDB code 2A18 ) and S. aureus PDF (mangenta, PDB code 2A19). The bound nickel is shown in red and His-132, His-136 and Cys-90 from E. coli PDF are shown as ball and stick representation.
the active site regions, which are structurally quite similar between type I and II PDFs.
METAL-BINDING SITE
Fe2+-PDF While PDF was originally proposed to be a zinc-metalloprotease [51], it is now generally accepted that Fe2+ is the physiologically relevant metal ion occupying the active site in vivo [52]. The native forms of most PDF enzymes are highly unstable due to propensity to oxidation, rendering them difficult to purify [53, 54]. However, the Fe2+ can be suitably replaced by either Ni2+ or Co2+, both of which provide a stable enzyme and maintain nearly identical catalytic activity to the native Fe2+ form (Table 3.1) [45, 55]. Replacement of Fe2+ with Zn2+ is also possible, but the catalytic activity of the Zn2+ form of the enzyme is greatly diminished, presumably
K. AUBART AND M. ZALACAIN
115
Table 3.1 COMPARISON OF THE CATALYTIC ACTIVITY OF VARIOUS METAL FORMS OF E. COLI PDF [45, 55] Protein
Substrate
Kcat/Km (M/s)
Fe2+-PDF Co2+-PDF Zn2+-PDF Fe2+-PDF Ni2+-PDF
f-ML-pNA f-ML-pNA f-ML-pNA f-MA f-MA
3.50 106 1.11 106 3.1 104 1.1 105 1.0 105
due to the tighter binding of the zinc ion to the active site metal-binding residues [56]. COMPARISON WITH OTHER METALLOPROTEASES
Although native PDFs utilise Fe2+ rather than Zn2+, the PDF metal-binding site is still very representative of a traditional zinc-metalloprotease [57], containing a conserved HEXXH motif. Crystal structures of the Fe2+, Ni2+, Co2+ and Zn2+ forms of E. coli PDF have been solved, and no significant structural differences are observed among the various metal forms [44, 56, 58]. Each metal displays a tetrahedral coordination pattern, bound to the two histidines from the HEXXH motif, as well as to a cysteine and a water molecule, although Zn2+-PDF shows a slightly smaller volume around the tetrahedron formed by the metal ligands [56]. PDF is similar to thermolysin and other zinc metalloproteases in that the conserved glutamate of the